



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C12N 15/12, C07K 14/47, C12N 9/12, 5/10, C07K 16/18, A61K 38/17</b>		<b>A2</b>	(11) International Publication Number: <b>WO 00/06728</b>
			(43) International Publication Date: 10 February 2000 (10.02.00)
(21) International Application Number: PCT/US99/17132		(72) Inventors; and	
(22) International Filing Date: 28 July 1999 (28.07.99)		(75) Inventors/Applicants (for US only): HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). AU-YOUNG, Janice [US/US]; 1419 Kains Avenue, Berkeley, CA 94709 (US). GORGONE, Gina, A. [US/US]; 1253 Pinecrest Drive, Boulder Creek, CA 95006 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US). REDDY, Roopa [IN/US]; 1233 W. McKinley Drive, Sunnyvale, CA 94086 (US). LU, Dyung, Aina, M. [US/US]; 55 Park Belmont Place, San Jose, CA 95136 (US). SHIH, Leo, L. [US/US]; Apt. B, 1081 Tanland Drive, Palo Alto, CA 94303 (US).	
(30) Priority Data:			
09/123,494	28 July 1998 (28.07.98)	US	
Not furnished	28 July 1998 (28.07.98)	US	
09/152,814	14 September 1998 (14.09.98)	US	
Not furnished	14 September 1998 (14.09.98)	US	
09/173,482	14 October 1998 (14.10.98)	US	
Not furnished	14 October 1998 (14.10.98)	US	
60/106,889	3 November 1998 (03.11.98)	US	
60/109,093	19 November 1998 (19.11.98)	US	
60/113,796	22 December 1998 (22.12.98)	US	
09/229,005	12 January 1999 (12.01.99)	US	
Not furnished	12 January 1999 (12.01.99)	US	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications			
US	Not furnished (CIP)		
Filed on	28 July 1998 (28.07.98)		
US	09/123,494 (CIP)		
Filed on	28 July 1998 (28.07.98)		
US	09/152,814 (CIP)		
Filed on	14 September 1998 (14.09.98)		
US	Not furnished (CIP)		
Filed on	14 September 1998 (14.09.98)		
US	09/173,482 (CIP)		
Filed on	14 October 1998 (14.10.98)		
US	Not furnished (CIP)		
Filed on	14 October 1998 (14.10.98)		
US	60/106,889 (CIP)		
Filed on	3 November 1998 (03.11.98)		
US	60/109,093 (CIP)		
Filed on	19 November 1998 (19.11.98)		
US	60/113,796 (CIP)		
Filed on	22 December 1998 (22.12.98)		
US	09/229,005 (CIP)		
Filed on	12 January 1999 (12.01.99)		
US	Not furnished (CIP)		
Filed on	12 January 1999 (12.01.99)		
(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
		Published Without international search report and to be republished upon receipt of that report.	
(54) Title: PHOSPHORYLATION EFFECTORS			
(57) Abstract			
<p>The invention provides human phosphorylation effectors (PHSP) and polynucleotides which identify and encode PHSP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of PHSP.</p>			

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

## PHOSPHORYLATION EFFECTORS

### TECHNICAL FIELD

5           This invention relates to nucleic acid and amino acid sequences of phosphorylation effectors and to the use of these sequences in the diagnosis, treatment, and prevention of cell proliferative, immune, and neuronal disorders.

          Kinases and phosphatases are critical components of intracellular signal transduction  
10 mechanisms. Kinases catalyze the transfer of high energy phosphate groups from adenosine triphosphate (ATP) to various target proteins. Phosphatases, in contrast, remove phosphate groups from proteins. Reversible protein phosphorylation is the main strategy for regulating protein activity in eukaryotic cells. In general, proteins are activated by phosphorylation in response to extracellular signals such as hormones, neurotransmitters, and growth and differentiation factors.  
15 Protein dephosphorylation occurs when down-regulation of a signaling pathway is required. The coordinate activities of kinases and phosphatases regulate key cellular processes such as proliferation, differentiation, and cell cycle progression. Kinases comprise the largest known enzyme superfamily and are widely varied in their substrate specificities. Kinases may be categorized based on the specific amino acid residues that are phosphorylated in their substrates:  
20 protein tyrosine kinases (PTK) phosphorylate tyrosine residues, and protein serine/threonine kinases (STK) phosphorylate serine and/or threonine residues. Almost all kinases contain a conserved 250-300 amino acid catalytic domain. This domain can be further divided into 11 subdomains. N-terminal subdomains I-IV fold into a two-lobed structure which binds and orients the ATP donor molecule, and subdomain V spans the two lobes. C-terminal subdomains VIA-XI  
25 bind the protein substrate and transfer the gamma phosphate from ATP to the hydroxyl group of a serine, threonine, or tyrosine residue. Each of the 11 subdomains contains specific catalytic residues or amino acid motifs characteristic of that subdomain. For example, subdomain I contains an 8-amino acid glycine-rich ATP binding consensus motif, subdomain II contains a critical lysine residue required for maximal catalytic activity, and subdomains VI and IX comprise  
30 the highly conserved catalytic core. Kinases may also be categorized by additional amino acid sequences, generally between 5 and 100 residues, which either flank or occur within the kinase domain. These additional amino acid sequences regulate kinase activity and determine substrate specificity. (Reviewed in Hardie, G. and Hanks, S. (1995) The Protein Kinase Facts Books, Vol I:7-20 Academic Press, San Diego, CA.)

35           STKs include both protein kinase A (PKA) and calcium-dependent protein kinase C

(PKC), both of which transduce signals from plasma membrane receptors. The activities of PKA and PKC are directly regulated by second messenger signaling molecules such as cyclic AMP and diacylglycerol, respectively. A novel kinase identified by genetic analysis in the fission yeast Schizosaccharomyces pombe is encoded by the *cek1*<sup>+</sup> gene and is related to both PKA and PKC  
5 (Samejima, I. and Yanagida, M. (1994) Mol. Cell. Biol. 14:6361-6371). *cek1*<sup>+</sup> encodes an unusually large kinase of 1309 amino acids. The kinase domain spans residues 585 to 987, and 112 additional amino acids are present in this domain between subdomains VII and VIII. Overexpression of *cek1*<sup>+</sup> suppresses mutations in *cut8*<sup>+</sup>, a gene required for chromosome segregation during mitosis. Therefore, *cek1*<sup>+</sup> may encode a unique member of the PKA/PKC  
10 protein family with a role in mitotic signaling and cell cycle progression.

PTKs may be classified as either transmembrane or nontransmembrane proteins.

Transmembrane tyrosine kinases function as receptors for most growth factors. Binding of growth factor to the receptor activates the transfer of a phosphate group from ATP to selected tyrosine side chains of the receptor itself and other specific second messenger proteins. Growth factors  
15 (GF) that associate with receptor PTKs include epidermal GF, platelet-derived GF, fibroblast GF, hepatocyte GF, insulin and insulin-like GFs, nerve GF, vascular endothelial GF, and macrophage colony stimulating factor. Nontransmembrane PTKs form signaling complexes with the cytosolic domains of plasma membrane receptors. Receptors that signal through nontransmembrane PTKs include cytokine, hormone, and antigen-specific lymphocytic receptors. Many PTKs were first  
20 identified as oncogene products in cancer cells in which PTK activation was no longer subject to normal cellular controls. In fact, about one third of the known oncogenes encode PTKs. Furthermore, cellular transformation (oncogenesis) is often accompanied by increased tyrosine phosphorylation activity (Charbonneau, H. and Tonks, N. K. (1992) Annu. Rev. Cell Biol. 8:463-93). Regulation of PTK activity may therefore be an important strategy in controlling some  
25 types of cancer.

Some kinases utilize carbohydrates as their substrates and are important for glucose metabolism. For example, glycolysis employs four distinct kinases to effect the conversion of glucose to pyruvate, a key metabolite in the production of ATP. One of these enzymes is phosphofructokinase (PFK) which catalyzes the transfer of phosphate from ATP to fructose 6-  
30 phosphate. PFK is an allosteric enzyme and a key regulator of glycolysis. In certain genetic muscle disorders, such as muscle phosphofructokinase deficiency type VII, phosphofructokinase activity is absent in muscle and deficient in red blood cells. As a result, afflicted individuals suffer from mild hemolytic anemia and muscle pain (Isselbacher, K.J. et al. (1994) Harrison's Principles of Internal Medicine, McGraw-Hill, New York, NY, p. 2102).

35 Kinase-mediated phosphorylation is antagonized by the activity of phosphatases, which

remove phosphate groups by hydrolysis. Phosphatases are classified into one of three evolutionarily distinct families: the protein serine/threonine phosphatases (PPs), the protein tyrosine phosphatases, and the acid/alkaline phosphatases. PPs may be further categorized into four distinct groups: PP-I, PP-IIA, PP-IIB, and PP-IIC. (Cohen, P. (1989) *Annu. Rev. Biochem.* 58:453-508). PP-I, in particular, dephosphorylates many of the proteins phosphorylated by PKA and is therefore an important regulator of signal transduction pathways. Kinase-activated proteins which bind to and inhibit PP-I have been identified. These inhibitors potentiate the activity of kinases such as PKA by allowing protein substrates to remain in their phosphorylated, activated state. A novel inhibitor of PP-1 has been purified from porcine aorta (Eto, M. et al. (1995) *J. Biochem.* 118:1104-1107; Eto, M. et al. (1997) *FEBS Lett.* 410:356-360). This inhibitor, called CPI17, is 147 amino acids in length and is activated by PKC. CPI17 expression is restricted to smooth muscle tissues such as aorta and bladder, suggesting that CPI17 functions in PKC-mediated signal transduction pathways in these tissues, possibly through a calcium-dependent mechanism.

15       The discovery of new phosphorylation effectors and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cell proliferative, immune, and neuronal disorders.

#### SUMMARY OF THE INVENTION

20

The invention features substantially purified polypeptides, phosphorylation effectors, referred to collectively as "PHSP" and individually as "PHSP-1 to PHSP-31". In one aspect, the invention provides a substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-31, and fragments thereof.

25

The invention further provides a substantially purified variant having at least 90% amino acid identity to at least one of the amino acid sequences selected from the group consisting of SEQ ID NO:1-31, and fragments thereof. The invention also provides an isolated and purified polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-31, and fragments thereof. The invention also includes an isolated and purified polynucleotide variant having at least 80% polynucleotide sequence identity to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-31, and fragments thereof.

30

Additionally, the invention provides an isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-31, and fragments

35

thereof. The invention also provides an isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide encoding the polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1-31, and fragments thereof.

The invention also provides a method for detecting a polynucleotide in a sample  
5 containing nucleic acids, the method comprising the steps of (a) hybridizing the complement of the polynucleotide sequence to at least one of the polynucleotides of the sample, thereby forming a hybridization complex; and (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of a polynucleotide in the sample. In one aspect, the method further comprises amplifying the polynucleotide prior to hybridization.

10 The invention also provides an isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:32-62, and fragments thereof. The invention further provides an isolated and purified polynucleotide variant having at least 80% polynucleotide sequence identity to the polynucleotide sequence selected from the group consisting of SEQ ID NO:32-62, and fragments thereof. The invention also provides an  
15 isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:32-62, and fragments thereof.

The invention further provides an expression vector containing at least a fragment of the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the  
20 group consisting of SEQ ID NO:1-31, and fragments thereof. In another aspect, the expression vector is contained within a host cell.

The invention also provides a method for producing a polypeptide, the method comprising the steps of: (a) culturing the host cell containing an expression vector containing at least a fragment of a polynucleotide under conditions suitable for the expression of the polypeptide; and  
25 (b) recovering the polypeptide from the host cell culture.

The invention also provides a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-31, and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

The invention further includes a purified antibody which binds to a polypeptide selected  
30 from the group consisting of SEQ ID NO:1-31, and fragments thereof. The invention also provides a purified agonist and a purified antagonist to the polypeptide.

The invention also provides a method for treating or preventing a disorder associated with decreased expression or activity of PHSP, the method comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a  
35 substantially purified polypeptide having the amino acid sequence selected from the group

consisting of SEQ ID NO:1-31, and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

The invention also provides a method for treating or preventing a disorder associated with increased expression or activity of PHSP, the method comprising administering to a subject in  
5 need of such treatment an effective amount of an antagonist of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-31, and fragments thereof.

### BRIEF DESCRIPTION OF THE TABLES

Table 1 shows nucleotide and polypeptide sequence identification numbers (SEQ ID NO),  
10 clone identification numbers (clone ID), cDNA libraries, and cDNA fragments used to assemble full-length sequences encoding PHSP.

Table 2 shows features of each polypeptide sequence, including potential motifs, homologous sequences, and methods and algorithms used for identification of PHSP.

Table 3 shows the tissue-specific expression patterns of each nucleic acid sequence as  
15 determined by northern analysis, diseases, disorders, or conditions associated with these tissues, and the vector into which each cDNA was cloned.

Table 4 describes the tissues used to construct the cDNA libraries from which cDNA clones encoding PHSP were isolated.

Table 5 shows the tools, programs, and algorithms used to analyze PHSP, along with  
20 applicable descriptions, references, and threshold parameters.

### DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods  
25 described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for  
30 example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention  
35 belongs. Although any machines, materials, and methods similar or equivalent to those described

herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

#### DEFINITIONS

"PHSP" refers to the amino acid sequences of substantially purified PHSP obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and preferably the human species, from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which, when bound to PHSP, increases or prolongs the duration of the effect of PHSP. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to and modulate the effect of PHSP.

An "allelic variant" is an alternative form of the gene encoding PHSP. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding PHSP include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polynucleotide the same as PHSP or a polypeptide with at least one functional characteristic of PHSP. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding PHSP, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding PHSP. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent PHSP. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of PHSP is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, positively charged amino acids may include lysine and arginine, and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine,



and valine; glycine and alanine; asparagine and glutamine; serine and threonine; and phenylalanine and tyrosine.

The terms "amino acid" or "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. In this context, "fragments," "immunogenic fragments," or "antigenic fragments" refer to fragments of PHSP which are preferably at least 5 to about 15 amino acids in length, most preferably at least 14 amino acids, and which retain some biological activity or immunological activity of PHSP. Where "amino acid sequence" is recited to refer to an amino acid sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

The term "antagonist" refers to a molecule which, when bound to PHSP, decreases the amount or the duration of the effect of the biological or immunological activity of PHSP. Antagonists may include proteins, nucleic acids, carbohydrates, antibodies, or any other molecules which decrease the effect of PHSP.

The term "antibody" refers to intact molecules as well as to fragments thereof, such as Fab, F(ab')<sub>2</sub>, and Fv fragments, which are capable of binding the epitopic determinant. Antibodies that bind PHSP polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant" refers to that fragment of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (given regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense" refers to any composition containing a nucleic acid sequence which is complementary to the "sense" strand of a specific nucleic acid sequence. Antisense molecules may be produced by any method including synthesis or transcription. Once introduced into a cell,

the complementary nucleotides combine with natural sequences produced by the cell to form duplexes and to block either transcription or translation. The designation "negative" can refer to the antisense strand, and the designation "positive" can refer to the sense strand.

The term "biologically active," refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic PHSP, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The terms "complementary" or "complementarity" refer to the natural binding of polynucleotides by base pairing. For example, the sequence "5' A-G-T 3'" bonds to the complementary sequence "3' T-C-A 5'." Complementarity between two single-stranded molecules may be "partial," such that only some of the nucleic acids bind, or it may be "complete," such that total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acids strands, and in the design and use of peptide nucleic acid (PNA) molecules.

A "composition comprising a given polynucleotide sequence" or a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding PHSP or fragments of PHSP may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, extended using the XL-PCR kit (Perkin-Elmer, Norwalk CT) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from the overlapping sequences of more than one Incyte Clone using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI). Some sequences have been both extended and assembled to produce the consensus sequence.

The term "correlates with expression of a polynucleotide" indicates that the detection of the presence of nucleic acids, the same or related to a nucleic acid sequence encoding PHSP, by northern analysis is indicative of the presence of nucleic acids encoding PHSP in a sample, and

thereby correlates with expression of the transcript from the polynucleotide encoding PHSP.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to the chemical modification of a polypeptide sequence, or a  
5 polynucleotide sequence. Chemical modifications of a polynucleotide sequence can include, for  
example, replacement of hydrogen by an alkyl, acyl, or amino group. A derivative polynucleotide  
encodes a polypeptide which retains at least one biological or immunological function of the  
natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any  
similar process that retains at least one biological or immunological function of the polypeptide  
10 from which it was derived.

The term "similarity" refers to a degree of complementarity. There may be partial  
similarity or complete similarity. The word "identity" may substitute for the word "similarity." A  
partially complementary sequence that at least partially inhibits an identical sequence from  
hybridizing to a target nucleic acid is referred to as "substantially similar." The inhibition of  
15 hybridization of the completely complementary sequence to the target sequence may be examined  
using a hybridization assay (Southern or northern blot, solution hybridization, and the like) under  
conditions of reduced stringency. A substantially similar sequence or hybridization probe will  
compete for and inhibit the binding of a completely similar (identical) sequence to the target  
sequence under conditions of reduced stringency. This is not to say that conditions of reduced  
20 stringency are such that non-specific binding is permitted, as reduced stringency conditions  
require that the binding of two sequences to one another be a specific (i.e., a selective) interaction.  
The absence of non-specific binding may be tested by the use of a second target sequence which  
lacks even a partial degree of complementarity (e.g., less than about 30% similarity or identity).  
In the absence of non-specific binding, the substantially similar sequence or probe will not  
25 hybridize to the second non-complementary target sequence.

The phrases "percent identity" and "% identity" refer to the percentage of sequence  
similarity found in a comparison of two or more amino acid or nucleic acid sequences. Percent  
identity can be determined electronically, e.g., by using the MEGALIGN program (DNASTAR,  
Madison WI) which creates alignments between two or more sequences according to methods  
30 selected by the user, e.g., the clustal method. (See, e.g., Higgins, D.G. and P.M. Sharp (1988)  
Gene 73:237-244.) The clustal algorithm groups sequences into clusters by examining the  
distances between all pairs. The clusters are aligned pairwise and then in groups. The percentage  
similarity between two amino acid sequences, e.g., sequence A and sequence B, is calculated by  
dividing the length of sequence A, minus the number of gap residues in sequence A, minus the  
35 number of gap residues in sequence B, into the sum of the residue matches between sequence A

and sequence B, times one hundred. Gaps of low or of no similarity between the two amino acid sequences are not included in determining percentage similarity. Percent identity between nucleic acid sequences can also be counted or calculated by other methods known in the art, e.g., the Jotun Hein method. (See, e.g., Hein, J. (1990) *Methods Enzymol.* 183:626-645.) Identity between  
5 sequences can also be determined by other methods known in the art, e.g., by varying hybridization conditions.

"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for stable mitotic chromosome segregation and maintenance.

10 The term "humanized antibody" refers to antibody molecules in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

"Hybridization" refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing.

15 The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g.,  $C_0t$  or  $R_0t$  analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate  
20 substrate to which cells or their nucleic acids have been fixed).

The words "insertion" or "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively, to the sequence found in the naturally occurring molecule.

"Immune response" can refer to conditions associated with inflammation, trauma, immune  
25 disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

The term "microarray" refers to an arrangement of distinct polynucleotides on a substrate.

The terms "element" or "array element" in a microarray context, refer to hybridizable  
30 polynucleotides arranged on the surface of a substrate.

The term "modulate" refers to a change in the activity of PHSP. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of PHSP.

The phrases "nucleic acid" or "nucleic acid sequence," as used herein, refer to a  
35 nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to

DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material. In this context, "fragments" refers to those nucleic acid sequences which, comprise a region of unique polynucleotide sequence that specifically identifies  
5 SEQ ID NO:32-62, for example, as distinct from any other sequence in the same genome. For example, a fragment of SEQ ID NO:32-62 is useful in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:32-62 from related polynucleotide sequences. A fragment of SEQ ID NO:32-62 is at least about 15-20 nucleotides in length. The precise length of the fragment of SEQ ID NO:32-62 and the region of SEQ ID  
10 NO:32-62 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment. In some cases, a fragment, when translated, would produce polypeptides retaining some functional characteristic, e.g., antigenicity, or structural domain characteristic, e.g., ATP-binding site, of the full-length polypeptide

The terms "operably associated" or "operably linked" refer to functionally related nucleic  
15 acid sequences. A promoter is operably associated or operably linked with a coding sequence if the promoter controls the translation of the encoded polypeptide. While operably associated or operably linked nucleic acid sequences can be contiguous and in the same reading frame, certain genetic elements, e.g., repressor genes, are not contiguously linked to the sequence encoding the polypeptide but still bind to operator sequences that control expression of the polypeptide.

20 The term "oligonucleotide" refers to a nucleic acid sequence of at least about 6 nucleotides to 60 nucleotides, preferably about 15 to 30 nucleotides, and most preferably about 20 to 25 nucleotides, which can be used in PCR amplification or in a hybridization assay or microarray. "Oligonucleotide" is substantially equivalent to the terms "amplimer," "primer," "oligomer," and "probe," as these terms are commonly defined in the art.

25 "Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

30 The term "sample" is used in its broadest sense. A sample suspected of containing nucleic acids encoding PHSP, or fragments thereof, or PHSP itself, may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" or "specifically binding" refer to that interaction between a  
35 protein or peptide and an agonist, an antibody, or an antagonist. The interaction is dependent upon

the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide containing the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds  
5 to the antibody.

The term "stringent conditions" refers to conditions which permit hybridization between polynucleotides and the claimed polynucleotides. Stringent conditions can be defined by salt concentration, the concentration of organic solvent, e.g., formamide, temperature, and other conditions well known in the art. In particular, stringency can be increased by reducing the  
10 concentration of salt, increasing the concentration of formamide, or raising the hybridization temperature.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least about 60% free, preferably about 75% free, and most preferably about 90% free from other components with  
15 which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers,  
20 microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

"Transformation" describes a process by which exogenous DNA enters and changes a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of  
25 foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed" cells includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host  
30 chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "variant" of PHSP polypeptides refers to an amino acid sequence that is altered by one or more amino acid residues. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties (e.g., replacement of leucine with  
35 isoleucine). More rarely, a variant may have "nonconservative" changes (e.g., replacement of

glycine with tryptophan). Analogous minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, LASERGENE software (DNASTAR).

5       The term "variant," when used in the context of a polynucleotide sequence, may encompass a polynucleotide sequence related to PHSP. This definition may also include, for example, "allelic" (as defined above), "splice," "species," or "polymorphic" variants. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The  
10       corresponding polypeptide may possess additional functional domains or an absence of domains. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide  
15       polymorphisms" (SNPs) in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

#### THE INVENTION

      The invention is based on the discovery of new human phosphorylation effectors (PHSP),  
20       the polynucleotides encoding PHSP, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative, immune, and neuronal disorders.

      Table 1 lists the Incyte clones used to assemble full length nucleotide sequences encoding PHSP. Columns 1 and 2 show the sequence identification numbers (SEQ ID NOs) of the polypeptide and nucleotide sequences, respectively. Column 3 shows the clone IDs of the Incyte  
25       clones in which nucleic acids encoding each PHSP were identified, and column 4 shows the cDNA libraries from which these clones were isolated. Column 5 shows Incyte clones and their corresponding cDNA libraries. Clones for which cDNA libraries are not indicated were derived from pooled cDNA libraries. The clones in column 5 were used to assemble the consensus nucleotide sequence of each PHSP and are useful as fragments in hybridization technologies.

30       The columns of Table 2 show various properties of each of the polypeptides of the invention: column 1 references the SEQ ID NO and column 2 shows the number of amino acid residues in each polypeptide. Columns 3 and 4 show potential phosphorylation sites and potential glycosylation sites, respectively. Column 5 shows the amino acid residues comprising signature sequences and motifs. Column 6 shows homologous sequences as identified by BLAST analysis,  
35       while column 7 shows analytical methods used to identify each polypeptide through sequence

homology and protein motifs.

The columns of Table 3 show the tissue-specificity and diseases, disorders, or conditions associated with nucleotide sequences encoding PHSP. The first column of Table 3 lists the SEQ ID NOs. Column 2 lists tissue categories which express PHSP as a fraction of total tissue  
 5 categories expressing PHSP. Column 3 lists diseases, disorders, or conditions associated with those tissues expressing PHSP. Column 4 lists the vectors used to subclone the cDNA library.

The columns of Table 4 show descriptions of the tissues used to construct the cDNA libraries from which cDNA clones encoding PHSP were isolated. Column 1 references the SEQ ID NO, column 2 shows the cDNA libraries from which these clones were isolated, and column 3  
 10 shows the tissue origins and other descriptive information relevant to the cDNA libraries in column 2.

The following fragments of the nucleotide sequences encoding PHSP are useful, for example, in hybridization or amplification technologies to identify SEQ ID NO:32-62 and to distinguish between SEQ ID NO:32-62 and related polynucleotide sequences. The useful  
 15 fragments include, the fragment of SEQ ID NO:32 from about nucleotide 81 to about nucleotide 110; the fragment of SEQ ID NO:33 from about nucleotide 323 to about nucleotide 352; the fragment of SEQ ID NO:34 from about nucleotide 83 to about nucleotide 112; the fragment of SEQ ID NO:35 from about nucleotide 524 to about nucleotide 553; the fragment of SEQ ID NO:36 from about nucleotide 275 to about nucleotide 346; the fragment of SEQ ID NO:37 from  
 20 about nucleotide 1328 to about nucleotide 1396; the fragment of SEQ ID NO:38 from about nucleotide 245 to about nucleotide 304; the fragment of SEQ ID NO:39 from about nucleotide 1253 to about nucleotide 1312; the fragment of SEQ ID NO:41 from about nucleotide 117 to about nucleotide 170; the fragments of SEQ ID NO:42 from about nucleotide 109 to about nucleotide 153, and from about nucleotide 325 to about nucleotide 369; the fragments of SEQ ID NO:43 from  
 25 about nucleotide 380 to about nucleotide 424, and from about nucleotide 1190 to about nucleotide 1234; the fragment of SEQ ID NO:44 from about nucleotide 1 to about nucleotide 46; the fragment of SEQ ID NO:45 from about nucleotide 533 to about nucleotide 577; the fragments of SEQ ID NO:46 from about nucleotide 109 to about nucleotide 153, and from about nucleotide 379 to about nucleotide 423; the fragment of SEQ ID NO:47 from about nucleotide 1730 to about  
 30 nucleotide 1774; the fragment of SEQ ID NO:48 from about nucleotide 433 to about nucleotide 477; the fragment of SEQ ID NO:49 from about nucleotide 1117 to about nucleotide 1155; the fragment of SEQ ID NO:50 from about nucleotide 166 to about nucleotide 213; the fragment of SEQ ID NO:51 from about nucleotide 60 to about nucleotide 95; the fragment of SEQ ID NO:52 from about nucleotide 326 to about nucleotide 370; the fragment of SEQ ID NO:53 from about  
 35 nucleotide 25 to about nucleotide 66; the fragment of SEQ ID NO:54 from about nucleotide 55 to



about nucleotide 102; the fragment of SEQ ID NO:55 from about nucleotide 138 to about nucleotide 167; the fragment of SEQ ID NO:56 from about nucleotide 29 to about nucleotide 58; the fragment of SEQ ID NO:57 from about nucleotide 455 to about nucleotide 484; the fragment of SEQ ID NO:58 from about nucleotide 226 to about nucleotide 255; the fragment of SEQ ID NO:59 from about nucleotide 557 to about nucleotide 598; the fragment of SEQ ID NO:60 from about nucleotide 284 to about nucleotide 325; the fragment of SEQ ID NO:61 from about nucleotide 1043 to about nucleotide 1090; and the fragment of SEQ ID NO:62 from about nucleotide 84 to about nucleotide 132. The polypeptides encoded by the fragments of SEQ ID NO:32-62 are useful, for example, as immunogenic peptides.

10       The invention also encompasses PHSP variants. A preferred PHSP variant is one which has at least about 80%, more preferably at least about 90%, and most preferably at least about 95% amino acid sequence identity to the PHSP amino acid sequence, and which contains at least one functional or structural characteristic of PHSP.

      The invention also encompasses polynucleotides which encode PHSP. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:32-62, which encodes PHSP.

      The invention also encompasses a variant of a polynucleotide sequence encoding PHSP. In particular, such a variant polynucleotide sequence will have at least about 80%, more preferably at least about 85%, and most preferably at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding PHSP. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:32-62 which has at least about 80%, more preferably at least about 85%, and most preferably at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:32-62. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of PHSP.

      It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding PHSP, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring PHSP, and all such variations are to be considered as being specifically disclosed.

      Although nucleotide sequences which encode PHSP and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring PHSP under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding

PHSP or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide  
5 sequence encoding PHSP and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode PHSP and PHSP derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the  
10 synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding PHSP or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID  
15 NO:32-62 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.* 152:507-511.) For example, stringent salt concentration will ordinarily be less than about 750 mM NaCl and 75 mM trisodium citrate, preferably less than about 500 mM NaCl and 50 mM trisodium citrate, and most preferably less than about 250 mM NaCl and 25 mM trisodium citrate. Low  
20 stringency hybridization can be obtained in the absence of organic solvent, e.g., formamide, while high stringency hybridization can be obtained in the presence of at least about 35% formamide, and most preferably at least about 50% formamide. Stringent temperature conditions will ordinarily include temperatures of at least about 30°C, more preferably of at least about 37°C, and most preferably of at least about 42°C. Varying additional parameters, such as hybridization time, the  
25 concentration of detergent, e.g., sodium dodecyl sulfate (SDS), and the inclusion or exclusion of carrier DNA, are well known to those skilled in the art. Various levels of stringency are accomplished by combining these various conditions as needed. In a preferred embodiment, hybridization will occur at 30°C in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS. In a more preferred embodiment, hybridization will occur at 37°C in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35%  
30 formamide, and 100 µg/ml denatured salmon sperm DNA (ssDNA). In a most preferred embodiment, hybridization will occur at 42°C in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50 % formamide, and 200 µg/ml ssDNA. Useful variations on these conditions will be readily apparent to those skilled in the art.

The washing steps which follow hybridization can also vary in stringency. Wash stringency  
35 conditions can be defined by salt concentration and by temperature. As above, wash stringency can

be increased by decreasing salt concentration or by increasing temperature. For example, stringent salt concentration for the wash steps will preferably be less than about 30 mM NaCl and 3 mM trisodium citrate, and most preferably less than about 15 mM NaCl and 1.5 mM trisodium citrate. Stringent temperature conditions for the wash steps will ordinarily include temperature of at least  
5 about 25°C, more preferably of at least about 42°C, and most preferably of at least about 68°C. In a preferred embodiment, wash steps will occur at 25°C in 30 mM NaCl, 3 mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, wash steps will occur at 42°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. In a most preferred embodiment, wash steps will occur at 68°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. Additional variations on these conditions will  
10 be readily apparent to those skilled in the art.

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Perkin-Elmer), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations  
15 of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 (Hamilton, Reno NV), Peltier thermal cycler 200 (PTC200; MJ Research, Watertown MA) and the ABI CATALYST 800 (Perkin-Elmer). Sequencing is then carried out using the ABI 373 or 377 DNA sequencing systems (Perkin-Elmer), or the MEGABACE  
20 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

25 The nucleic acid sequences encoding PHSP may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) *PCR Methods Applic.* 2:318-322.)  
30 Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) *Nucleic Acids Res.* 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et  
35 al. (1991) *PCR Methods Applic.* 1:111-119.) In this method, multiple restriction enzyme digestions

and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) *Nucleic Acids Res.* 19:3055-306). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Perkin-Elmer), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode PHSP may be cloned in recombinant DNA molecules that direct expression of PHSP, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express PHSP.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter PHSP-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction

sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

In another embodiment, sequences encoding PHSP may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucl. Acids Res. Symp. Ser. 215-223, and Horn, T. et al. (1980) Nucl. Acids Res. Symp. Ser. 225-232.)

5 Alternatively, PHSP itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solid-phase techniques. (See, e.g., Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A Peptide Synthesizer (Perkin-Elmer). Additionally, the amino acid sequence of PHSP, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other  
10 proteins, or any part thereof, to produce a variant polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.)

The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New  
15 York NY.)

In order to express a biologically active PHSP, the nucleotide sequences encoding PHSP or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and  
20 inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding PHSP. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding PHSP. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding PHSP and its initiation codon and upstream regulatory sequences are inserted into  
25 the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion  
30 of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding PHSP and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and  
35 in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory

Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding PHSP. These include, but are not limited to, microorganisms such as bacteria transformed  
5 with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. The invention is not limited by the host cell employed.

10 In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding PHSP. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding PHSP can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or pSPORT1 plasmid (Life Technologies). Ligation of sequences encoding PHSP into the vector's multiple cloning site  
15 disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of PHSP are needed, e.g. for the production of antibodies,  
20 vectors which direct high level expression of PHSP may be used. For example, vectors containing the strong, inducible T5 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of PHSP. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct  
25 either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra; Grant et al. (1987) Methods Enzymol. 153:516-54; and Scorer, C. A. et al. (1994) Bio/Technology 12:181-184.)

Plant systems may also be used for expression of PHSP. Transcription of sequences encoding PHSP may be driven viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in  
30 combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See,  
35 e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY,

pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding PHSP may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader  
5 sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses PHSP in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

10 Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat Genet. 15:345-355.)

15 For long term production of recombinant proteins in mammalian systems, stable expression of PHSP in cell lines is preferred. For example, sequences encoding PHSP can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before  
20 being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These  
25 include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk* or *apr* cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides, neomycin and G-418; and *als* or *pat*  
30 confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP;  
35 Clontech),  $\beta$  glucuronidase and its substrate  $\beta$ -glucuronide, or luciferase and its substrate luciferin may

be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) *Methods Mol. Biol.* 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding PHSP is inserted within a marker gene sequence, transformed cells containing sequences encoding PHSP can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding PHSP under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding PHSP and that express PHSP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of PHSP using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on PHSP is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St Paul MN, Sect. IV; Coligan, J. E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding PHSP include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding PHSP, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for



ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding PHSP may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein  
5 produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode PHSP may be designed to contain signal sequences which direct secretion of PHSP through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the  
10 inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational  
15 activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC, Bethesda MD) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding PHSP may be ligated to a heterologous sequence resulting in translation of a  
20 fusion protein in any of the aforementioned host systems. For example, a chimeric PHSP protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of PHSP activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST),  
25 maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity  
30 purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the PHSP encoding sequence and the heterologous protein sequence, so that PHSP may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, *supra*, ch 10). A variety of commercially available kits may also be used to facilitate expression and purification of  
35 fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled PHSP may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract systems (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, preferably  $^{35}\text{S}$ -methionine.

Fragments of PHSP may be produced not only by recombinant production, but also by direct peptide synthesis using solid-phase techniques. (See, e.g., Creighton, supra, pp. 55-60.) Protein synthesis may be performed by manual techniques or by automation. Automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin-Elmer). Various fragments of PHSP may be synthesized separately and then combined to produce the full length molecule.

### THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of PHSP and protein phosphatases. In addition, the expression of PHSP is closely associated with reproductive tissue, nervous tissue, gastrointestinal tissue, cell proliferation, cancer, inflammation, and immune response. Therefore, PHSP appears to play a role in cell proliferative, immune, and neuronal disorders. In the treatment of disorders associated with increased PHSP expression or activity, it is desirable to decrease the expression or activity of PHSP. In the treatment of disorders associated with decreased PHSP expression or activity, it is desirable to increase the expression or activity of PHSP.

Therefore, in one embodiment, PHSP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PHSP. Examples of such disorders include, but are not limited to, a cell proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an immune disorder, such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis,

hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner  
5 syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; and a neuronal disorder, such as akathisia, Alzheimer's disease, amnesia, amyotrophic lateral sclerosis, bipolar disorder, catatonia, dementia, depression, diabetic neuropathy, Down's syndrome, tardive dyskinesia, dystonias, epilepsy, Huntington's disease, peripheral neuropathy, multiple sclerosis, neurofibromatosis, Parkinson's  
10 disease, paranoid psychoses, postherpetic neuralgia, schizophrenia, and Tourette's disorder.

In another embodiment, a vector capable of expressing PHSP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PHSP including, but not limited to, those described above.

In a further embodiment, a pharmaceutical composition comprising a substantially purified  
15 PHSP in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PHSP including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of PHSP may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity  
20 of PHSP including, but not limited to, those listed above.

In a further embodiment, an antagonist of PHSP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of PHSP. Examples of such disorders include, but are not limited to, those described above. In one aspect, an antibody which specifically binds PHSP may be used directly as an antagonist or indirectly as a targeting or delivery  
25 mechanism for bringing a pharmaceutical agent to cells or tissue which express PHSP.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding PHSP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of PHSP including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary  
30 sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic  
35 efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of PHSP may be produced using methods which are generally known in the art. In particular, purified PHSP may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind PHSP. Antibodies to PHSP may also be generated using methods that are well known in the art. Such antibodies may include, but are not  
5 limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with PHSP or with any fragment or oligopeptide thereof  
10 which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

15 It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to PHSP have an amino acid sequence consisting of at least about 5 amino acids, and, more preferably, of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein and contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of PHSP amino acids may be  
20 fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to PHSP may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma  
25 technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. 80:2026-2030; and Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate  
30 antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce PHSP-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be  
35 generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton

D.R. (1991) Proc. Natl. Acad. Sci. 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. 86: 3833-3837; 5 Winter, G. et al. (1991) Nature 349:293-299.)

Antibody fragments which contain specific binding sites for PHSP may also be generated. For example, such fragments include, but are not limited to, F(ab')<sub>2</sub> fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')<sub>2</sub> fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and 10 easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such 15 immunoassays typically involve the measurement of complex formation between PHSP and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering PHSP epitopes is preferred, but a competitive binding assay may also be employed (Pound, supra).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay 20 techniques may be used to assess the affinity of antibodies for PHSP. Affinity is expressed as an association constant,  $K_a$ , which is defined as the molar concentration of PHSP-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The  $K_a$  determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple PHSP epitopes, represents the average affinity, or avidity, of the antibodies for 25 PHSP. The  $K_a$  determined for a preparation of monoclonal antibodies, which are monospecific for a particular PHSP epitope, represents a true measure of affinity. High-affinity antibody preparations with  $K_a$  ranging from about  $10^9$  to  $10^{12}$  L/mole are preferred for use in immunoassays in which the PHSP-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with  $K_a$  ranging from about  $10^6$  to  $10^7$  L/mole are preferred for use in immunopurification and similar 30 procedures which ultimately require dissociation of PHSP, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington, DC; Liddell, J. E. and Cryer, A. (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to 35 determine the quality and suitability of such preparations for certain downstream applications. For

example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is preferred for use in procedures requiring precipitation of PHSP-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra,  
5 and Coligan et al. supra.)

In another embodiment of the invention, the polynucleotides encoding PHSP, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding PHSP may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary  
10 to polynucleotides encoding PHSP. Thus, complementary molecules or fragments may be used to modulate PHSP activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding PHSP.

Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or  
15 from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used to construct vectors to express nucleic acid sequences complementary to the polynucleotides encoding PHSP. (See, e.g., Sambrook, supra; Ausubel, 1995, supra.)

Genes encoding PHSP can be turned off by transforming a cell or tissue with expression  
20 vectors which express high levels of a polynucleotide, or fragment thereof, encoding PHSP. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector, and may last even longer if appropriate replication elements are part of the  
25 vector system.

As mentioned above, modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5', or regulatory regions of the gene encoding PHSP. Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, are preferred. Similarly,  
30 inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A  
35 complementary sequence or antisense molecule may also be designed to block translation of mRNA

by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding PHSP.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding PHSP. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable for use *in vivo*, *in vitro*, and *ex vivo*. For *ex vivo* therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nature Biotechnology 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such

therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

An additional embodiment of the invention relates to the administration of a pharmaceutical or sterile composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of PHSP, antibodies to PHSP, and mimetics, agonists, antagonists, or inhibitors of PHSP. The compositions may be administered alone or in combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs, or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combining active compounds with solid excipient and processing the resultant mixture of granules (optionally, after grinding) to obtain tablets or dragee cores. Suitable auxiliaries can be added, if desired. Suitable excipients include carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, and sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, and alginic acid or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.



Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol.

- 5 Push-fit capsules can contain active ingredients mixed with fillers or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

- Pharmaceutical formulations suitable for parenteral administration may be formulated in  
10 aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil,  
15 or synthetic fatty acid esters, such as ethyl oleate, triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents to increase the solubility of the compounds and allow for the preparation of highly concentrated solutions.

- For topical or nasal administration, penetrants appropriate to the particular barrier to be  
20 permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

- The pharmaceutical composition may be provided as a salt and can be formed with many  
25 acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acid. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder which may contain any or all of the following: 1 mM to 50 mM histidine, 0.1% to 2% sucrose, and 2% to 7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

- 30 After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of PHSP, such labeling would include amount, frequency, and method of administration.

- Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The  
35 determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells or in animal models such as mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for  
5 administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example PHSP or fragments thereof, antibodies of PHSP, and agonists, antagonists or inhibitors of PHSP, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by  
10 calculating the  $ED_{50}$  (the dose therapeutically effective in 50% of the population) or  $LD_{50}$  (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the  $LD_{50}/ED_{50}$  ratio. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such  
15 compositions is preferably within a range of circulating concentrations that includes the  $ED_{50}$  with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the  
20 active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular  
25 formulation.

Normal dosage amounts may vary from about 0.1  $\mu\text{g}$  to 100,000  $\mu\text{g}$ , up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their  
30 inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

#### DIAGNOSTICS

In another embodiment, antibodies which specifically bind PHSP may be used for the diagnosis of disorders characterized by expression of PHSP, or in assays to monitor patients being  
35 treated with PHSP or agonists, antagonists, or inhibitors of PHSP. Antibodies useful for diagnostic

purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for PHSP include methods which utilize the antibody and a label to detect PHSP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter  
5 molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring PHSP, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of PHSP expression. Normal or standard values for PHSP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to PHSP under conditions suitable  
10 for complex formation. The amount of standard complex formation may be quantitated by various methods, preferably by photometric means. Quantities of PHSP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding PHSP may be used for  
15 diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of PHSP may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of PHSP, and to monitor regulation of PHSP levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide  
20 sequences, including genomic sequences, encoding PHSP or closely related molecules may be used to identify nucleic acid sequences which encode PHSP. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification (maximal, high,  
25 intermediate, or low), will determine whether the probe identifies only naturally occurring sequences encoding PHSP, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and should preferably have at least 50% sequence identity to any of the PHSP encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:32-  
30 62 or from genomic sequences including promoters, enhancers, and introns of the PHSP gene.

Means for producing specific hybridization probes for DNAs encoding PHSP include the cloning of polynucleotide sequences encoding PHSP or PHSP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA  
35 polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a

variety of reporter groups, for example, by radionuclides such as  $^{32}\text{P}$  or  $^{35}\text{S}$ , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding PHSP may be used for the diagnosis of disorders associated with expression of PHSP. Examples of such disorders include, but are not limited to, a cell  
5 proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall  
10 bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an immune disorder, such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-  
15 candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation,  
20 osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; and a neuronal disorder, such as akathisia,  
25 Alzheimer's disease, amnesia, amyotrophic lateral sclerosis, bipolar disorder, catatonia, dementia, depression, diabetic neuropathy, Down's syndrome, tardive dyskinesia, dystonias, epilepsy, Huntington's disease, peripheral neuropathy, multiple sclerosis, neurofibromatosis, Parkinson's disease, paranoid psychoses, postherpetic neuralgia, schizophrenia, and Tourette's disorder. The polynucleotide sequences encoding PHSP may be used in Southern or northern analysis, dot blot, or  
30 other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered PHSP expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding PHSP may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide  
35 sequences encoding PHSP may be labeled by standard methods and added to a fluid or tissue sample

from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding PHSP in the sample  
5 indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of PHSP, a normal or standard profile for expression is established. This may be accomplished by combining  
10 body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding PHSP, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples  
15 from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from  
20 successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance  
25 of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding PHSP may involve the use of PCR. These oligomers may be chemically synthesized, generated  
30 enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding PHSP, or a fragment of a polynucleotide complementary to the polynucleotide encoding PHSP, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantitation of closely related DNA or RNA sequences.

35 Methods which may also be used to quantify the expression of PHSP include radiolabeling

or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format where the oligomer of interest is presented in  
5 various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as targets in a microarray. The microarray can be used to monitor the expression level of large numbers of genes simultaneously and to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene  
10 function, to understand the genetic basis of a disorder, to diagnose a disorder, and to develop and monitor the activities of therapeutic agents.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al.  
15 (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.)

In another embodiment of the invention, nucleic acid sequences encoding PHSP may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to  
20 artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome  
25 mapping techniques and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) site. Correlation between the location of the gene encoding PHSP on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder. The nucleotide  
30 sequences of the invention may be used to detect differences in gene sequences among normal, carrier, and affected individuals.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may  
35 reveal associated markers even if the number or arm of a particular human chromosome is not known.

New sequences can be assigned to chromosomal arms by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that  
5 area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) *Nature* 336:577-580.) The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, PHSP, its catalytic or immunogenic fragments, or  
10 oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between PHSP and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds  
15 having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with PHSP, or fragments thereof, and washed. Bound PHSP is then detected by methods well known in the art. Purified PHSP can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively,  
20 non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding PHSP specifically compete with a test compound for binding PHSP. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with PHSP.

25 In additional embodiments, the nucleotide sequences which encode PHSP may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding  
30 description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications, and publications mentioned above and below, in particular U.S. Ser. No. 09/173,482, 09/123,494, 09/152,814, 09/229,005, 60/106,889, 60/109,093,  
35 and 60/113,796, are hereby expressly incorporated by reference.

## EXAMPLES

### I. Construction of cDNA Libraries

RNA was purchased from Clontech or isolated from tissues described in Table 4. Some  
5 tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized  
and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a  
monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged  
over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either  
isopropanol or sodium acetate and ethanol, or by other routine methods.

10 Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA  
purity. In some cases, RNA was treated with DNase. For most libraries, poly(A+) RNA was isolated  
using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN,  
Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was  
isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA  
15 purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA  
libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP  
vector system (Stratagene) or SUPERScript plasmid system (Life Technologies), using the  
recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, *supra*, units  
20 5.1-6.6). Reverse transcription was initiated using oligo d(T) or random primers. Synthetic  
oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the  
appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000  
bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column  
chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs  
25 were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g.,  
PBLUESCRIPT plasmid (Stratagene), pSPORT1 plasmid (Life Technologies), or pINCY (Incyte  
Pharmaceuticals, Palo Alto CA). Recombinant plasmids were transformed into competent *E. coli* cells  
including XL1-BLUE, XL1-BLUERF, or SOLR from Stratagene or DH5 $\alpha$ , DH10B, or  
ELECTROMAX DH10B from Life Technologies.

### 30 II. Isolation of cDNA Clones

Plasmids were recovered from host cells by *in vivo* excision, using the UNIZAP vector  
system (Stratagene) or cell lysis. Plasmids were purified using at least one of the following: a Magic  
or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit  
(Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid,  
35 QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid kit from QIAGEN.



Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) *Anal. Biochem.* 216:1-14). Host cell lysis and thermal  
5 cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a Fluoroskan II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

### III. Sequencing and Analysis

10 cDNA sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Perkin-Elmer) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing  
15 kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing systems (Perkin-Elmer) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading  
20 frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, *supra*, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example V.

The polynucleotide sequences derived from cDNA sequencing were assembled and analyzed using a combination of software programs which utilize algorithms well known to those skilled in the  
25 art. Table 5 summarizes the tools, programs, and algorithms used and provides applicable descriptions, references, and threshold parameters. The first column of Table 5 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other  
30 parameters used to evaluate the strength of a match between two sequences (the higher the score, the greater the homology between two sequences). Sequences were analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR).

The polynucleotide sequences were validated by removing vector, linker, and polyA  
35 sequences and by masking ambiguous bases, using algorithms and programs based on BLAST,

dynamic programing, and dinucleotide nearest neighbor analysis. The sequences were then queried against a selection of public databases, such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS to acquire annotation using programs based on BLAST, FASTA, and BLIMPS. The sequences were assembled into full length polynucleotide sequences  
5 using programs based on Phred, Phrap, and Consed, and were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length amino acid sequences, and these full length sequences were subsequently analyzed by querying against databases such as the GenBank databases (described above), SwissProt, BLOCKS, PRINTS, Prosite, and Hidden Markov Model (HMM)-based  
10 protein family databases such as PFAM. HMM is a probabilistic approach which analyzes consensus primary structures of gene families. (See, e.g., Eddy, S.R. (1996) Curr. Opin. Str. Biol. 6:361-365.)

The programs described above for the assembly and analysis of full length polynucleotide and amino acid sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:32-62. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and  
15 amplification technologies were described in The Invention section above.

#### IV. Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel,  
20 1995, supra, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in nucleotide databases such as GenBank or LIFESEQ database (Incyte Pharmaceuticals). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as  
25 exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within  
30 a 1% to 2% error, and, with a product score of 70, the match will be exact. Similar molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analyses are reported as a percentage distribution of libraries in which the transcript encoding PHSP occurred. Analysis involved the categorization of cDNA libraries by  
35 organ/tissue and disease. The organ/tissue categories included cardiovascular, dermatologic,

developmental, endocrine, gastrointestinal, hematopoietic/immune, musculoskeletal, nervous, reproductive, and urologic. The disease/condition categories included cancer, inflammation/trauma, cell proliferation, neurological, and pooled. For each category, the number of libraries expressing the sequence of interest was counted and divided by the total number of libraries across all categories.

- 5 Percentage values of tissue-specific and disease- or condition-specific expression are reported in Table 3.

#### V. Extension of PHSP Encoding Polynucleotides

The full length nucleic acid sequences of SEQ ID NO:32-62 were produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this  
10 fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer, to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in  
15 hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction  
20 mix contained DNA template, 200 nmol of each primer, reaction buffer containing  $Mg^{2+}$ ,  $(NH_4)_2SO_4$ , and  $\beta$ -mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the  
25 alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100  $\mu$ l PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE  
30 and 0.5  $\mu$ l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5  $\mu$ l to 10  $\mu$ l aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose mini-gel to determine which reactions were successful in extending  
35 the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviII cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulphoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer).

In like manner, the nucleotide sequences of SEQ ID NO:32-62 are used to obtain 5' regulatory sequences using the procedure above, oligonucleotides designed for such extension, and an appropriate genomic library.

#### VI. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:32-62 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 µCi of [ $\gamma$ -<sup>32</sup>P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10<sup>7</sup> counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon

membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are compared.

5 **VII. Microarrays**

A chemical coupling procedure and an ink jet device can be used to synthesize array elements on the surface of a substrate. (See, e.g., Baldeschweiler, supra.) An array analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced by hand  
10 or using available methods and machines and contain any appropriate number of elements. After hybridization, nonhybridized probes are removed and a scanner used to determine the levels and patterns of fluorescence. The degree of complementarity and the relative abundance of each probe which hybridizes to an element on the microarray may be assessed through analysis of the scanned images.

15 Full-length cDNAs, Expressed Sequence Tags (ESTs), or fragments thereof may comprise the elements of the microarray. Fragments suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). Full-length cDNAs, ESTs, or fragments thereof corresponding to one of the nucleotide sequences of the present invention, or selected at random from a cDNA library relevant to the present invention, are arranged on an  
20 appropriate substrate, e.g., a glass slide. The cDNA is fixed to the slide using, e.g., UV cross-linking followed by thermal and chemical treatments and subsequent drying. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645.) Fluorescent probes are prepared and used for hybridization to the elements on the substrate. The substrate is analyzed by procedures described above.

25 **VIII. Complementary Polynucleotides**

Sequences complementary to the PHSP-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring PHSP. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are  
30 designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of PHSP. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the PHSP-encoding transcript.

**IX. Expression of PHSP**

35 Expression and purification of PHSP is achieved using bacterial or virus-based expression

systems. For expression of PHSP in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac (tac)* hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express PHSP upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of PHSP in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding PHSP by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, PHSP is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from PHSP at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch 10 and 16). Purified PHSP obtained by these methods can be used directly in the following activity assay.

#### X. Demonstration of PHSP Activity

PHSP protein kinase is measured by the phosphorylation of a substrate in the presence of gamma-labeled  $^{32}\text{P}$ -ATP. PHSP is incubated with an appropriate substrate and  $^{32}\text{P}$ -ATP in a buffered solution.  $^{32}\text{P}$ -labeled product is separated from free  $^{32}\text{P}$ -ATP by gel electrophoresis or chromatographic procedures, and the incorporated  $^{32}\text{P}$  is quantified by phosphorimage analysis or using a scintillation counter. The amount of  $^{32}\text{P}$  detected is proportional to the activity of PHSP in this assay. The specific amino acid residue phosphorylated by PHSP may be determined by

phosphoamino acid analysis of the labeled, hydrolyzed protein.

PHSP phosphatase activity is measured by the removal of phosphate from a [ $^{32}\text{P}$ ]-labelled substrate. PHSP is incubated with an appropriate [ $^{32}\text{P}$ ]-labelled substrate in a buffered solution. Reaction products are separated by gel electrophoresis or chromatographic procedures, and the level of  $^{32}\text{P}$  associated with the substrate molecule is quantified by phospho-image analysis or scintillation counting. The difference in  $^{32}\text{P}$  associated with untreated substrate versus PHSP-treated substrate is a measure of phosphatase activity and is proportional to PHSP activity.

#### XI. Functional Assays

PHSP function is assessed by expressing the sequences encoding PHSP at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT (Life Technologies) and pCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10  $\mu\text{g}$  of recombinant vector are transiently transfected into a human cell line, preferably of endothelial or hematopoietic origin, using either liposome formulations or electroporation. 1-2  $\mu\text{g}$  of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate properties, for example, their apoptotic state. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M. G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of PHSP on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding PHSP and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art.

Expression of mRNA encoding PHSP and other genes of interest can be analyzed by northern analysis or microarray techniques.

## **XII. Production of PHSP Specific Antibodies**

PHSP substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g.,

- 5 Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the PHSP amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for  
10 selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, *supra*, ch. 11.)

Typically, oligopeptides 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Perkin-Elmer) using fmoc-chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase  
15 immunogenicity. (See, e.g., Ausubel, 1995, *supra*.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide activity by, for example, binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

## **XIII. Purification of Naturally Occurring PHSP Using Specific Antibodies**

20 Naturally occurring or recombinant PHSP is substantially purified by immunoaffinity chromatography using antibodies specific for PHSP. An immunoaffinity column is constructed by covalently coupling anti-PHSP antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

25 Media containing PHSP are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of PHSP (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/PHSP binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and PHSP is collected.

## **30 XIV. Identification of Molecules Which Interact with PHSP**

PHSP, or biologically active fragments thereof, are labeled with <sup>125</sup>I Bolton-Hunter reagent. (See, e.g., Bolton et al. (1973) *Biochem. J.* 133:529.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled PHSP, washed, and any wells with labeled PHSP complex are assayed. Data obtained using different concentrations of PHSP are used to  
35 calculate values for the number, affinity, and association of PHSP with the candidate molecules.



Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific  
5   embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

TABLE 1

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
1	32	132240	BMARNOT02	132240H1 and 132240R1 (BMARNOT02), 3254142H1 (OVRTUT01), 1453821X14F1 and 1453821F6 (PENITUT01)
2	33	2180116	SININOT01	2180116H1 and 2180116T6 (SININOT01), 3046645H1 (HEAANOT01), 1918183H1 (PROSNOT06), and 1482405F1 (CORENOT02)
3	34	2197671	SPLNFET02	2197671H1 (SPLNFET02), 666366X22R1 (SCORNOT01), 693783X14 (SYNORAT03), 824265X33F1 (PROSNOT06), 039482R1 and 039482F1 (HUVENOB01), 1453984T6 (PENITUT01), 1663987H1 (BRSTNOT09), and 125901R1 (LUNGNOT01)
4	35	2594943	OVRTUT02	2594943H1 (OVRTUT02), 3617557H1 (EPIPNOT01), 2269005R6 (UTRSNOT02), 1307764F6 (COLNFET02), 1377794F6 (LUNGNOT10), and 1286608H1 (BRAINOT11)
5	36	1513871	PANCTUT01	754239R6 (BRAITUT02), 1513871H1 (PANCTUT01), 2414420F6 (HNT3AZT01), 3291775F6 (BONRFET01), 3821451F6 (BONSTUT01)
6	37	156108	THP1PLB02	156108F1 and 156108H1 (THP1PLB02), 336346R6 (EOSIHET02), 1319528F1 (BLADNOT04), 2375549F6 (ISLTNOT01), SBFA04563F1, SBFA04977F1
7	38	2883243	UTRSTUT05	1342082F6 (COLNTUT03), 1933387T6 (COLNNOT16), 2766460F6 (BRSTNOT12), 2883243H1 (UTRSTUT05), 3524262H1 (ESOGTUN01), 3766487F6 (BRSTNOT24)

TABLE 1 cont.

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
8	39	3173355	UTRSTUT04	1300803F6 and 1300803T6 (BRSTNOT07), 2477542F6 (SMCANOT01), 2477542T6 (SMCANOT01), 2875968H1 (THYRNOT10), 3173355F6 and 3173355H1 (UTRSTUT04), 3290825H1 (BONRFET01), 5192561H1 (OVARDIT06)
9	40	5116906	SMCBUNT01	267517F1 (HNT2NOT01), 263823R1 (HNT2AGT01), 5116906H1 (SMCBUNT01)
10	41	940589	ADRENOT03	029801R6 (SPLNFET01), 940589H1 (ADRENOT03), 1737403T6 (COLNNOT22), 1805477F6 and 1805477T6 (SINTNOT13), 2447613H1 (THPLNOT03), 3408563H1 (PROSTUS08), 3519506H1 (LUNGNOT03), 3637343T6 (LUNGNOT30)
11	42	304421	TESTNOT04	304421H1, 304421X318B2, and 304421X323B2 (TESTNOT04), 2639579F6 (BONTNOT01), 2951859H1 (KIDNFET01)
12	43	1213802	BRSTTUT01	894574R1 (BRSTNOT05), 1213802H1 (BRSTTUT01), 1233414F1 and 1234238H1 (LUNGFET03), 1255782F2 and 1255782T1 (MENITUT03), 1455429F1 (COLNFET02), 1576102T1 (LNODNOT03), 2189267F6 (PROSNOT26), 2748179F6 (LUNGUTUT11), 2831667H1 (TLYMNOT03), 3031229H1 (TLYMNOT05), 3054893H1 (LNODNOT08), 3797030F6 (SPLNNOT12), 3880154H1 (SPLNNOT11), 4852525H1 (TESTNOT10), 5514137H1 (BRADDIR01), 5518378H1 (LIVDIR01)
13	44	1378134	LUNGNOT10	1378134H1 and 1378134X11 (LUNGNOT10), 2205185F6 (SPLNFET02), 4959694H1 (TLYMNOT05), SAMA00107F1, SAMA00160F1, SAMA0020F1

TABLE I cont.

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
14	45	1490070	UCMCL5T01	432218H1 (BRAVUNT02), 1490070H1 (UCMCL5T01), 1535394F1 (SPLNNOT04), 1616509F6 and 1616509T6 (BRAITUT12), 2490845H1 (EOSITXT01), 2723789F6 (LUNGUT01), SAOA00263F1
15	46	1997814	BRSTTUT03	855350R1 (NGANNOT01), 875417R1 (LUNGAST01), 895096R1 (BRSTNOT05), 1271348F1 (TESTTUT02), 1331289F6 (PANCNOT07), 1359243F1 (LUNGNOT12), 1540824T1 (SINTTUT01), 1839828H1 (EOSITXT01), 1997814H1 (BRSTTUT03), 2170638F6 (ENDCNOT03), 3751363F6 (UTRSNOT18)
16	47	2299715	BRSTNOT05	637354R6 and 637354T6 (NEUTGMT01), 1852144F6 (LUNGFET03), 2172576F6 (ENDCNOT03), 2232449F6 (PROSNOT16), 2299715H1 (BRSTNOT05), 2509737X325D2 (CONUTUT01), 2606210F6 (LUNGUT07), 2692024F6 (LUNGNOT23), 2805893F6 (BLADTUT08), 2986160H1 (CARGDIT01), 3085382H1 (HEAONOT03), 3136101F6 and 3136587H1 (SMCCNOT01), 4249977H1 (BRADDIR01)
17	48	209854	SPLNNOT02	209854H1 and 209854T6 (SPLNNOT02), 3152165R6 and 3152165T6 (ADRENON04)
18	49	1384286	BRAITUT08	676123R6 and 676123T6 (CRBLNOT01), 989218X11 and 989218X12 (LVENNOT03), 1384286H1 (BRAITUT08), 3099868H1 (PROSBPT03), 4693167H1 (BRAENOT02)
19	50	1512656	PANCTUT01	322847X5 (EOSIHET02), 1253795T6 (LUNGFET03), 1512656H1 (PANCTUT01), 1561686X303D1 (SPLNNOT04), 2212305H1 (SINTFET03), 2697679H1 (UTRSNOT12), 3205172H1 (PENCNOT03), 5313318H1 (KIDETXS02)

TABLE 1 cont.

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
20	51	2098635	BRAITUT02	1268848T1, 1268848X301F1, and 2157157H1 (BRAINOT09), 2098635H1 and 2098635R6 (BRAITUT02), 2198819F6, 2198819X301D4, 2198819X303D1, 2198819X309B2, and 2198819X309D4 (SPLNFET02), 2784975H2 (BRSTNOT13), 3320340H1 (PROSBPT03)
21	52	2446646	THP1NOT03	000297R6 and 000297X61 (U937NOT01), 2446646H1 (THP1NOT03), 2557274F6 (THYMNOT03)
22	53	2764911	BRSTNOT12	678618T6 and 678618X14 (UTRSNOT02), 2304126R6 (BRSTNOT05), 2764911H1 (BRSTNOT12), 2834475F6 (TLYMNOT03), 2915803F6 (THYMFET03), 3035012F6 (TLYMNOT05), SAFC00027F1, SAFC00254F1, SAFC02376F1, SAFC01609F1
23	54	3013946	MUSCNOT07	673753H1 (CRBLNOT01), 989218X11 and 989218X14 (LVENNOT03), 2821720F6 (ADRETUT06), 3013946F6, 3013946H1, and 3013946T6 (MUSCNOT07), 4693167H1 (BRAENOT02)
24	55	067967	HUVESTB01	067967X92, 067966R1, and 067967H1 (HUVESTB01), SAIA02074F1, SAIA03254F1, SAIA03603F1, and SAIA02259F1
25	56	346275	THYMNOT02	346275H1 (THYMNOT02), 609792X12 (COLNNOT01), SAGA03543F1, SAGA02528F1, and SAGA00285F1
26	57	283746	CARDNOT01	283746H1 and 283746X10 (CARDNOT01), 4903108H1 (TLYMNOT08), 557918X15 (MPHGLPT02), and 2379045F6 (ISLTNOT01)
27	58	2696537	UTRSNOT12	2696537H1 (UTRSNOT12), 3173337F6 (UTRSTUT04), 082658X100 (HUVESTB01), and 603219T6 (BRSTTUT01)

TABLE 1 cont.

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
28	59	551178	BEPINOT01	551178H1 (BEPINOT01), 861522R1 (BRAITUT03), 965838R1 (BRSTNOT05), 1574007F1 and 1574007T1 (LNODNOT03), 1830083T6 and 1831194T6 (THP1AZT01), 3098496H1 (CERVNOT03), 3293481H1 (TLYJINT01)
29	60	619292	PGANNOT01	613165F1 (COLNTUT02), 619292H1 and 619292X13 (PGANNOT01)
30	61	2054049	BEPINOT01	1736355F6 (COLNNOT22), 2054049H1 (BEPINOT01), 2379092T6 (ISLTNOT01), 3127284T3 (LUNGUT12), 3136377F6 (SMCCNOT01), SBMA00545F1, SBMA00827F1, SBMA02930F1, SBMA02853F1
31	62	2843910	DRGLNOT01	036294X71 (HUVENOB01), 066017X102, 068399R1, and 068399X3 (HUVESTB01), 1527276H1 (UCMCL5T01), 1846570T6 (COLNNOT09), 2843910H1 (DRGLNOT01)

TABLE 2

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Homologous sequences	Analytical Methods
1	300	S3 S15 S19 S20 S24 T98 S125 S231 T238 S257 S282 S12 S41 S70 T120 T143 S146 T242	N85 N88 N96	Protein kinase motifs: G161-F256 catalytic tk domain IX: V180-E202	Protein kinase	BLAST PFAM PRINTS
2	147	S85 T38 S90		Calcium-binding repeat motifs: G28-L115	PKC- potentiated inhibitory protein of PP1 (CPI17)	BLAST PRINTS BLOCKS
3	431	T178 S282 T25 S34 S75 S106 S194 S198 T208 T264 S299 S303 S304 S308 T328 S345 S388 T46 S137 S260	N44 N242	PTK signatures: A18-Y283 ATP-binding site: I30-K53, E127-G164 Y196-H219 PK catalytic subdomains: M99-E112, Y134-L152 G181-I191, Y243- A265	Ste20-like protein kinase	BLOCKS PRINTS PROFILES SCAN BLAST
4	218	S108 S68 S90 T133 T170 S172 T34 T123 T207		Phosphofructokinase domains: I47, V177-Q195 L148-Y164		PRINTS

TABLE 2 cont.

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Homologous sequences	Analytical Methods
5	474	S14 S89 S98 S132 S472 T22 S26 S62 S66 T204 T320 T345 T359 S427 S443 S94 S128 T211 T336 S443 Y155		Protein kinase family signature: Y144-F425	serine /threonine protein kinase	MOTIFS PFAM BLOCKS PRINTS ProfileScan BLAST
6	540	S102 S183 S267 T296 T301 S442 S34 S58 S180 S207 S224 T360 S374 S401 S428 S478 T484 Y23	N100 N391 N457 N537	Protein kinase family signature: L18-L287	serine /threonine protein kinase	MOTIFS PFAM BLOCKS PRINTS PROFILES SCAN BLAST
7	454	S57 S69 S130 T203 T212 S338 S420 S91 T101 T220 S271 S295 T315 S359 S381 Y197	N55 N140 N218 N403 N437 N441	SH2 domain: W63-Y138, W354-Y428 PI 3 kinase P85 regulator: K153-G176, A216- N257, R287-N332	phosphatidyl- inositol 3- kinase	PFAM BLOCKS PRINTS BLAST
8	502	S246 T498 T21 S65 S76 T193 T203 S275 S312 S355 T484 S106 T222 S323 T498 Y347	N302 N414	Signal peptide: M1-T21 SH2 domain: V70-E80 ER targeting signal: K499-L502	tyrosine kinase	SigPept BLOCKS MOTIFS BLAST



TABLE 2 (cont.)

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Homologous sequences	Analytical Methods
9	281	T66 T140 T141 T182 S210	N117 N139	Signal peptide: M1-I76	calcium /calmodulin- dependent protein kinase	PFAM BLAST
10	510	T297 S323 S358 S51 T312 S323 T325 S329 T377 T390 T483 S24 S152 T201 S210 S247 T292 T406 T407	N185 N349 N381 N405	Protein kinase family signature: R52-V261	Serine /threonine protein kinase	PFAM BLOCKS PRINTS MOTIFS BLAST
11	248	S5 S20 S36 T210 T245	N208	Tyrosine specific phosphatase active site: F166-A220 Dual specificity phosphatase: H95-R240	Tyrosine phosphatase or Dual specificity phosphatase	BLAST, MOTIFS BLOCKS, PRINTS PROFILESCAN PFAM

TABLE 2 cont.

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Homologous sequences	Analytical Methods
12	810	S62 S290 T429 S758 T17 T104 S108 T216 S279 T316 S330 T360 S386 T405 S425 S465 T473 S497 T547 T561 T715 S733 S738 S768 S196 S222 S229 S267 T281 T321 T347 S370 T400 T512 S534 T609 S617 S663 S751 T754 T762 Y67	N33		Protein kinase	BLAST, MOTIFS
13	549	S6 T502 T21 T116 S125 S320 T417 S46 S87 T240 S390 S397 S405 S430 S497	N238	ATP/GTP-binding site (p-loop): G58-T65 Protein kinase signature: I176-K199 I292-L304 Y347-L370 F456-L483	Dual specificity tyrosine /serine protein kinase	BLAST, MOTIFS BLOCKS, PRINTS PFAM
14	416	S312 T20 T97 S104 S183 T185 T211 T274 S381 S411 S72 S79 S140 S318 Y53		SH3 domain: A366-D384 N402-E414	PEST phosphatase interacting protein	BLAST, MOTIFS BLOCKS, PRINTS PFAM

TABLE 2 cont.

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Homologous sequences	Analytical Methods
15	425	T34 S233 S234 S25 S107 T144 T198 T250 S251 S258 S282 S300 S324 S345 T390 T51 T133 S365 S383 Y71	N23 N176 N362		SH3 binding protein	BLAST, MOTIFS
16	1135	S77 T187 S259 S554 S815 S9 S17 T59 S112 T124 T222 S264 T319 S324 S326 S550 T572 S625 S681 S682 T688 T689 S706 S720 T931 S958 S978 S999 S255 T309 T351 T543 S550 S624 S632 S726 T811 S898 S1012 S1113 Y321 Y323 Y467	N33 N570 N718 N1067	Protein kinase signature: V31-K54 V149-L161 W129-V182 Tyrosine kinase catalytic site: G190-I200 S214-M236 NIK1-like kinase domain: Y836-R1115	NIK kinase	BLAST, MOTIFS PROFILES BLOCKS, PRINTS PFAM
17	228	T163 S60 T78 T68 S88 S147	N19 N100 N114		Interferon- induced PK regulator (P52rIPK)	BLAST

TABLE 2 cont.

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Homologous sequences	Analytical Methods
18	503	S51 T262 T36 S79 T94 S109 T361 T362 T403 S472 T47 S334 S343 Y17	N313 N333 N360	Protein kinase signature: I20-K43 V132-L144 V195-E217 Protein kinase domain: Y14-V272	calcium /calmodulin- dependent protein kinase II, beta 3 isoform	BLAST, BLOCKS, PRINTS, MOTIFS, PFAM, PROFILES CAN
19	433	S12 S77 S124 S131 S255 S290 T327 S365 S402 T70 Y88			Choline kinase isolog 384D8_3	BLAST, MOTIFS
20	527	S417 S154 S199 T367 S453 T120 S178 S413 T447 S473	N470	Protein kinase signature: I144-K167 I260-V172 ATP-binding site: Q247-G284 Y318-F341 Protein kinase domain: I138-L427	MAP-related protein kinase	BLAST, BLOCKS MOTIFS, PFAM, PROFILES CAN

TABLE 2 cont.

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Homologous sequences	Analytical Methods
21	322	S19 S122 T198 T200 T236 S251 T260 S264 T301 S14 S52 T181 T225	N196 N249	Protein kinase signature: L163-I175 ATP-binding site: M150-V187 I224-H247 Protein kinase domain: S32-E316	Protein tyrosine kinase	BLAST, BLOCKS, PRINTS, MOTIFS, PFAM, PROFILESCAN
22	802	S70 T87 S750 T14 T98 S144 T150 S230 S263 T353 T465 T470 S517 S633 T751 S758 T27 T74 T100 T207 S268 S368 S458	N36 N655	Protein kinase signature: L55-K81, L432-K455 ATP-binding site: E160-G197, H232-F255 PTK catalytic domain: H534-F552, C603-H625 Protein kinase domains: F49-F318, L427-L687 Protein kinase C domain: Q319-I382	Ribosomal S6 protein kinase	BLAST, BLOCKS, PRINTS, MOTIFS, PFAM, PROFILESCAN
23	641	S51 T262 S398 S436 S479 T36 S79 T94 S109 T375 T376 T541 S610 T47 S315 S333 S342 S393 S422 S431 S465 S474 S508 Y17	N313 N332 N374	Protein kinase signature: I20-K43 V132-L144 ATP-binding site: Q119-A156 Y191-F214 Protein kinase domain: Y14-V272	Ca2+ /calmodulin dependent protein kinase	BLAST, BLOCKS, PRINTS, MOTIFS, PFAM, PROFILESCAN

TABLE 2 cont.

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Homologous sequences	Analytical Methods
24	588	S106 T155 S359 T388 T456 T531 T4, S58 S108 T126 S132 T279 S350 S436 S469 S508 S537 Y32	N63 N130 N574	Protein kinase catalytic domain: Y209-S445, F495-I522 ATP-binding site: I215-K238 STK core catalytic motif: I331-L343	Protein kinase Dyrk2	MOTIFS PFAM BLOCKS PRINTS BLAST
25	389	S31 T301 S56 S96 S134 T149 S186 S201 S283 S358 S375 Y148 Y165	N257 N343 N364	Protein kinase catalytic domain: E73-I311 STK core catalytic motif: I172-Y184 PTK core domain: D152-D208	CaM-like protein kinase	BLAST PFAM MOTIFS BLOCKS PRINTS PROFILES SCAN
26	343	S68 S81 S137 S184 T219 S276 S297 T29 T125 Y86 Y211	N332	EF hand calcium-binding signature: D176-L188	protein phosphatase 2A (PR72)	BLAST MOTIFS BLOCKS
27	184	S36 T105 S40 S70 T117 Y50	N62	Tyrosine phosphatase active site domain: L63-V118	MAP kinase phosphatase (X17C)	BLAST PROFILES SCAN BLOCKS PRINTS MOTIFS

TABLE 2 cont.

Polypeptide SEQ ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Homologous sequences	Analytical Methods
28	367	S10 S21 S44 S103 T116 T267 T309 S191 S213 S218 S256 T305 S352 Y159 Y344	N16 N17		protein phosphatase 2A, A-subunit	BLAST
29	118	S34 S84	N43	Signal peptide: M1-A27 PDZ domain: H8-S73	tyrosine phosphatase	SPScan PFAM BLAST
30	356	S9 S94 T209 T220 S259 S337 S5 S26 S75 S121 T154 S282 S332 S339 Y15 Y84	N333	tyrosine-specific protein phosphatase active site: I108-K164	tyrosine phosphatase (myotubularin)	PROFILES MOTIFS BLOCKS PRINTS BLAST
31	453	S38 S73 S119 S131 S193 S200 T236 S293 S341 T379 T124 S173 T214 S252 T256 S282 S302 S313 S391 S397	N43 N67 N357	protein phosphatase 2A p55 subunit: P10-K451	protein phosphatase 2A p55 regulatory subunit, alpha isoform	PFAM MOTIFS BLOCKS PRINTS BLAST

TABLE 3

Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
32	Hematopoietic/Immune (0.333) Reproductive (0.333)	Cell proliferation (0.500) Inflammation (0.333)	PBLUESCRIPT
33	Nervous (0.216) Reproductive (0.235) Cardiovascular (0.118)	Cell proliferation (0.530) Inflammation (0.352)	pINCY
34	Reproductive (0.293) Gastrointestinal (0.192)	Cell proliferation (0.641) Inflammation (0.335)	pINCY
35	Reproductive (0.284) Nervous (0.210) Cardiovascular (0.1213)	Cell proliferation (0.729) Inflammation (0.272)	pINCY
36	Nervous (0.529) Developmental (0.118) Gastrointestinal (0.118)	Cell proliferation (0.588) Neurological (0.118) Inflammation (0.118)	pINCY
37	Hematopoietic/Immune (0.268) Reproductive (0.244) Nervous (0.122)	Inflammation (0.488) Cell Proliferative (0.415)	PBLUESCRIPT
38	Reproductive (0.400) Hematopoietic/Immune (0.160) Nervous (0.160)	Cell proliferation (0.600) Inflammation (0.320)	pINCY
39	Cardiovascular (0.312) Reproductive (0.312) Developmental (0.188)	Cell proliferation (0.938) Inflammation (0.125)	pINCY
40	Nervous (0.400) Gastrointestinal (0.267) Developmental (0.133)	Cell proliferation (0.733) Neurological (0.133) Inflammation (0.133)	pINCY
41	Gastrointestinal (0.267) Nervous (0.233) Reproductive (0.167)	Inflammation (0.533) Cell proliferation (0.534)	pSPORT1



Table 3 cont.

Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
42	Musculoskeletal (0.500) Developmental (0.167) Gastrointestinal (0.167)	Cancer (0.834) Inflammation (0.167)	PBLUESCRIPT
43	Reproductive (0.240) Nervous (0.151) Gastrointestinal (0.135)	Cell proliferation (0.536) Inflammation (0.417)	pSPORT1
44	Hematopoietic/Immune (0.278) Nervous (0.222) Dermatologic (0.111)	Cell proliferation (0.444) Inflammation (0.389)	PINCY
45	Hematopoietic/Immune (0.500) Gastrointestinal (0.125) Nervous (0.125)	Inflammation (0.500) Cell proliferative (0.500)	PBLUESCRIPT
46	Nervous (0.220) Reproductive (0.213) Hematopoietic/Immune (0.140)	Cell proliferation (0.573) Inflammation (0.380)	pSPORT1
47	Hematopoietic/Immune (0.190) Gastrointestinal (0.165) Nervous (0.139)	Cell proliferation (0.582) Inflammation (0.354)	pSPORT1

Table 3 cont.

Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
48	Nervous (0.333) Reproductive (0.333) Hematopoietic/Immune (0.111)	Cancer (0.444) Inflammation (0.222) Neurological (0.111)	PBLUESCRIPT
49	Nervous (0.724) Cardiovascular (0.103)	Inflammation (0.276) Cancer (0.241) Neurological (0.172)	pINCY
50	Reproductive (0.235) Hematopoietic/Immune (0.188) Gastrointestinal (0.129)	Cancer (0.447) Inflammation (0.282) Fetal (0.153)	pINCY
51	Nervous (0.368) Developmental (0.158) Gastrointestinal (0.105)	Cancer (0.368) Fetal (0.211) Inflammation (0.105)	pSPORT1
52	Cardiovascular (0.312) Hematopoietic/Immune (0.312) Reproductive (0.158)	Fetal (0.688) Cancer (0.421) Inflammation (0.125)	pINCY
53	Reproductive (0.412) Nervous (0.235) Developmental (0.118)	Cancer (0.471) Fetal (0.235) Inflammation (0.235)	pINCY
54	Nervous (0.714) Cardiovascular (0.107)	Cancer (0.250) Inflammation (0.250) Neurological (0.179)	pINCY

Table 3 cont.

Nucleotide SEQ ID NO:	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	PBLUESCRIPT
55	Reproductive (0.533) Nervous (0.133)	Cell proliferation (0.601) Inflammation (0.270)	PBLUESCRIPT
56	Hematopoietic/Immune (0.278) Nervous (0.222) Reproductive (0.154)	Cell proliferation (0.388) Inflammation (0.333) Neurological (0.111)	PBLUESCRIPT
57	Hematopoietic/Immune (0.211) Cardiovascular (0.193) Nervous (0.175)	Cell proliferation (0.474) Inflammation (0.491)	PBLUESCRIPT
58	Reproductive (0.286) Cardiovascular (0.229) Musculoskeletal (0.143)	Cell proliferation (0.715) Inflammation (0.200)	PINCY
59	Reproductive (0.253) Gastrointestinal (0.211) Nervous (0.147)	Cancer and Cell proliferation (0.684) Inflammation and Immune Response (0.242)	PSPORT1
60	Nervous (0.667) Reproductive (0.333)	Cancer (1.000)	PSPORT1
61	Reproductive (0.357) Cardiovascular (0.179) Nervous (0.125)	Cancer and Cell proliferation (0.642) Inflammation and Immune Response (0.232)	PSPORT1
62	Nervous (0.228) Reproductive (0.175) Cardiovascular (0.158) Hematopoietic/Immune (0.158)	Cancer (0.368) Inflammation and Immune Response (0.263) Fetal (0.211)	PINCY

TABLE 4

Polynucleotide SEQ ID NO:	Library	Library Comment
32	BMARNOT02	Library was constructed using RNA isolated from the bone marrow of 24 male and female Caucasian donors, 16 to 70 years old.
33	SININOT01	Library was constructed using RNA isolated from ileum tissue removed from the small intestine of a 4-year-old Caucasian female, who died from a closed head injury. Patient history included jaundice as a baby. Previous surgeries included a double hernia repair
34	SPLNFET02	Library was constructed using RNA isolated from spleen tissue removed from a Caucasian male fetus, who died at 23 weeks' gestation from premature birth. Family history included diabetes.
35	OVARTUT02	Library was constructed using RNA isolated from ovarian tumor tissue removed from a 51-year-old Caucasian female during an exploratory laparotomy, total abdominal hysterectomy, salpingo-oophorectomy, and an incidental appendectomy. Pathology indicated mucinous cystadenoma presenting as a multiloculated neoplasm involving the entire left ovary. The right ovary contained a follicular cyst and a hemorrhagic corpus luteum. The uterus showed proliferative endometrium and a single intramural leiomyoma. The peritoneal biopsy indicated benign glandular inclusions consistent with endosalpingiosis. The patient presented with abnormal weight gain and ascites. Patient history included depressive disorder, joint pain, allergies, alcohol use, and a normal delivery. Family history included atherosclerotic coronary artery disease, benign hypertension, breast cancer and uterine cancer.

TABLE 4 cont.

Polynucleotide SEQ ID NO:	Library	Library Comment
36	PANCTUT01	Library was constructed using RNA isolated from pancreatic tumor tissue removed from a 65-year-old Caucasian female during radical subtotal pancreatectomy. Pathology indicated an invasive grade 2 adenocarcinoma. Patient history included type II diabetes, osteoarthritis, cardiovascular disease, and benign neoplasm in the large bowel. Previous surgeries included a total splenectomy, cholecystectomy, and abdominal hysterectomy. Family history included cardiovascular disease, type II diabetes, and stomach cancer.
37	SMCBUNT01	Library was constructed using RNA isolated from bronchial smooth muscle cell tissue removed from a 21-year-old Caucasian male.
38	UTRSTUT05	Library was constructed using RNA isolated from uterine tumor tissue removed from a 41-year-old Caucasian female during a vaginal hysterectomy with dilation and curettage. Pathology indicated uterine leiomyoma. The endometrium was secretory and contained fragments of endometrial polyps. Benign endo- and ectocervical mucosa were identified in the endocervix. Patient history included a ventral hernia and a benign ovarian neoplasm.
39	UTRSTUT04	Library was constructed using RNA isolated from uterine tumor tissue removed from a 34-year-old Caucasian female during a hysteroscopy and an exploratory laparotomy with dilation and curettage. Pathology indicated an endometrial polyp, subserosal leiomyoma, and fragments of leiomyoma. Family history included hyperlipidemia, depressive disorder, benign hypertension, cerebrovascular disease, arteriosclerotic cardiovascular disease, and type II diabetes.

TABLE 4 cont.

Polynucleotide SEQ ID NO:	Library	Library Comment
40	SMCBUNT01	library was constructed using RNA isolated from bronchial smooth muscle cell tissue removed from a 21-year-old Caucasian male.
41	ADRENOT03	library was constructed using RNA isolated from the adrenal tissue of a 17-year-old Caucasian male, who died from cerebral anoxia.
42	TESTNOT04	library was constructed using RNA isolated from testicular tissue removed from a 37-year-old Caucasian male who died from liver disease. Patient history included cirrhosis, jaundice, and liver failure.
43	BRSTTUT01	library was constructed using RNA isolated from breast tumor tissue removed from a 55-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated invasive grade 4 mammary adenocarcinoma of mixed lobular and ductal type, extensively involving the left breast. The tumor was identified in the deep dermis near the lactiferous ducts with extracapsular extension. Seven mid and low and five high axillary lymph nodes were positive for tumor. Proliferative fibrocystic changes were characterized by apocrine metaplasia, sclerosing adenosis, cyst formation, and ductal hyperplasia without atypia. Patient history included atrial tachycardia, blood in the stool, and a benign breast neoplasm. Family history included benign hypertension, atherosclerotic coronary artery disease, cerebrovascular disease, and depressive disorder.
44	LUNGNOT10	library was constructed using RNA isolated from the lung tissue of a Caucasian male fetus who died at 23 weeks' gestation.
45	UCMCL5T01	library was constructed using RNA isolated from mononuclear cells obtained from the umbilical cord blood of 12 individuals. The cells were cultured for 12 days with IL-5 before RNA was isolated from the pooled lysates.

TABLE 4 cont.

Polynucleotide SEQ ID NO:	Library	Library Comment
46	BRSTTUT03	Library was constructed using RNA isolated from breast tumor tissue removed from a 58-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated multicentric invasive grade 4 lobular carcinoma. The mass was identified in the upper outer quadrant, and three separate nodules were found in the lower outer quadrant of the left breast. Patient history included skin cancer, rheumatic heart disease, osteoarthritis, and tuberculosis. Family history included cerebrovascular disease, coronary artery aneurysm, breast cancer, prostate cancer, atherosclerotic coronary artery disease, and type I diabetes.
47	BRSTNOT05	Library was constructed using RNA isolated from breast tissue removed from a 58-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology for the associated tumor tissue indicated multicentric invasive grade 4 lobular carcinoma. Patient history included skin cancer, rheumatic heart disease, osteoarthritis, and tuberculosis. Family history included cerebrovascular and cardiovascular disease, breast and prostate cancer, and type I diabetes.

TABLE 4 cont.

Polynucleotide SEQ ID NO:	Library	Library Comment
48	SPLNNOT02	The library was constructed using RNA isolated from the spleen tissue of a 29-year-old Caucasian male, who died from head trauma. Serologies were positive for cytomegalovirus (CMV). Patient history included alcohol, marijuana, and tobacco use.
49	BRAITUT08	The library was constructed using RNA isolated from brain tumor tissue removed from the left frontal lobe of a 47-year-old Caucasian male during excision of cerebral meningeal tissue. Pathology indicated grade 4 fibrillary astrocytoma with focal tumoral radionecrosis. Patient history included cerebrovascular disease, deficiency anemia, hyperlipidemia, epilepsy, and tobacco use. Family history included cerebrovascular disease and a malignant prostate neoplasm.
50	PANCTUT01	The library was constructed using RNA isolated from pancreatic tumor tissue removed from a 65-year-old Caucasian female during radical subtotal pancreatectomy. Pathology indicated an invasive grade 2 adenocarcinoma. Patient history included type II diabetes, osteoarthritis, cardiovascular disease, benign neoplasm in the large bowel, and a cataract. Previous surgeries included a total splenectomy, cholecystectomy, and abdominal hysterectomy. Family history included cardiovascular disease, type II diabetes, and stomach cancer.
51	BRAITUT02	The library was constructed using RNA isolated from brain tumor tissue removed from the frontal lobe of a 58-year-old Caucasian male during excision of a cerebral meningeal lesion. Pathology indicated a grade 2 metastatic hypernephroma. Patient history included a grade 2 renal cell carcinoma, insomnia, and chronic airway obstruction. Family history included a malignant neoplasm of the kidney.



TABLE 4 cont.

Polynucleotide SEQ ID NO:	Library	Library Comment
52	THP1NOT03	The library was constructed using RNA isolated from untreated THP-1 cells. THP-1 (ATCC TIB 202) is a human promonocyte line derived from the peripheral blood of a 1-year-old Caucasian male with acute monocytic leukemia (ref: Int. J. Cancer (1980) 26:171).
53	BRSTNOT12	The library was constructed using RNA isolated from diseased breast tissue removed from a 32-year-old Caucasian female during a bilateral reduction mammoplasty. Pathology indicated nonproliferative fibrocystic disease. Family history included cardiovascular disease.
54	MUSCNOT07	The library was constructed using RNA isolated from muscle tissue removed from the forearm of a 38-year-old Caucasian female during a soft tissue excision. Pathology for the associated tumor tissue indicated intramuscular hemangioma. Family history included breast cancer, benign hypertension, cerebrovascular disease, colon cancer, and type II diabetes.
55	HUVESB01	Library was constructed using RNA isolated from shear-stressed HUV-EC-C (ATCC CRL 1730) cells. HUV-EC-C is an endothelial cell line derived from the vein of a normal human umbilical cord (ref:PNAS 81:6413).
56	THYMNOT02	Library was constructed using polyA RNA isolated from thymus tissue removed from a 3-year-old Caucasian male, who died from drowning.
57	CARDNOT01	Library was constructed using RNA isolated from the cardiac muscle of a 65-year-old Caucasian male, who died from a self-inflicted gunshot wound.

TABLE 4 cont.

Polynucleotide SEQ ID NO:	Library	Library Comment
58	UTRSNOT12	Library was constructed using RNA isolated from uterine myometrial tissue removed from a 41-year-old Caucasian female during a vaginal hysterectomy with a dilatation and curettage. The endometrium was secretory and contained fragments of endometrial polyps. Benign endo- and ectocervical mucosa were identified in the endocervix. Pathology for the associated tumor tissue indicated uterine leiomyoma. The patient presented with an unspecified menstrual disorder. Patient history included ventral hernia, normal delivery, a benign ovarian neoplasm, and tobacco abuse. Previous surgeries included a bilateral destruction of fallopian tubes, removal of a solitary ovary, and an exploratory laparotomy.
59	BEPINOT01	Library was constructed using RNA isolated from a bronchial epithelium primary cell line derived from a 54-year-old Caucasian male.
60	PGANNOT01	Library was constructed using RNA isolated from paraganglionic tumor tissue removed from the intra-abdominal region of a 46-year-old Caucasian male during exploratory laparotomy. Pathology indicated a benign paraganglioma and association with a grade 2 renal cell carcinoma, clear cell type.
61	BEPINOT01	Library was constructed using RNA isolated from a bronchial epithelium primary cell line derived from a 54-year-old Caucasian male.
62	DRGLNOT01	Library was constructed using RNA isolated from dorsal root ganglion tissue removed from the low thoracic/high lumbar region of a 32-year-old Caucasian male who died from acute pulmonary edema and bronchopneumonia, bilateral pleural and pericardial effusions, and malignant lymphoma (natural killer cell type). Patient history included probable cytomegalovirus infection, hepatic congestion and steatosis, splenomegaly, hemorrhagic cystitis, thyroid hemorrhage, and Bell's palsy.

Table 5

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25: 3389-3402.	ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183: 63-98; and Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489.	ESTs: fasta E value=1.06E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less Full Length sequences: fastx score=100 or greater
BLIMPS	A BLocks IMProved Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S and J.G. Henikoff, Nucl. Acid Res., 19:6565-72, 1991. J.G. Henikoff and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37: 417-424.	Score=1000 or greater; Ratio of Score/Strength = 0.75 or larger; and, if applicable, Probability value= 1.0E-3 or less
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) J. Mol. Biol., 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322.	Score= 10-50 bits for PFAM hits, depending on individual protein families

Table 5 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25: 217-221.	Normalized quality score $\geq$ GCG-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M. S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12: 431-439.	Score=3.5 or greater
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch et al. <u>supra</u> ; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. A substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-31, and fragments thereof.
- 5 2. A substantially purified variant having at least 90% amino acid sequence identity to the amino acid sequence of claim 1.
3. An isolated and purified polynucleotide encoding the polypeptide of claim 1.
4. An isolated and purified polynucleotide variant having at least 80% polynucleotide sequence identity to the polynucleotide of claim 3.
- 10 5. An isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide of claim 3.
6. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 3.
7. A method for detecting a polynucleotide, the method comprising the steps of:
  - 15 (a) hybridizing the polynucleotide of claim 6 to at least one nucleic acid in a sample, thereby forming a hybridization complex; and
  - (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of the polynucleotide in the sample.
8. The method of claim 7 further comprising amplifying the polynucleotide prior to  
20 hybridization.
9. An isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:32-62 and fragments thereof.
10. An isolated and purified polynucleotide variant having at least 80% polynucleotide sequence identity to the polynucleotide of claim 9.
- 25 11. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 9.
12. An expression vector comprising at least a fragment of the polynucleotide of claim 3.
13. A host cell comprising the expression vector of claim 12.
- 30 14. A method for producing a polypeptide, the method comprising the steps of:
  - a) culturing the host cell of claim 13 under conditions suitable for the expression of the polypeptide; and
  - b) recovering the polypeptide from the host cell culture.
15. A pharmaceutical composition comprising the polypeptide of claim 1 in conjunction  
35 with a suitable pharmaceutical carrier.
16. A purified antibody which specifically binds to the polypeptide of claim 1.

17. A purified agonist of the polypeptide of claim 1.
18. A purified antagonist of the polypeptide of claim 1.
19. A method for treating or preventing a disorder associated with decreased expression or activity of PHSP, the method comprising administering to a subject in need of such treatment an  
5 effective amount of the pharmaceutical composition of claim 15.
20. A method for treating or preventing a disorder associated with increased expression or activity of PHSP, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 18.

## SEQUENCE LISTING

<110> INYCTE PHARMACEUTICALS, INC.  
 HILLMAN, Jennifer L.  
 LAL, Preeti  
 TANG, Y. Tom  
 CORLEY, Neil C.  
 GUEGLER, Karl J.  
 BAUGHN, Mariah R.  
 PATTERSON, Chandra  
 BANDMAN, Olga  
 AU-YOUNG, Janice  
 GORGONE, Gina A.  
 YUE, Henry  
 AZIMZAI, Yalda  
 REDDY, Roopa  
 LU, Dyung Aina M.  
 SHIH, Leo L.

<120> PHOSPHORYLATION EFFECTORS

<130> PF-0565 PCT

<140> To Be Assigned

<141> Herewith

<150> 09/123,494; unassigned; 09/152,814; unassigned; 09/173,482;  
 unassigned; 60/106,889; 60/109,093; 60/113,796;

<151> 1998-07-28; 1998-07-28; 1998-07-28; 1998-09-14; 1998-09-14; 1998-10-14;  
 1998-10-14; 1998-11-03; 1998-11-19; 1998-12-22

<160> 61

<170> PERL Program

<210> 1

<211> 300

<212> PRT

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte Clone Number: 132240

<400> 1

Met	Glu	Ser	Pro	Leu	Glu	Ser	Gln	Pro	Leu	Asp	Ser	Asp	Arg	Ser
1				5					10					15
Ile	Lys	Glu	Ser	Ser	Phe	Glu	Glu	Ser	Asn	Ile	Glu	Asp	Pro	Leu
				20					25					30
Ile	Val	Thr	Pro	Asp	Cys	Gln	Glu	Lys	Thr	Ser	Pro	Lys	Gly	Val
				35					40					45
Glu	Asn	Pro	Ala	Val	Gln	Glu	Ser	Asn	Gln	Lys	Met	Leu	Gly	Pro
				50					55					60
Pro	Leu	Glu	Val	Leu	Lys	Thr	Leu	Ala	Ser	Lys	Arg	Asn	Ala	Val
				65					70					75

Ala Phe Arg Ser Phe Asn Ser His Ile Asn Ala Ser Asn Asn Ser		
80	85	90
Glu Pro Ser Arg Met Asn Met Thr Ser Leu Asp Ala Met Asp Ile		
95	100	105
Ser Cys Ala Tyr Ser Gly Ser Tyr Pro Met Ala Ile Thr Pro Thr		
110	115	120
Gln Lys Arg Arg Ser Cys Met Pro His Gln Thr Pro Asn Gln Ile		
125	130	135
Lys Ser Gly Thr Pro Tyr Arg Thr Pro Lys Ser Val Arg Arg Gly		
140	145	150
Val Ala Pro Val Asp Asp Gly Arg Ile Leu Gly Thr Pro Asp Tyr		
155	160	165
Leu Ala Pro Glu Leu Leu Gly Arg Ala His Gly Pro Ala Val		
170	175	180
Asp Trp Trp Ala Leu Gly Val Cys Leu Phe Glu Phe Leu Thr Gly		
185	190	195
Ile Pro Pro Phe Asn Asp Glu Thr Pro Gln Gln Val Phe Gln Asn		
200	205	210
Ile Leu Lys Arg Asp Ile Pro Trp Pro Glu Gly Glu Glu Lys Leu		
215	220	225
Ser Asp Asn Ala Gln Ser Ala Val Glu Ile Leu Leu Thr Ile Asp		
230	235	240
Asp Thr Lys Arg Ala Gly Met Lys Glu Leu Lys Arg His Pro Leu		
245	250	255
Phe Ser Asp Val Asp Trp Glu Asn Leu Gln His Gln Thr Met Pro		
260	265	270
Phe Ile Pro Gln Pro Asp Asp Glu Thr Asp Thr Ser Tyr Phe Glu		
275	280	285
Ala Arg Asn Thr Ala Gln His Leu Thr Val Ser Gly Phe Ser Leu		
290	295	300

&lt;210&gt; 2

&lt;211&gt; 147

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2180116

&lt;400&gt; 2

Met Ala Ala Gln Arg Leu Gly Lys Arg Val Leu Ser Lys Leu Gln		
1	5	10
Ser Pro Ser Arg Ala Arg Gly Pro Gly Gly Ser Pro Gly Gly Met		
20	25	30
Gln Lys Arg His Ala Arg Val Thr Val Lys Tyr Asp Arg Arg Glu		
35	40	45
Leu Gln Arg Arg Leu Asp Val Glu Lys Trp Ile Asp Gly Arg Leu		
50	55	60
Glu Glu Leu Tyr Arg Gly Met Glu Ala Asp Met Pro Asp Glu Ile		
65	70	75
Asn Ile Asp Glu Leu Leu Glu Leu Glu Ser Glu Glu Glu Arg Ser		
80	85	90
Arg Lys Ile Gln Gly Leu Leu Lys Ser Cys Gly Lys Pro Val Glu		
95	100	105



Asp Phe Ile Gln Glu Leu Leu Ala Lys Leu Gln Gly Leu His Arg  
 110 115 120  
 Gln Pro Gly Leu Arg Gln Pro Ser Pro Ser His Asp Gly Ser Leu  
 125 130 135  
 Ser Pro Leu Gln Asp Arg Ala Arg Thr Ala His Pro  
 140 145

<210> 3

<211> 431

<212> PRT

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte Clone Number: 2197671

<400> 3

Met Ala His Ser Pro Val Gln Ser Gly Leu Pro Gly Met Gln Asn  
 1 5 10 15  
 Leu Lys Ala Asp Pro Glu Glu Leu Phe Thr Lys Leu Glu Lys Ile  
 20 25 30  
 Gly Lys Gly Ser Phe Gly Glu Val Phe Lys Gly Ile Asp Asn Arg  
 35 40 45  
 Thr Gln Lys Val Val Ala Ile Lys Ile Ile Asp Leu Glu Glu Ala  
 50 55 60  
 Glu Asp Glu Ile Glu Asp Ile Gln Gln Glu Ile Thr Val Leu Ser  
 65 70 75  
 Gln Cys Asp Ser Pro Tyr Val Thr Lys Tyr Tyr Gly Ser Tyr Leu  
 80 85 90  
 Lys Asp Thr Lys Leu Trp Ile Ile Met Glu Tyr Leu Gly Gly Gly  
 95 100 105  
 Ser Ala Leu Asp Leu Leu Glu Pro Gly Arg Leu Asp Glu Thr Gln  
 110 115 120  
 Ile Ala Thr Ile Leu Arg Glu Ile Leu Lys Gly Leu Asp Tyr Leu  
 125 130 135  
 His Ser Glu Lys Lys Ile His Arg Asp Ile Lys Ala Ala Asn Val  
 140 145 150  
 Leu Leu Ser Glu His Gly Glu Val Lys Leu Ala Asp Phe Gly Val  
 155 160 165  
 Ala Gly Gln Leu Thr Asp Thr Gln Ile Lys Arg Asn Thr Phe Val  
 170 175 180  
 Gly Thr Pro Phe Trp Met Ala Pro Glu Val Ile Lys Gln Ser Ala  
 185 190 195  
 Tyr Asp Ser Lys Ala Asp Ile Trp Ser Leu Gly Ile Thr Ala Ile  
 200 205 210  
 Glu Leu Ala Arg Gly Glu Pro Pro His Ser Glu Leu His Pro Met  
 215 220 225  
 Lys Val Leu Phe Leu Ile Pro Lys Asn Asn Pro Pro Thr Leu Glu  
 230 235 240  
 Gly Asn Tyr Ser Lys Pro Leu Lys Glu Phe Val Glu Ala Cys Leu  
 245 250 255  
 Asn Lys Glu Pro Ser Phe Arg Pro Thr Ala Lys Glu Leu Leu Lys  
 260 265 270  
 His Lys Phe Ile Leu Arg Asn Ala Lys Lys Thr Ser Tyr Leu Thr  
 275 280 285

```

Glu Leu Ile Asp Arg Tyr Lys Arg Trp Lys Ala Glu Gln Ser His
290                295                300
Asp Asp Ser Ser Ser Glu Asp Ser Asp Ala Glu Thr Asp Gly Gln
305                310                315
Ala Ser Gly Gly Ser Asp Ser Gly Asp Trp Ile Phe Thr Ile Arg
320                325                330
Glu Lys Asp Pro Lys Asn Leu Glu Asn Gly Ala Leu Gln Pro Ser
335                340                345
Asp Leu Asp Arg Asn Lys Met Lys Asp Ile Pro Lys Arg Pro Phe
350                355                360
Ser Gln Cys Leu Ser Thr Ile Ile Ser Pro Leu Phe Ala Glu Leu
365                370                375
Lys Glu Lys Ser Gln Ala Cys Gly Gly Asn Leu Gly Ser Ile Glu
380                385                390
Glu Leu Arg Gly Ala Ile Tyr Leu Ala Glu Glu Ala Cys Pro Gly
395                400                405
Ile Ser Asp Thr Met Val Ala Gln Leu Val Gln Arg Leu Gln Arg
410                415                420
Tyr Ser Leu Ser Gly Gly Gly Thr Ser Ser His
425                430

```

&lt;210&gt; 4

&lt;211&gt; 218

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2594943

&lt;400&gt; 4

```

Met Asn Cys Arg Ser Glu Val Leu Glu Val Ser Val Glu Gly Arg
1                5                10                15
Gln Val Glu Glu Ala Met Leu Ala Val Leu His Thr Val Leu Leu
20                25                30
His Arg Ser Thr Gly Lys Phe His Tyr Lys Lys Glu Gly Thr Tyr
35                40                45
Ser Ile Gly Thr Val Gly Thr Gln Asp Val Asp Cys Asp Phe Ile
50                55                60
Asp Phe Thr Tyr Val Arg Val Ser Ser Glu Glu Leu Asp Arg Ala
65                70                75
Leu Arg Lys Val Val Gly Glu Phe Lys Asp Ala Leu Arg Asn Ser
80                85                90
Gly Gly Asp Gly Leu Gly Gln Met Ser Leu Glu Phe Tyr Gln Lys
95                100               105
Lys Lys Ser Arg Trp Pro Phe Ser Asp Glu Cys Ile Pro Trp Glu
110               115               120
Val Trp Thr Val Lys Val His Val Val Ala Leu Ala Thr Glu Gln
125               130               135
Glu Arg Gln Ile Cys Arg Glu Lys Val Gly Glu Lys Leu Cys Glu
140               145               150
Lys Ile Ile Asn Ile Val Glu Val Met Asn Arg His Glu Tyr Leu
155               160               165
Pro Lys Met Pro Thr Gln Ser Glu Val Asp Asn Val Phe Asp Thr
170               175               180

```

Gly Leu Arg Asp Val Gln Pro Tyr Leu Tyr Lys Ile Ser Phe Gln  
 185 190 195  
 Ile Thr Asp Ala Leu Gly Thr Ser Val Thr Thr Thr Met Arg Arg  
 200 205 210  
 Leu Ile Lys Asp Thr Leu Ala Leu  
 215

&lt;210&gt; 5

&lt;211&gt; 474

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 1513871

&lt;400&gt; 5

Met Ile Met Asn Lys Met Lys Asn Phe Lys Arg Arg Phe Ser Leu  
 1 5 10 15  
 Ser Val Pro Arg Thr Glu Thr Ile Glu Glu Ser Leu Ala Glu Phe  
 20 25 30  
 Thr Glu Gln Phe Asn Gln Leu His Asn Arg Arg Asn Glu Asn Leu  
 35 40 45  
 Gln Leu Gly Pro Leu Gly Arg Asp Pro Pro Gln Glu Cys Ser Thr  
 50 55 60  
 Phe Ser Pro Thr Asp Ser Gly Glu Glu Pro Gly Gln Leu Ser Pro  
 65 70 75  
 Gly Val Gln Phe Gln Arg Arg Gln Asn Gln Arg Arg Phe Ser Met  
 80 85 90  
 Glu Asp Val Ser Lys Arg Leu Ser Leu Pro Met Asp Ile Arg Leu  
 95 100 105  
 Pro Gln Glu Phe Leu Gln Lys Leu Gln Met Glu Ser Pro Asp Leu  
 110 115 120  
 Pro Lys Pro Leu Ser Arg Met Ser Arg Arg Ala Ser Leu Ser Asp  
 125 130 135  
 Ile Gly Phe Gly Lys Leu Glu Thr Tyr Val Lys Leu Asp Lys Leu  
 140 145 150  
 Gly Glu Gly Thr Tyr Ala Thr Val Phe Lys Gly Arg Ser Lys Leu  
 155 160 165  
 Thr Glu Asn Leu Val Ala Leu Lys Glu Ile Arg Leu Glu His Glu  
 170 175 180  
 Glu Gly Ala Pro Cys Thr Ala Ile Arg Glu Val Ser Leu Leu Lys  
 185 190 195  
 Asn Leu Lys His Ala Asn Ile Val Thr Leu His Asp Leu Ile His  
 200 205 210  
 Thr Asp Arg Ser Leu Thr Leu Val Phe Glu Tyr Leu Asp Ser Asp  
 215 220 225  
 Leu Lys Gln Tyr Leu Asp His Cys Gly Asn Leu Met Ser Met His  
 230 235 240  
 Asn Val Lys Ile Phe Met Phe Gln Leu Leu Arg Gly Leu Ala Tyr  
 245 250 255  
 Cys His His Arg Lys Ile Leu His Arg Asp Leu Lys Pro Gln Asn  
 260 265 270  
 Leu Leu Ile Asn Glu Arg Gly Glu Leu Lys Leu Ala Asp Phe Gly  
 275 280 285

```

Leu Ala Arg Ala Lys Ser Val Pro Thr Lys Thr Tyr Ser Asn Glu
290                      295                      300
Val Val Thr Leu Trp Tyr Arg Pro Pro Asp Val Leu Leu Gly Ser
305                      310                      315
Thr Glu Tyr Ser Thr Pro Ile Asp Met Trp Gly Val Gly Cys Ile
320                      325                      330
His Tyr Glu Met Ala Thr Gly Arg Pro Leu Phe Pro Gly Ser Thr
335                      340                      345
Val Lys Glu Glu Leu His Leu Ile Phe Arg Leu Leu Gly Thr Pro
350                      355                      360
Thr Glu Glu Thr Trp Pro Gly Val Thr Ala Phe Ser Glu Phe Arg
365                      370                      375
Thr Tyr Ser Phe Pro Cys Tyr Leu Pro Gln Pro Leu Ile Asn His
380                      385                      390
Ala Pro Arg Leu Asp Thr Asp Gly Ile His Leu Leu Ser Ser Leu
395                      400                      405
Leu Leu Tyr Glu Ser Lys Ser Arg Met Ser Ala Glu Ala Ala Leu
410                      415                      420
Ser His Ser Tyr Phe Arg Ser Leu Gly Glu Arg Val His Gln Leu
425                      430                      435
Glu Asp Thr Ala Ser Ile Phe Ser Leu Lys Glu Ile Gln Leu Gln
440                      445                      450
Lys Asp Pro Gly Tyr Arg Gly Leu Ala Phe Gln Gln Pro Gly Arg
455                      460                      465
Gly Lys Asn Arg Arg Gln Ser Ile Phe
470

```

&lt;210&gt; 6

&lt;211&gt; 540

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 156108

&lt;400&gt; 6

```

Met Asn Gly Glu Ala Ile Cys Ser Ala Leu Pro Thr Ile Pro Tyr
1                      5                      10                      15
His Lys Leu Ala Asp Leu Arg Tyr Leu Ser Arg Gly Ala Ser Gly
20                      25                      30
Thr Val Ser Ser Ala Arg His Ala Asp Trp Arg Val Gln Val Ala
35                      40                      45
Val Lys His Leu His Ile His Thr Pro Leu Leu Asp Ser Glu Arg
50                      55                      60
Lys Asp Val Leu Arg Glu Ala Glu Ile Leu His Lys Ala Arg Phe
65                      70                      75
Ser Tyr Ile Leu Pro Ile Leu Gly Ile Cys Asn Glu Pro Glu Phe
80                      85                      90
Leu Gly Ile Val Thr Glu Tyr Met Pro Asn Gly Ser Leu Asn Glu
95                      100                     105
Leu Leu His Arg Lys Thr Glu Tyr Pro Asp Val Ala Trp Pro Leu
110                     115                     120
Arg Phe Arg Ile Leu His Glu Ile Ala Leu Gly Val Asn Tyr Leu

```

	125	130	135
His Asn Met Thr	Pro Pro Leu Leu His	His Asp Leu Lys Thr	Gln
	140	145	150
Asn Ile Leu Leu	Asp Asn Glu Phe His	Val Lys Ile Ala Asp	Phe
	155	160	165
Gly Leu Ser Lys	Trp Arg Met Met Ser	Leu Ser Gln Ser Arg	Ser
	170	175	180
Ser Lys Ser Ala	Pro Glu Gly Gly Thr	Ile Ile Tyr Met Pro	Pro
	185	190	195
Glu Asn Tyr Glu	Pro Gly Gln Lys Ser	Arg Ala Ser Ile Lys	His
	200	205	210
Asp Ile Tyr Ser	Tyr Ala Val Ile Thr	Trp Glu Val Leu Ser	Arg
	215	220	225
Lys Gln Pro Phe	Glu Asp Val Thr Asn	Pro Leu Gln Ile Met	Tyr
	230	235	240
Ser Val Ser Gln	Gly His Arg Pro Val	Ile Asn Glu Glu Ser	Leu
	245	250	255
Pro Tyr Asp Ile	Pro His Arg Ala Arg	Met Ile Ser Leu Ile	Glu
	260	265	270
Ser Gly Trp Ala	Gln Asn Pro Asp Glu	Arg Pro Ser Phe Leu	Lys
	275	280	285
Cys Leu Ile Glu	Leu Glu Pro Val Leu	Arg Thr Phe Glu Glu	Ile
	290	295	300
Thr Phe Leu Glu	Ala Val Ile Gln Leu	Lys Lys Thr Lys Leu	Gln
	305	310	315
Ser Val Ser Ser	Ala Ile His Leu Cys	Asp Lys Lys Lys Met	Glu
	320	325	330
Leu Ser Leu Asn	Ile Pro Val Asn His	Gly Pro Gln Glu Glu	Ser
	335	340	345
Cys Gly Ser Ser	Gln Leu His Glu Asn	Ser Gly Ser Pro Glu	Thr
	350	355	360
Ser Arg Ser Leu	Pro Ala Pro Gln Asp	Asn Asp Phe Leu Ser	Arg
	365	370	375
Lys Ala Gln Asp	Cys Tyr Phe Met Lys	Leu His His Cys Pro	Gly
	380	385	390
Asn His Ser Trp	Asp Ser Thr Ile Ser	Gly Ser Gln Arg Ala	Ala
	395	400	405
Phe Cys Asp His	Lys Thr Thr Pro Cys	Ser Ser Ala Ile Ile	Asn
	410	415	420
Pro Leu Ser Thr	Ala Gly Asn Ser Glu	Arg Leu Gln Pro Gly	Ile
	425	430	435
Ala Gln Gln Trp	Ile Gln Ser Lys Arg	Glu Asp Ile Val Asn	Gln
	440	445	450
Met Thr Glu Ala	Cys Leu Asn Gln Ser	Leu Asp Ala Leu Leu	Ser
	455	460	465
Arg Asp Leu Ile	Met Lys Glu Asp Tyr	Glu Leu Val Ser Thr	Lys
	470	475	480
Pro Thr Arg Thr	Ser Lys Val Arg Gln	Leu Leu Asp Thr Thr	Asp
	485	490	495
Ile Gln Gly Glu	Glu Phe Ala Lys Val	Ile Val Gln Lys Leu	Lys
	500	505	510
Asp Asn Lys Gln	Met Gly Leu Gln Pro	Tyr Pro Glu Ile Leu	Val
	515	520	525
Val Ser Arg Ser	Pro Ser Leu Asn Leu	Leu Gln Asn Lys Ser	Met
	530	535	540

<210> 7  
 <211> 454  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte Clone Number: 2883243

<400> 7  
 Met Tyr Asn Thr Val Trp Asn Met Glu Asp Leu Asp Leu Glu Tyr  
 1 5 10 15  
 Ala Lys Thr Asp Ile Asn Cys Gly Thr Asp Leu Met Phe Tyr Ile  
 20 25 30  
 Glu Met Asp Pro Pro Ala Leu Pro Pro Lys Pro Pro Lys Pro Thr  
 35 40 45  
 Thr Val Ala Asn Asn Gly Met Asn Asn Asn Met Ser Leu Gln Asp  
 50 55 60  
 Ala Glu Trp Tyr Trp Gly Asp Ile Ser Arg Glu Glu Val Asn Glu  
 65 70 75  
 Lys Leu Arg Asp Thr Ala Asp Gly Thr Phe Leu Val Arg Asp Ala  
 80 85 90  
 Ser Thr Lys Met His Gly Asp Tyr Thr Leu Thr Leu Arg Lys Gly  
 95 100 105  
 Gly Asn Asn Lys Leu Ile Lys Ile Phe His Arg Asp Gly Lys Tyr  
 110 115 120  
 Gly Phe Ser Asp Pro Leu Thr Phe Ser Ser Val Val Glu Leu Ile  
 125 130 135  
 Asn His Tyr Arg Asn Glu Ser Leu Ala Gln Tyr Asn Pro Lys Leu  
 140 145 150  
 Asp Val Lys Leu Leu Tyr Pro Val Ser Lys Tyr Gln Gln Asp Gln  
 155 160 165  
 Val Val Lys Glu Asp Asn Ile Glu Ala Val Gly Lys Lys Leu His  
 170 175 180  
 Glu Tyr Asn Thr Gln Phe Gln Glu Lys Ser Arg Glu Tyr Asp Arg  
 185 190 195  
 Leu Tyr Glu Glu Tyr Thr Arg Thr Ser Gln Glu Ile Gln Met Lys  
 200 205 210  
 Arg Thr Ala Ile Glu Ala Phe Asn Glu Thr Ile Lys Ile Phe Glu  
 215 220 225  
 Glu Gln Cys Gln Thr Gln Glu Arg Tyr Ser Lys Glu Tyr Ile Glu  
 230 235 240  
 Lys Phe Lys Arg Glu Gly Asn Glu Lys Glu Ile Gln Arg Ile Met  
 245 250 255  
 His Asn Tyr Asp Lys Leu Lys Ser Arg Ile Ser Glu Ile Ile Asp  
 260 265 270  
 Ser Arg Arg Arg Leu Glu Glu Asp Leu Lys Lys Gln Ala Ala Glu  
 275 280 285  
 Tyr Arg Glu Ile Asp Lys Arg Met Asn Ser Ile Lys Pro Asp Leu  
 290 295 300  
 Ile Gln Leu Arg Lys Thr Arg Asp Gln Tyr Leu Met Trp Leu Thr  
 305 310 315  
 Gln Lys Gly Val Arg Gln Lys Lys Leu Asn Glu Trp Leu Gly Asn  
 320 325 330  
 Glu Asn Thr Glu Asp Gln Tyr Ser Leu Val Glu Asp Asp Glu Asp  
 335 340 345

```

Leu Pro His His Asp Glu Lys Thr Trp Asn Val Gly Ser Ser Asn
350 355 360
Arg Asn Lys Ala Glu Asn Leu Leu Arg Gly Lys Arg Asp Gly Thr
365 370 375
Phe Leu Val Arg Glu Ser Ser Lys Gln Gly Cys Tyr Ala Cys Ser
380 385 390
Val Val Val Asp Gly Glu Val Lys His Cys Val Ile Asn Lys Thr
395 400 405
Ala Thr Gly Tyr Gly Phe Ala Glu Pro Tyr Asn Leu Tyr Ser Ser
410 415 420
Leu Lys Glu Leu Val Leu His Tyr Gln His Thr Ser Leu Val Gln
425 430 435
His Asn Asp Ser Leu Asn Val Thr Leu Ala Tyr Pro Val Tyr Ala
440 445 450
Gln Gln Arg Arg

```

&lt;210&gt; 8

&lt;211&gt; 502

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 3173355

&lt;400&gt; 8

```

Met Phe Gly Thr Leu Leu Leu Tyr Cys Phe Phe Leu Ala Thr Val
1 5 10 15
Pro Ala Leu Ala Glu Thr Gly Gly Glu Arg Gln Leu Ser Pro Glu
20 25 30
Lys Ser Glu Ile Trp Gly Pro Gly Leu Lys Ala Asp Val Val Leu
35 40 45
Pro Ala Arg Tyr Phe Tyr Ile Gln Ala Val Asp Thr Ser Gly Asn
50 55 60
Lys Phe Thr Ser Ser Pro Gly Glu Lys Val Phe Gln Val Lys Val
65 70 75
Ser Ala Pro Glu Glu Gln Phe Thr Arg Val Gly Val Gln Val Leu
80 85 90
Asp Arg Lys Asp Gly Ser Phe Ile Val Arg Tyr Arg Met Tyr Ala
95 100 105
Ser Tyr Lys Asn Leu Lys Val Glu Ile Lys Phe Gln Gly Gln His
110 115 120
Val Ala Lys Ser Pro Tyr Ile Leu Lys Gly Pro Val Tyr His Glu
125 130 135
Asn Cys Asp Cys Pro Leu Gln Asp Ser Ala Ala Trp Leu Arg Glu
140 145 150
Met Asn Cys Pro Glu Thr Ile Ala Gln Ile Gln Arg Asp Leu Ala
155 160 165
His Phe Pro Ala Val Asp Pro Glu Lys Ile Ala Val Glu Ile Pro
170 175 180
Lys Arg Phe Gly Gln Arg Gln Ser Leu Cys His Tyr Thr Leu Lys
185 190 195
Asp Asn Lys Val Tyr Ile Lys Thr His Gly Glu His Val Gly Phe
200 205 210
Arg Ile Phe Met Asp Ala Ile Leu Leu Ser Leu Thr Arg Lys Val

```

215	220	225
Lys Met Pro Asp Val Glu Leu Phe Val Asn Leu Gly Asp Trp Pro		
230	235	240
Leu Glu Lys Lys Lys Ser Asn Ser Asn Ile His Pro Ile Phe Ser		
245	250	255
Trp Cys Gly Ser Thr Asp Ser Lys Asp Ile Val Met Pro Thr Tyr		
260	265	270
Asp Leu Thr Asp Ser Val Leu Glu Thr Met Gly Arg Val Ser Leu		
275	280	285
Asp Met Met Ser Val Gln Ala Asn Thr Gly Pro Pro Trp Glu Ser		
290	295	300
Lys Asn Ser Thr Ala Val Trp Arg Gly Arg Asp Ser Arg Lys Glu		
305	310	315
Arg Leu Glu Leu Val Lys Leu Ser Arg Lys His Pro Glu Leu Ile		
320	325	330
Asp Ala Ala Phe Thr Asn Phe Phe Phe Phe Lys His Asp Glu Asn		
335	340	345
Leu Tyr Gly Pro Ile Val Lys His Ile Ser Phe Phe Asp Phe Phe		
350	355	360
Lys His Lys Tyr Gln Ile Asn Ile Asp Gly Thr Val Ala Ala Tyr		
365	370	375
Arg Leu Pro Tyr Leu Leu Val Gly Asp Ser Val Val Leu Lys Gln		
380	385	390
Asp Ser Ile Tyr Tyr Glu His Phe Tyr Asn Glu Leu Gln Pro Trp		
395	400	405
Lys His Tyr Ile Pro Val Lys Ser Asn Leu Ser Asp Leu Leu Glu		
410	415	420
Lys Leu Lys Trp Ala Lys Asp His Asp Glu Glu Ala Lys Lys Ile		
425	430	435
Ala Lys Ala Gly Gln Glu Phe Ala Arg Asn Asn Leu Met Gly Asp		
440	445	450
Asp Ile Phe Cys Tyr Tyr Phe Lys Leu Phe Gln Glu Tyr Ala Asn		
455	460	465
Leu Gln Val Ser Glu Pro Gln Ile Arg Glu Gly Met Lys Arg Val		
470	475	480
Glu Pro Gln Thr Glu Asp Asp Leu Phe Pro Cys Thr Cys His Arg		
485	490	495
Lys Lys Thr Lys Asp Glu Leu		
500		

&lt;210&gt; 9

&lt;211&gt; 282

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 5116906

&lt;400&gt; 9

Met Trp Ala Cys Gly Val Ile Leu Tyr Ile Leu Leu Val Gly Tyr		
1	5	10
Pro Pro Phe Trp Asp Glu Asp Gln His Arg Leu Tyr Gln Gln Ile		
20	25	30
Lys Ala Gly Ala Tyr Asp Phe Pro Ser Pro Glu Trp Asp Thr Val		
35	40	45



```

Thr Pro Glu Ala Lys Asp Leu Ile Asn Lys Met Leu Thr Ile Asn
      50              55              60
Pro Ala Lys Arg Ile Thr Ala Ser Glu Ala Leu Lys His Pro Trp
      65              70              75
Ile Cys Gln Arg Ser Thr Val Ala Ser Met Met His Arg Gln Glu
      80              85              90
Thr Val Asp Cys Leu Lys Lys Phe Asn Ala Arg Arg Lys Leu Lys
      95              100             105
Gly Ala Ile Leu Thr Thr Met Leu Ala Thr Arg Asn Phe Ser Ala
      110             115             120
Ala Lys Ser Leu Leu Lys Lys Pro Asp Gly Val Lys Glu Ser Thr
      125             130             135
Glu Ser Ser Asn Thr Thr Ile Glu Asp Glu Asp Val Lys Ala Arg
      140             145             150
Lys Gln Glu Ile Ile Lys Val Thr Glu Gln Leu Ile Glu Ala Ile
      155             160             165
Asn Asn Gly Asp Phe Glu Ala Tyr Thr Lys Ile Cys Asp Pro Gly
      170             175             180
Leu Thr Ala Phe Glu Pro Glu Ala Leu Gly Asn Leu Val Glu Gly
      185             190             195
Met Asp Phe His Arg Phe Tyr Phe Glu Asn Ala Leu Ser Lys Ser
      200             205             210
Asn Lys Pro Ile His Thr Ile Ile Leu Asn Pro His Val His Leu
      215             220             225
Val Gly Asp Asp Ala Ala Cys Ile Ala Tyr Ile Arg Leu Thr Gln
      230             235             240
Tyr Met Asp Gly Ser Gly Met Pro Lys Thr Met Gln Ser Glu Glu
      245             250             255
Thr Arg Val Trp His Arg Arg Asp Gly Lys Trp Gln Asn Val His
      260             265             270
Phe His Arg Ser Gly Ser Pro Thr Val Pro Ile Asn
      275             280

```

&lt;210&gt; 10

&lt;211&gt; 510

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 940589

&lt;400&gt; 10

```

Met Lys Ala Asp Ile Lys Ile Trp Ile Leu Thr Gly Asp Lys Gln
      1              5              10             15
Glu Thr Ala Ile Asn Ile Gly His Ser Cys Lys Leu Leu Lys Lys
      20             25             30
Asn Met Gly Met Ile Val Ile Asn Glu Gly Ser Leu Asp Ser Phe
      35             40             45
Ser Asn Thr Gln Asn Ser Arg Lys Glu Ala Val Leu Leu Ala Lys
      50             55             60
Met Lys His Pro Asn Ile Val Ala Phe Lys Glu Ser Phe Glu Ala
      65             70             75
Glu Gly His Leu Tyr Ile Val Met Glu Tyr Cys Asp Gly Gly Asp
      80             85             90

```

Leu Met Gln Lys Ile Lys Gln Gln Lys Gly Lys Leu Phe Pro Glu		
95	100	105
Asp Met Ile Leu Asn Trp Phe Thr Gln Met Cys Leu Gly Val Asn		
110	115	120
His Ile His Lys Lys Arg Val Leu His Arg Asp Ile Lys Ser Lys		
125	130	135
Asn Ile Phe Leu Thr Gln Asn Gly Lys Val Lys Leu Gly Asp Phe		
140	145	150
Gly Ser Ala Arg Leu Leu Ser Asn Pro Met Ala Phe Ala Cys Thr		
155	160	165
Tyr Val Gly Thr Pro Tyr Tyr Val Pro Pro Glu Ile Trp Glu Asn		
170	175	180
Leu Pro Tyr Asn Asn Lys Ser Asp Ile Trp Ser Leu Gly Cys Ile		
185	190	195
Leu Tyr Glu Leu Cys Thr Leu Lys His Pro Phe Gln Ala Asn Ser		
200	205	210
Trp Lys Asn Leu Ile Leu Lys Val Cys Gln Gly Cys Ile Ser Pro		
215	220	225
Leu Pro Ser His Tyr Ser Tyr Glu Leu Gln Phe Leu Val Lys Gln		
230	235	240
Met Phe Lys Arg Asn Pro Ser His Arg Pro Ser Ala Thr Thr Leu		
245	250	255
Leu Ser Arg Gly Ile Val Ala Arg Leu Val Gln Lys Cys Leu Pro		
260	265	270
Pro Glu Ile Ile Met Glu Tyr Gly Glu Glu Val Leu Glu Glu Ile		
275	280	285
Lys Asn Ser Lys His Asn Thr Pro Arg Lys Lys Thr Asn Pro Ser		
290	295	300
Arg Ile Arg Ile Ala Leu Gly Asn Glu Ala Ser Thr Val Gln Glu		
305	310	315
Glu Glu Gln Asp Arg Lys Gly Ser His Thr Asp Leu Glu Ser Ile		
320	325	330
Asn Glu Asn Leu Val Glu Ser Ala Leu Arg Arg Val Asn Arg Glu		
335	340	345
Glu Lys Gly Asn Lys Ser Val His Leu Arg Lys Ala Ser Ser Pro		
350	355	360
Asn Leu His Arg Arg Gln Trp Glu Lys Asn Val Pro Asn Thr Ala		
365	370	375
Leu Thr Ala Leu Glu Asn Ala Ser Ile Leu Thr Ser Ser Leu Thr		
380	385	390
Ala Glu Asp Asp Arg Gly Gly Ser Val Ile Lys Tyr Ser Lys Asn		
395	400	405
Thr Thr Arg Lys Gln Trp Leu Lys Glu Thr Pro Asp Thr Leu Leu		
410	415	420
Asn Ile Leu Lys Asn Ala Asp Leu Ser Leu Ala Phe Gln Thr Tyr		
425	430	435
Thr Ile Tyr Arg Pro Gly Ser Glu Gly Phe Leu Lys Gly Pro Leu		
440	445	450
Ser Glu Glu Thr Glu Ala Ser Asp Ser Val Asp Gly Gly His Asp		
455	460	465
Ser Val Ile Leu Asp Pro Glu Arg Leu Glu Pro Gly Leu Asp Glu		
470	475	480
Glu Asp Thr Asp Phe Glu Glu Glu Asp Asp Asn Pro Asp Trp Val		
485	490	495
Ser Glu Leu Lys Lys Arg Ala Gly Trp Gln Gly Leu Cys Asp Arg		
500	505	510

<210> 11  
 <211> 248  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte Clone Number: 304421

<400> 11  
 Met Ala Glu Thr Ser Leu Pro Glu Leu Gly Gly Glu Asp Lys Ala  
                   5                  10                  15  
 Thr Pro Cys Pro Ser Ile Leu Glu Leu Glu Glu Leu Leu Arg Ala  
                   20                  25                  30  
 Gly Lys Ser Ser Cys Ser Arg Val Asp Glu Val Trp Pro Asn Leu  
                   35                  40                  45  
 Phe Ile Gly Asp Ala Met Asp Ser Leu Gln Lys Gln Asp Leu Arg  
                   50                  55                  60  
 Arg Pro Lys Ile His Gly Ala Val Gln Ala Ser Pro Tyr Gln Pro  
                   65                  70                  75  
 Pro Thr Leu Ala Ser Leu Gln Arg Leu Leu Trp Val Arg Gln Ala  
                   80                  85                  90  
 Ala Thr Leu Asn His Ile Asp Glu Val Trp Pro Ser Leu Phe Leu  
                   95                  100                 105  
 Gly Asp Ala Tyr Ala Ala Arg Asp Lys Ser Lys Leu Ile Gln Leu  
                  110                 115                 120  
 Gly Ile Thr His Val Val Asn Ala Ala Ala Gly Lys Phe Gln Val  
                  125                 130                 135  
 Asp Thr Gly Ala Lys Phe Tyr Arg Gly Met Ser Leu Glu Tyr Tyr  
                  140                 145                 150  
 Gly Ile Glu Ala Asp Asp Asn Pro Phe Phe Asp Leu Ser Val Tyr  
                  155                 160                 165  
 Phe Leu Pro Val Ala Arg Tyr Ile Arg Ala Ala Leu Ser Val Pro  
                  170                 175                 180  
 Gln Gly Arg Val Leu Val His Cys Ala Met Gly Val Ser Arg Ser  
                  185                 190                 195  
 Ala Thr Leu Val Leu Ala Phe Leu Met Ile Tyr Glu Asn Met Thr  
                  200                 205                 210  
 Leu Val Glu Ala Ile Gln Thr Val Gln Ala His Arg Asn Ile Cys  
                  215                 220                 225  
 Pro Asn Ser Gly Phe Leu Arg Gln Leu Gln Val Leu Asp Asn Arg  
                  230                 235                 240  
 Leu Gly Arg Glu Thr Gly Arg Phe  
                  245

<210> 12  
 <211> 810  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte Clone Number: 1213802

&lt;400&gt; 12

```

Met Pro Asn Gln Gly Glu Asp Cys Tyr Phe Phe Phe Tyr Ser Thr
 1           5           10           15
Cys Thr Lys Gly Asp Ser Cys Pro Phe Arg His Cys Glu Ala Ala
      20           25           30
Ile Gly Asn Glu Thr Val Cys Thr Leu Trp Gln Glu Gly Arg Cys
      35           40           45
Phe Arg Gln Val Cys Arg Phe Arg His Met Glu Ile Asp Lys Lys
      50           55           60
Arg Ser Glu Ile Pro Cys Tyr Trp Glu Asn Gln Pro Thr Gly Cys
      65           70           75
Gln Lys Leu Asn Cys Ala Phe His His Asn Arg Gly Arg Tyr Val
      80           85           90
Asp Gly Leu Phe Leu Pro Pro Ser Lys Thr Val Leu Pro Thr Val
      95          100          105
Pro Glu Ser Pro Glu Glu Glu Val Lys Ala Ser Gln Leu Ser Val
      110          115          120
Gln Gln Asn Lys Leu Ser Val Gln Ser Asn Pro Ser Pro Gln Leu
      125          130          135
Arg Ser Val Met Lys Val Glu Ser Ser Glu Asn Val Pro Ser Pro
      140          145          150
Thr His Pro Pro Val Val Ile Asn Ala Ala Asp Asp Asp Glu Asp
      155          160          165
Asp Asp Asp Gln Phe Ser Glu Glu Gly Asp Glu Thr Lys Thr Pro
      170          175          180
Thr Leu Gln Pro Thr Pro Glu Val His Asn Gly Leu Arg Val Thr
      185          190          195
Ser Val Arg Lys Pro Ala Val Asn Ile Lys Gln Gly Glu Cys Leu
      200          205          210
Asn Phe Gly Ile Lys Thr Leu Glu Glu Ile Lys Ser Lys Lys Met
      215          220          225
Lys Glu Lys Ser Lys Lys Gln Gly Glu Gly Ser Ser Gly Val Ser
      230          235          240
Ser Leu Leu Leu His Pro Glu Pro Val Pro Gly Pro Glu Lys Glu
      245          250          255
Asn Val Arg Thr Val Val Arg Thr Val Thr Leu Ser Thr Lys Gln
      260          265          270
Gly Glu Glu Pro Leu Val Arg Leu Ser Leu Thr Glu Arg Leu Gly
      275          280          285
Lys Arg Lys Phe Ser Ala Gly Gly Asp Ser Asp Pro Pro Leu Lys
      290          295          300
Arg Ser Leu Ala Gln Arg Leu Gly Lys Lys Val Glu Ala Pro Glu
      305          310          315
Thr Asn Ile Asp Lys Thr Pro Lys Lys Ala Gln Val Ser Lys Ser
      320          325          330
Leu Lys Glu Arg Leu Gly Met Ser Ala Asp Pro Asp Asn Glu Asp
      335          340          345
Ala Thr Asp Lys Val Asn Lys Val Gly Glu Ile His Val Lys Thr
      350          355          360
Leu Glu Glu Ile Leu Leu Glu Arg Ala Ser Gln Lys Arg Gly Glu
      365          370          375
Leu Gln Thr Lys Leu Lys Thr Glu Gly Pro Ser Lys Thr Asp Asp
      380          385          390
Ser Thr Ser Gly Ala Arg Ser Ser Ser Thr Ile Arg Ile Lys Thr
      395          400          405
Phe Ser Glu Val Leu Ala Glu Lys Lys His Arg Gln Gln Glu Ala

```

410	415	420
Glu Arg Gln Lys Ser Lys Lys Asp Thr	Thr Cys Ile Lys Leu Lys	
425	430	435
Ile Asp Ser Glu Ile Lys Lys Thr Val	Val Leu Pro Pro Ile Val	
440	445	450
Ala Ser Arg Gly Gln Ser Glu Glu Pro	Ala Gly Lys Thr Lys Ser	
455	460	465
Met Gln Glu Val His Ile Lys Thr Leu	Glu Glu Ile Lys Leu Glu	
470	475	480
Lys Ala Leu Arg Val Gln Gln Ser Ser	Glu Ser Ser Thr Ser Ser	
485	490	495
Pro Ser Gln His Glu Ala Thr Pro Gly	Ala Arg Arg Leu Leu Arg	
500	505	510
Ile Thr Lys Arg Thr Gly Met Lys Glu	Glu Lys Asn Leu Gln Glu	
515	520	525
Gly Asn Glu Val Asp Ser Gln Ser Ser	Ile Arg Thr Glu Ala Lys	
530	535	540
Glu Ala Ser Gly Glu Thr Thr Gly Val	Asp Ile Thr Lys Ile Gln	
545	550	555
Val Lys Arg Cys Glu Thr Met Arg Glu	Lys His Met Gln Lys Gln	
560	565	570
Gln Glu Arg Glu Lys Ser Val Leu Thr	Pro Leu Arg Gly Asp Val	
575	580	585
Ala Ser Cys Asn Thr Gln Val Ala Glu	Lys Pro Val Leu Thr Ala	
590	595	600
Val Pro Gly Ile Thr Arg His Leu Thr	Lys Arg Leu Pro Thr Lys	
605	610	615
Ser Ser Gln Lys Val Glu Val Glu Thr	Ser Gly Ile Gly Asp Ser	
620	625	630
Leu Leu Asn Val Lys Cys Ala Ala Gln	Thr Leu Glu Lys Arg Gly	
635	640	645
Lys Ala Lys Pro Lys Val Asn Val Lys	Pro Ser Val Val Lys Val	
650	655	660
Val Ser Ser Pro Lys Leu Ala Pro Lys	Arg Lys Ala Val Glu Met	
665	670	675
His Ala Ala Val Ile Ala Ala Val Lys	Pro Leu Ser Ser Ser Ser	
680	685	690
Val Leu Gln Glu Pro Pro Ala Lys Lys	Ala Ala Val Ala Val Val	
695	700	705
Pro Leu Val Ser Glu Asp Lys Ser Val	Thr Val Pro Glu Ala Glu	
710	715	720
Asn Pro Arg Asp Ser Leu Val Leu Pro	Pro Thr Gln Ser Ser Ser	
725	730	735
Asp Ser Ser Pro Pro Glu Val Ser Gly	Pro Ser Ser Ser Gln Met	
740	745	750
Ser Met Lys Thr Arg Arg Leu Ser Ser	Ala Ser Thr Gly Lys Pro	
755	760	765
Pro Leu Ser Val Glu Asp Asp Phe Glu	Lys Leu Ile Trp Glu Ile	
770	775	780
Ser Gly Gly Lys Leu Glu Ala Glu Ile	Asp Leu Asp Pro Gly Lys	
785	790	795
Asp Glu Asp Asp Leu Leu Leu Glu Leu	Ser Glu Met Ile Asp Ser	
800	805	810

<211> 549  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte Clone Number: 1378134

<400> 13  
 Met Arg Arg Arg Ala Ser Asn Ala Ala Ala Ala Ala His Thr Ile  
           1                  5                  10                  15  
 Gly Gly Ser Lys His Thr Met Asn Asp His Leu His Val Gly Ser  
                   20                  25                  30  
 His Ala His Gly Gln Ile Gln Val Arg Gln Leu Phe Glu Asp Asn  
                   35                  40                  45  
 Ser Asn Lys Arg Thr Val Leu Thr Thr Gln Pro Asn Gly Leu Thr  
                   50                  55                  60  
 Thr Val Gly Lys Thr Gly Leu Pro Val Val Pro Glu Arg Gln Leu  
                   65                  70                  75  
 Asp Ser Ile His Arg Arg Gln Gly Ser Ser Thr Ser Leu Lys Ser  
                   80                  85                  90  
 Met Glu Gly Met Gly Lys Val Lys Ala Thr Pro Met Thr Pro Glu  
                   95                  100                  105  
 Gln Ala Met Lys Gln Tyr Met Gln Lys Leu Thr Ala Phe Glu His  
                   110                  115                  120  
 His Glu Ile Phe Ser Tyr Pro Glu Ile Tyr Phe Leu Gly Leu Asn  
                   125                  130                  135  
 Ala Lys Lys Arg Gln Gly Met Thr Gly Gly Pro Asn Asn Gly Gly  
                   140                  145                  150  
 Tyr Asp Asp Asp Gln Gly Ser Tyr Val Gln Val Pro His Asp His  
                   155                  160                  165  
 Val Ala Tyr Arg Tyr Glu Val Leu Lys Val Ile Gly Lys Gly Ser  
                   170                  175                  180  
 Phe Gly Gln Val Val Lys Ala Tyr Asp His Lys Val His Gln His  
                   185                  190                  195  
 Val Ala Leu Lys Met Val Arg Asn Glu Lys Arg Phe His Arg Gln  
                   200                  205                  210  
 Ala Ala Glu Glu Ile Arg Ile Leu Glu His Leu Arg Lys Gln Asp  
                   215                  220                  225  
 Lys Asp Asn Thr Met Asn Val Ile His Met Leu Glu Asn Phe Thr  
                   230                  235                  240  
 Phe Arg Asn His Ile Cys Met Thr Phe Glu Leu Leu Ser Met Asn  
                   245                  250                  255  
 Leu Tyr Glu Leu Ile Lys Lys Asn Lys Phe Gln Gly Phe Ser Leu  
                   260                  265                  270  
 Pro Leu Val Arg Lys Phe Ala His Ser Ile Leu Gln Cys Leu Asp  
                   275                  280                  285  
 Ala Leu His Lys Asn Arg Ile Ile His Cys Asp Leu Lys Pro Glu  
                   290                  295                  300  
 Asn Ile Leu Leu Lys Gln Gln Gly Arg Ser Gly Ile Lys Val Ile  
                   305                  310                  315  
 Asp Phe Gly Ser Ser Cys Tyr Glu His Gln Arg Val Tyr Thr Tyr  
                   320                  325                  330  
 Ile Gln Ser Arg Phe Tyr Arg Ala Pro Glu Val Ile Leu Gly Ala  
                   335                  340                  345  
 Arg Tyr Gly Met Pro Ile Asp Met Trp Ser Leu Gly Cys Ile Leu

350	355	360
Ala Glu Leu Leu Thr Gly Tyr Pro Leu	Leu Pro Gly Glu Asp Glu	
365	370	375
Gly Asp Gln Leu Ala Cys Met Ile Glu	Leu Leu Gly Met Pro Ser	
380	385	390
Gln Lys Leu Leu Asp Ala Ser Lys Arg	Ala Lys Asn Phe Val Ser	
395	400	405
Ser Lys Gly Tyr Pro Arg Tyr Cys Thr	Val Thr Thr Leu Ser Asp	
410	415	420
Gly Ser Val Val Leu Asn Gly Gly Arg	Ser Arg Arg Gly Lys Leu	
425	430	435
Arg Gly Pro Pro Glu Ser Arg Glu Trp	Gly Asn Ala Leu Lys Gly	
440	445	450
Cys Asp Asp Pro Leu Phe Leu Asp Phe	Leu Lys Gln Cys Leu Glu	
455	460	465
Trp Asp Pro Ala Val Arg Met Thr Pro	Gly Gln Ala Leu Arg His	
470	475	480
Pro Trp Leu Arg Arg Arg Leu Pro Lys	Pro Pro Thr Gly Glu Lys	
485	490	495
Thr Ser Val Lys Arg Ile Thr Glu Ser	Thr Gly Ala Ile Thr Ser	
500	505	510
Ile Ser Lys Leu Pro Pro Pro Ser Ser	Ser Ala Ser Lys Leu Arg	
515	520	525
Thr Asn Leu Ala Gln Met Thr Asp Ala	Asn Gly Asn Ile Gln Gln	
530	535	540
Arg Thr Val Leu Pro Lys Leu Val Ser		
545		

&lt;210&gt; 14

&lt;211&gt; 416

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 1490070

&lt;400&gt; 14

Met Met Pro Gln Leu Gln Phe Lys Asp Ala Phe Trp Cys Arg Asp	
1	5
Phe Thr Ala His Thr Gly Tyr Glu Val Leu Leu Gln Arg Leu Leu	10
20	25
Asp Gly Arg Lys Met Cys Lys Asp Met Val Glu Leu Leu Trp Gln	30
35	40
Arg Ala Gln Ala Glu Glu Arg Tyr Gly Lys Glu Leu Val Gln Ile	45
50	55
Ala Arg Lys Ala Gly Gly Gln Thr Glu Ile Asn Ser Leu Arg Ala	60
65	70
Ser Phe Asp Ser Leu Lys Gln Gln Met Glu Asn Val Gly Ser Ser	75
80	85
His Ile Gln Leu Ala Leu Thr Leu Arg Glu Glu Leu Arg Ser Leu	90
95	100
Glu Glu Phe Arg Glu Arg Gln Lys Glu Gln Arg Lys Lys Tyr Glu	105
110	115
Ala Val Met Asp Arg Val Gln Lys Ser Lys Leu Ser Leu Tyr Lys	120

	125	130	135
Lys Ala Met Glu	Ser Lys Lys Thr Tyr Glu Gln Lys Cys Arg Asp		
	140	145	150
Ala Asp Asp Ala	Glu Gln Ala Phe Glu Arg Ile Ser Ala Asn Gly		
	155	160	165
His Gln Lys Gln	Val Glu Lys Ser Gln Asn Lys Ala Arg Gln Cys		
	170	175	180
Lys Asp Ser Ala	Thr Glu Ala Glu Arg Val Tyr Arg Gln Ser Ile		
	185	190	195
Ala Gln Leu Glu	Lys Val Arg Ala Glu Trp Glu Gln Glu His Arg		
	200	205	210
Thr Thr Cys Glu	Ala Phe Gln Leu Gln Glu Phe Asp Arg Leu Thr		
	215	220	225
Ile Leu Arg Asn	Ala Leu Trp Val His Ser Asn Gln Leu Ser Met		
	230	235	240
Gln Cys Val Lys	Asp Asp Glu Leu Tyr Glu Glu Val Arg Leu Thr		
	245	250	255
Leu Glu Gly Cys	Ser Ile Asp Ala Asp Ile Asp Ser Phe Ile Gln		
	260	265	270
Ala Lys Ser Thr	Gly Thr Glu Pro Pro Ala Pro Val Pro Tyr Gln		
	275	280	285
Asn Tyr Tyr Asp	Arg Glu Val Thr Pro Leu Thr Ser Ser Pro Gly		
	290	295	300
Ile Gln Pro Ser	Cys Gly Met Ile Lys Arg Phe Ser Gly Leu Leu		
	305	310	315
His Gly Ser Pro	Lys Thr Thr Ser Leu Ala Ala Ser Ala Ala Ser		
	320	325	330
Thr Glu Thr Leu	Thr Pro Thr Pro Glu Arg Asn Glu Gly Val Tyr		
	335	340	345
Thr Ala Ile Ala	Val Gln Glu Ile Gln Gly Asn Pro Ala Ser Pro		
	350	355	360
Ala Gln Glu Tyr	Arg Ala Leu Tyr Asp Tyr Thr Ala Gln Asn Pro		
	365	370	375
Asp Glu Leu Asp	Leu Ser Ala Gly Asp Ile Leu Glu Val Ile Leu		
	380	385	390
Glu Gly Glu Asp	Gly Trp Trp Thr Val Glu Arg Asn Gly Gln Arg		
	395	400	405
Gly Phe Val Pro	Gly Ser Tyr Leu Glu Lys Leu		
	410	415	

&lt;210&gt; 15

&lt;211&gt; 425

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 1997814

&lt;400&gt; 15

Met Glu Gln Gly	Leu Glu Glu Glu Glu Val Asp Pro Arg Ile	
1	5	10
Gln Gly Glu Leu	Glu Lys Leu Asn Gln Ser Thr Asp Asp Ile Asn	15
	20	25
Arg Arg Glu Thr	Glu Leu Glu Asp Ala Arg Gln Lys Phe Arg Ser	30
	35	40
		45



Val	Leu	Val	Glu	Ala	Thr	Val	Lys	Leu	Asp	Glu	Leu	Val	Lys	Lys	50	55	60
Ile	Gly	Lys	Ala	Val	Glu	Asp	Ser	Lys	Pro	Tyr	Trp	Glu	Ala	Arg	65	70	75
Arg	Val	Ala	Arg	Gln	Ala	Gln	Leu	Glu	Ala	Gln	Lys	Ala	Thr	Gln	80	85	90
Asp	Phe	Gln	Arg	Ala	Thr	Glu	Val	Leu	Arg	Ala	Ala	Lys	Glu	Thr	95	100	105
Ile	Ser	Leu	Ala	Glu	Gln	Arg	Leu	Leu	Glu	Asp	Asp	Lys	Arg	Gln	110	115	120
Phe	Asp	Ser	Ala	Trp	Gln	Glu	Met	Leu	Asn	His	Ala	Thr	Gln	Arg	125	130	135
Val	Met	Glu	Ala	Glu	Gln	Thr	Lys	Thr	Arg	Ser	Glu	Leu	Val	His	140	145	150
Lys	Glu	Thr	Ala	Ala	Arg	Tyr	Asn	Ala	Ala	Met	Gly	Arg	Met	Arg	155	160	165
Gln	Leu	Glu	Lys	Lys	Leu	Lys	Arg	Ala	Ile	Asn	Lys	Ser	Lys	Pro	170	175	180
Tyr	Phe	Glu	Leu	Lys	Ala	Lys	Tyr	Tyr	Val	Gln	Leu	Glu	Gln	Leu	185	190	195
Lys	Lys	Thr	Val	Asp	Leu	Gln	Ala	Lys	Leu	Thr	Leu	Ala	Lys		200	205	210
Gly	Glu	Tyr	Lys	Met	Ala	Leu	Lys	Asn	Leu	Glu	Met	Ile	Ser	Asp	215	220	225
Glu	Ile	His	Glu	Arg	Arg	Arg	Ser	Ser	Ala	Met	Gly	Pro	Arg	Gly	230	235	240
Cys	Gly	Val	Gly	Ala	Glu	Gly	Ser	Ser	Thr	Ser	Val	Glu	Asp	Leu	245	250	255
Pro	Gly	Ser	Lys	Pro	Glu	Pro	Asp	Ala	Ile	Ser	Val	Ala	Ser	Glu	260	265	270
Ala	Phe	Glu	Asp	Asp	Ser	Cys	Ser	Asn	Phe	Val	Ser	Glu	Asp	Asp	275	280	285
Ser	Glu	Thr	Gln	Ser	Val	Ser	Ser	Phe	Ser	Ser	Gly	Pro	Thr	Ser	290	295	300
Pro	Ser	Glu	Met	Pro	Asp	Gln	Phe	Pro	Ala	Val	Val	Arg	Pro	Gly	305	310	315
Ser	Leu	Asp	Leu	Pro	Ser	Pro	Val	Ser	Leu	Ser	Glu	Phe	Gly	Met	320	325	330
Met	Phe	Pro	Val	Leu	Gly	Pro	Arg	Ser	Glu	Cys	Ser	Gly	Ala	Ser	335	340	345
Ser	Pro	Glu	Cys	Glu	Val	Glu	Arg	Gly	Asp	Arg	Ala	Glu	Gly	Ala	350	355	360
Glu	Asn	Lys	Thr	Ser	Asp	Lys	Ala	Asn	Asn	Asn	Arg	Gly	Leu	Ser	365	370	375
Ser	Ser	Ser	Gly	Ser	Gly	Gly	Ser	Ser	Lys	Ser	Gln	Ser	Ser	Thr	380	385	390
Ser	Pro	Glu	Gly	Gln	Ala	Leu	Glu	Asn	Arg	Met	Lys	Gln	Leu	Ser	395	400	405
Leu	Gln	Cys	Ser	Lys	Gly	Arg	Asp	Gly	Ile	Ile	Ala	Asp	Ile	Lys	410	415	420
Met	Val	Gln	Ile	Gly											425		

&lt;210&gt; 16

&lt;211&gt; 1135

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2299715

&lt;400&gt; 16

```

Met Ala Asn Asp Ser Pro Ala Lys Ser Leu Val Asp Ile Asp Leu
  1              5              10              15
Ser Ser Leu Arg Asp Pro Ala Gly Ile Phe Glu Leu Val Glu Val
              20              25              30
Val Gly Asn Gly Thr Tyr Gly Gln Val Tyr Lys Gly Arg His Val
              35              40              45
Lys Thr Gly Gln Leu Ala Ala Ile Lys Val Met Asp Val Thr Glu
              50              55              60

Asp Glu Glu Glu Glu Ile Lys Leu Glu Ile Asn Met Leu Lys Lys
              65              70              75
Tyr Ser His His Arg Asn Ile Ala Thr Tyr Tyr Gly Ala Phe Ile
              80              85              90
Lys Lys Ser Pro Gly His Asp Asp Gln Leu Trp Leu Val Met
              95              100             105
Glu Phe Cys Gly Ala Gly Ser Ile Thr Asp Leu Val Lys Asn Thr
              110             115             120
Lys Gly Asn Thr Leu Lys Glu Asp Trp Ile Ala Tyr Ile Ser Arg
              125             130             135
Glu Ile Leu Arg Gly Leu Ala His Leu His Ile His His Val Ile
              140             145             150
His Arg Asp Ile Lys Gly Gln Asn Val Leu Leu Thr Glu Asn Ala
              155             160             165
Gly Val Lys Leu Val Asp Phe Gly Val Ser Ala Gln Leu Asp Arg
              170             175             180
Thr Val Gly Arg Arg Asn Thr Phe Ile Gly Thr Pro Tyr Trp Met
              185             190             195
Ala Pro Glu Val Ile Ala Cys Asp Glu Asn Pro Asp Ala Thr Tyr
              200             205             210
Asp Tyr Arg Ser Asp Leu Trp Ser Cys Gly Ile Thr Ala Ile Glu
              215             220             225
Met Ala Glu Gly Ala Pro Pro Leu Cys Asp Met His Pro Met Arg
              230             235             240
Ala Leu Phe Leu Ile Pro Arg Asn Pro Pro Pro Arg Leu Lys Ser
              245             250             255
Lys Lys Trp Ser Lys Lys Phe Phe Ser Phe Ile Glu Gly Cys Leu
              260             265             270
Val Lys Asn Tyr Met Gln Arg Pro Ser Thr Glu Gln Leu Leu Lys
              275             280             285
His Pro Phe Ile Arg Asp Gln Pro Asn Glu Arg Gln Val Arg Ile
              290             295             300
Gln Leu Lys Asp His Ile Asp Arg Thr Arg Lys Lys Arg Gly Glu
              305             310             315
Lys Asp Glu Thr Glu Tyr Glu Tyr Ser Gly Ser Glu Glu Glu Glu
              320             325             330
Glu Glu Val Pro Glu Gln Glu Gly Glu Pro Ser Ser Ile Val Asn
              335             340             345
Val Pro Gly Glu Ser Thr Leu Arg Arg Asp Phe Leu Arg Leu Gln

```

350	355	360
Gln Glu Asn Lys Glu Arg Ser Glu Ala	Leu Arg Arg Gln Gln Leu	
365	370	375
Leu Gln Glu Gln Gln Leu Arg Glu Gln	Glu Glu Tyr Lys Arg Gln	
380	385	390
Leu Leu Ala Glu Arg Gln Lys Arg Ile	Glu Gln Gln Lys Glu Gln	
395	400	405
Arg Arg Arg Leu Glu Glu Gln Gln Arg	Arg Glu Arg Glu Ala Arg	
410	415	420
Arg Gln Gln Glu Arg Glu Gln Arg Arg	Arg Glu Gln Glu Glu Lys	
425	430	435
Arg Arg Leu Glu Glu Leu Glu Arg Arg	Arg Lys Glu Glu Glu Glu	
440	445	450
Arg Arg Arg Ala Glu Glu Lys Arg Arg	Val Glu Arg Glu Gln	
455	460	465
Glu Tyr Ile Arg Arg Gln Leu Glu Glu	Glu Gln Arg His Leu Glu	
470	475	480
Val Leu Gln Gln Gln Leu Leu Gln Glu	Gln Ala Met Leu Leu His	
485	490	495
Asp His Arg Arg Pro His Pro Gln His	Ser Gln Gln Pro Pro Pro	
500	505	510
Pro Gln Gln Glu Arg Ser Lys Pro Ser	Phe His Ala Pro Glu Pro	
515	520	525
Lys Ala His Tyr Glu Pro Ala Asp Arg	Ala Arg Glu Val Pro Val	
530	535	540
Arg Thr Thr Ser Arg Ser Pro Val Leu	Ser Arg Arg Asp Ser Pro	
545	550	555
Leu Gln Gly Ser Gly Gln Gln Asn Ser	Gln Ala Gly Gln Arg Asn	
560	565	570
Ser Thr Ser Ile Glu Pro Arg Leu Leu	Trp Glu Arg Val Glu Lys	
575	580	585
Leu Val Pro Arg Pro Gly Ser Gly Ser	Ser Ser Gly Ser Ser Asn	
590	595	600
Ser Gly Ser Gln Pro Gly Ser His Pro	Gly Ser Gln Ser Gly Ser	
605	610	615
Gly Glu Arg Phe Arg Val Arg Ser Ser	Ser Lys Ser Glu Gly Ser	
620	625	630
Pro Ser Gln Arg Leu Glu Asn Ala Val	Lys Lys Pro Glu Asp Lys	
635	640	645
Lys Glu Val Phe Arg Pro Leu Lys Pro	Ala Asp Leu Thr Ala Leu	
650	655	660
Ala Lys Glu Leu Arg Ala Val Glu Asp	Val Arg Pro Pro His Lys	
665	670	675
Val Thr Asp Tyr Ser Ser Ser Ser Glu	Glu Ser Gly Thr Thr Asp	
680	685	690
Glu Glu Asp Asp Asp Val Glu Gln Glu	Gly Ala Asp Glu Ser Thr	
695	700	705
Ser Gly Pro Glu Asp Thr Arg Ala Ala	Ser Ser Leu Asn Leu Ser	
710	715	720
Asn Gly Glu Thr Glu Ser Val Lys Thr	Met Ile Val His Asp Asp	
725	730	735
Val Glu Ser Glu Pro Ala Met Thr Pro	Ser Lys Glu Gly Thr Leu	
740	745	750
Ile Val Arg Gln Thr Gln Ser Ala Ser	Ser Thr Leu Gln Lys His	
755	760	765
Lys Ser Ser Ser Ser Phe Thr Pro Phe	Ile Asp Pro Arg Leu Leu	

	770		775		780
Gln Ile Ser Pro	Ser Ser Gly Thr Thr Val	Thr Ser Val Val Gly			
	785		790		795
Phe Ser Cys Asp	Gly Met Arg Pro Glu Ala Ile Arg Gln Asp Pro				
	800		805		810
Thr Arg Lys Gly	Ser Val Val Asn Val Asn Pro Thr Asn Thr Arg				
	815		820		825
Pro Gln Ser Asp	Thr Pro Glu Ile Arg Lys Tyr Lys Lys Arg Phe				
	830		835		840
Asn Ser Glu Ile	Leu Cys Ala Ala Leu Trp Gly Val Asn Leu Leu				
	845		850		855
Val Gly Thr Glu	Ser Gly Leu Met Leu Leu Asp Arg Ser Gly Gln				
	860		865		870
Gly Lys Val Tyr	Pro Leu Ile Asn Arg Arg Arg Phe Gln Gln Met				
	875		880		885
Asp Val Leu Glu	Gly Leu Asn Val Leu Val Thr Ile Ser Gly Lys				
	890		895		900
Lys Asp Lys Leu	Arg Val Tyr Tyr Leu Ser Trp Leu Arg Asn Lys				
	905		910		915
Ile Leu His Asn	Asp Pro Glu Val Glu Lys Lys Gln Gly Trp Thr				
	920		925		930
Thr Val Gly Asp	Leu Glu Gly Cys Val His Tyr Lys Val Val Lys				
	935		940		945
Tyr Glu Arg Ile	Lys Phe Leu Val Ile Ala Leu Lys Ser Ser Val				
	950		955		960
Glu Val Tyr Ala	Trp Ala Pro Lys Pro Tyr His Lys Phe Met Ala				
	965		970		975
Phe Lys Ser Phe	Gly Glu Leu Val His Gly Ser Cys Ala Gly Phe				
	980		985		990
His Ala Val Asp	Val Asp Ser Gly Ser Val Tyr Asp Ile Tyr Leu				
	995		1000		1005
Pro Thr His Ile	Gln Cys Ser Ile Lys Pro His Ala Ile Ile Ile				
	1010		1015		1020
Leu Pro Asn Thr	Asp Gly Met Glu Leu Leu Val Cys Tyr Glu Asp				
	1025		1030		1035
Glu Gly Val Tyr	Val Asn Thr Tyr Gly Arg Ile Thr Lys Asp Val				
	1040		1045		1050
Val Leu Gln Trp	Gly Glu Met Pro Thr Ser Val Ala Tyr Ile Arg				
	1055		1060		1065
Ser Asn Gln Thr	Met Gly Trp Gly Glu Lys Ala Ile Glu Ile Arg				
	1070		1075		1080
Ser Val Glu Thr	Gly His Leu Asp Gly Val Phe Met His Lys Arg				
	1085		1090		1095
Ala Gln Arg Leu	Lys Phe Leu Cys Glu Arg Asn Asp Lys Val Phe				
	1100		1105		1110
Phe Ala Ser Val	Arg Ser Gly Gly Ser Ser Gln Val Tyr Phe Met				
	1115		1120		1125
Thr Leu Gly Arg	Thr Ser Leu Leu Ser Trp				
	1130		1135		

&lt;210&gt; 17

&lt;211&gt; 228

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 209854

&lt;400&gt; 17

```

Met Pro Thr Asn Cys Ala Ala Ala Gly Cys Ala Thr Thr Tyr Asn
  1           5           10           15
Lys His Ile Asn Ile Ser Phe His Arg Phe Pro Leu Asp Pro Lys
           20           25           30
Arg Arg Lys Glu Trp Val Arg Leu Val Arg Arg Lys Asn Phe Val
           35           40           45
Pro Gly Lys His Thr Phe Leu Cys Ser Lys His Phe Glu Ala Ser
           50           55           60
Cys Phe Asp Leu Thr Gly Gln Thr Arg Arg Leu Lys Met Asp Ala
           65           70           75
Val Pro Thr Ile Phe Asp Phe Cys Thr His Ile Lys Ser Met Lys
           80           85           90
Leu Lys Ser Arg Asn Leu Leu Lys Lys Asn Asn Ser Cys Ser Pro
           95          100          105
Ala Gly Pro Ser Asn Leu Lys Ser Asn Ile Ser Ser Gln Gln Val
          110          115          120
Leu Leu Glu His Ser Tyr Ala Phe Arg Asn Pro Met Glu Ala Lys
          125          130          135
Lys Arg Ile Ile Lys Leu Glu Lys Glu Ile Ala Ser Leu Arg Arg
          140          145          150
Lys Met Lys Thr Cys Leu Gln Lys Glu Arg Arg Ala Thr Arg Arg
          155          160          165
Trp Ile Lys Ala Thr Cys Leu Val Lys Asn Leu Glu Ala Asn Ser
          170          175          180
Val Leu Pro Lys Gly Thr Ser Glu His Met Leu Pro Thr Ala Leu
          185          190          195
Ser Ser Leu Pro Leu Glu Asp Phe Lys Ile Leu Glu Gln Asp Gln
          200          205          210
Gln Asp Lys Thr Leu Leu Ser Leu Asn Leu Lys Gln Thr Lys Ser
          215          220          225
Thr Phe Ile

```

&lt;210&gt; 18

&lt;211&gt; 503

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 1384286

&lt;400&gt; 18

```

Met Ala Thr Thr Val Thr Cys Thr Arg Phe Thr Asp Glu Tyr Gln
  1           5           10           15
Leu Tyr Glu Asp Ile Gly Lys Gly Ala Phe Ser Val Val Arg Arg
          20           25           30
Cys Val Lys Leu Cys Thr Gly His Glu Tyr Ala Ala Lys Ile Ile
          35           40           45
Asn Thr Lys Lys Leu Ser Ala Arg Asp His Gln Lys Leu Glu Arg

```

50	55	60
Glu Ala Arg Ile Cys Arg Leu Leu Lys His Ser Asn Ile Val Arg		
65	70	75
Leu His Asp Ser Ile Ser Glu Glu Gly Phe His Tyr Leu Val Phe		
80	85	90
Asp Leu Val Thr Gly Gly Glu Leu Phe Glu Asp Ile Val Ala Arg		
95	100	105
Glu Tyr Tyr Ser Glu Ala Asp Ala Ser His Cys Ile Gln Gln Ile		
110	115	120
Leu Glu Ala Val Leu His Cys His Gln Met Gly Val Val His Arg		
125	130	135
Asp Leu Lys Pro Glu Asn Leu Leu Leu Ala Ser Lys Cys Lys Gly		
140	145	150
Ala Ala Val Lys Leu Ala Asp Phe Gly Leu Ala Ile Glu Val Gln		
155	160	165
Gly Asp Gln Gln Ala Trp Phe Gly Phe Ala Gly Thr Pro Gly Tyr		
170	175	180
Leu Ser Pro Glu Val Leu Arg Lys Glu Ala Tyr Gly Lys Pro Val		
185	190	195
Asp Ile Trp Ala Cys Gly Val Ile Leu Tyr Ile Leu Leu Val Gly		
200	205	210
Tyr Pro Pro Phe Trp Asp Glu Asp Gln His Lys Leu Tyr Gln Gln		
215	220	225
Ile Lys Ala Gly Ala Tyr Asp Phe Pro Ser Pro Glu Trp Asp Thr		
230	235	240
Val Thr Pro Glu Ala Lys Asn Leu Ile Asn Gln Met Leu Thr Ile		
245	250	255
Asn Pro Ala Lys Arg Ile Thr Ala His Glu Ala Leu Lys His Pro		
260	265	270
Trp Val Cys Gln Arg Ser Thr Val Ala Ser Met Met His Arg Gln		
275	280	285
Glu Thr Val Glu Cys Leu Lys Lys Phe Asn Ala Arg Arg Lys Leu		
290	295	300
Lys Gly Ala Ile Leu Thr Thr Met Leu Ala Thr Arg Asn Phe Ser		
305	310	315
Ala Ala Lys Ser Leu Leu Asn Lys Lys Ala Asp Gly Val Lys Pro		
320	325	330
His Thr Asn Ser Thr Lys Asn Ser Ala Ala Ala Thr Ser Pro Lys		
335	340	345
Gly Thr Leu Pro Pro Ala Ala Leu Glu Ser Ser Asp Ser Ala Asn		
350	355	360
Thr Thr Ile Glu Asp Glu Asp Ala Lys Ala Arg Lys Gln Glu Ile		
365	370	375
Ile Lys Thr Thr Glu Gln Leu Ile Glu Ala Val Asn Asn Gly Asp		
380	385	390
Phe Glu Ala Tyr Ala Lys Ile Cys Asp Pro Gly Leu Thr Ser Phe		
395	400	405
Glu Pro Glu Ala Leu Gly Asn Leu Val Glu Gly Met Asp Phe His		
410	415	420
Arg Phe Tyr Phe Glu Asn Leu Leu Ala Lys Asn Ser Lys Pro Ile		
425	430	435
His Thr Thr Ile Leu Asn Pro His Val His Val Ile Gly Glu Asp		
440	445	450
Ala Ala Cys Ile Ala Tyr Ile Arg Leu Thr Gln Tyr Ile Asp Gly		
455	460	465
Gln Gly Arg Pro Arg Thr Ser Gln Ser Glu Glu Thr Arg Val Trp		

	470		475		480
His Arg Arg Asp Gly Lys Trp Gln Asn Val His Phe His Cys Ser					
	485		490		495
Gly Ala Pro Val Ala Pro Leu Gln					
	500				

<210> 19  
 <211> 433  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte Clone Number: 1512656

<400> 19

Met Thr Gly Glu Ala Gln Ala Gly Arg Lys Arg Ser Arg Ala Arg		
1	5	10
Pro Glu Gly Thr Glu Pro Val Arg Arg Glu Arg Thr Gln Pro Gly		15
	20	25
Leu Gly Pro Gly Arg Ala Arg Ala Met Ala Ala Glu Ala Thr Ala		30
	35	40
Val Ala Gly Ser Gly Ala Val Gly Gly Cys Leu Ala Lys Asp Gly		45
	50	55
Leu Gln Gln Ser Lys Cys Pro Asp Thr Thr Pro Lys Arg Arg Arg		60
	65	70
Ala Ser Ser Leu Ser Arg Asp Ala Glu Arg Arg Ala Tyr Gln Trp		75
	80	85
Cys Arg Glu Tyr Leu Gly Gly Ala Trp Arg Arg Val Gln Pro Glu		90
	95	100
Glu Leu Arg Val Tyr Pro Val Ser Gly Gly Leu Ser Asn Leu Leu		105
	110	115
Phe Arg Cys Ser Leu Pro Asp His Leu Pro Ser Val Gly Glu Glu		120
	125	130
Pro Arg Glu Val Leu Leu Arg Leu Tyr Gly Ala Ile Leu Gln Gly		135
	140	145
Val Asp Ser Leu Val Leu Glu Ser Val Met Phe Ala Ile Leu Ala		150
	155	160
Glu Arg Ser Leu Gly Pro Gln Leu Tyr Gly Val Phe Pro Glu Gly		165
	170	175
Arg Leu Glu Gln Tyr Ile Pro Ser Arg Pro Leu Lys Thr Gln Glu		180
	185	190
Leu Arg Glu Pro Val Leu Ser Ala Ala Ile Ala Thr Lys Met Ala		195
	200	205
Gln Phe His Gly Met Glu Met Pro Phe Thr Lys Glu Pro His Trp		210
	215	220
Leu Phe Gly Thr Met Glu Arg Tyr Leu Lys Gln Ile Gln Asp Leu		225
	230	235
Pro Pro Thr Gly Leu Pro Glu Met Asn Leu Leu Glu Met Tyr Ser		240
	245	250
Leu Lys Asp Glu Met Gly Asn Leu Arg Lys Leu Leu Glu Ser Thr		255
	260	265
Pro Ser Pro Val Val Phe Cys His Asn Asp Ile Gln Glu Gly Asn		270

	275		280		285
Ile Leu Leu Leu	Ser Glu Pro Glu Asn	Ala Asp Ser Leu Met	Leu		
	290		295		300
Val Asp Phe Glu	Tyr Ser Ser Tyr Asn	Tyr Arg Gly Phe Asp	Ile		
	305		310		315
Gly Asn His Phe	Cys Glu Trp Val Tyr	Asp Tyr Thr His Glu	Glu		
	320		325		330
Trp Pro Phe Tyr	Lys Ala Arg Pro Thr	Asp Tyr Pro Thr Gln	Glu		
	335		340		345
Gln Gln Leu His	Phe Ile Arg His Tyr	Leu Ala Glu Ala Lys	Lys		
	350		355		360
Gly Glu Thr Leu	Ser Gln Glu Glu Gln	Arg Lys Leu Glu Glu	Asp		
	365		370		375
Leu Leu Val Glu	Val Ser Arg Tyr Ala	Leu Ala Ser His Phe	Phe		
	380		385		390
Trp Gly Leu Trp	Ser Ile Leu Gln Ala	Ser Met Ser Thr Ile	Glu		
	395		400		405
Phe Gly Tyr Leu	Asp Tyr Ala Gln Ser	Arg Phe Gln Phe Tyr	Phe		
	410		415		420
Gln Gln Lys Gly	Gln Leu Thr Ser Val	His Ser Ser Ser			
	425		430		

&lt;210&gt; 20

&lt;211&gt; 527

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2098635

&lt;400&gt; 20

Met Ser Leu Cys Gly Ala Arg Ala Asn Ala Lys Met Met Ala Ala		
1	5	10
Tyr Asn Gly Gly Thr Ser Ala Ala Ala Ala Gly His His His His		
	20	25
His His His His Leu Pro His Leu Pro Pro Pro His Leu Leu His		
	35	40
His His His Pro Gln His His Leu His Pro Gly Ser Ala Ala Ala		
	50	55
Val His Pro Val Gln Gln His Thr Ser Ser Ala Ala Ala Ala Ala		
	65	70
Ala Ala Ala Ala Ala Ala Ala Ala Met Leu Asn Pro Gly Gln Gln		
	80	85
Gln Pro Tyr Phe Pro Ser Pro Ala Pro Gly Gln Ala Pro Gly Pro		
	95	100
Ala Ala Ala Ala Pro Ala Gln Val Gln Ala Ala Ala Ala Ala Thr		
	110	115
Val Lys Ala His His His Gln His Ser His His Pro Gln Gln Gln		
	125	130
Leu Asp Ile Glu Pro Asp Arg Pro Ile Gly Tyr Gly Ala Phe Gly		
	140	145
Val Val Trp Ser Val Thr Asp Pro Arg Asp Gly Lys Arg Val Ala		
	155	160
Leu Lys Lys Met Pro Asn Val Phe Gln Asn Leu Val Ser Cys Lys		



170	175	180
Arg Val Phe Arg Glu Leu Lys Met Leu Cys Phe Phe Lys His Asp		
185	190	195
Asn Val Leu Ser Ala Leu Asp Ile Leu Gln Pro Pro His Ile Asp		
200	205	210
Tyr Phe Glu Glu Ile Tyr Val Val Thr Glu Leu Met Gln Ser Asp		
215	220	225
Leu His Lys Ile Ile Val Ser Pro Gln Pro Leu Ser Ser Asp His		
230	235	240
Val Lys Val Phe Leu Tyr Gln Ile Leu Arg Gly Leu Lys Tyr Leu		
245	250	255
His Ser Ala Gly Ile Leu His Arg Asp Ile Lys Pro Gly Asn Leu		
260	265	270
Leu Val Asn Ser Asn Cys Val Leu Lys Ile Cys Asp Phe Gly Leu		
275	280	285
Ala Arg Val Glu Glu Leu Asp Glu Ser Arg His Met Thr Gln Glu		
290	295	300
Val Val Thr Gln Tyr Tyr Arg Ala Pro Glu Ile Leu Met Gly Ser		
305	310	315
Arg His Tyr Ser Asn Ala Ile Asp Ile Trp Ser Val Gly Cys Ile		
320	325	330
Phe Ala Glu Leu Leu Gly Arg Arg Ile Leu Phe Gln Ala Gln Ser		
335	340	345
Pro Ile Gln Gln Leu Asp Leu Ile Thr Asp Leu Leu Gly Thr Pro		
350	355	360
Ser Leu Glu Ala Met Arg Thr Ala Cys Glu Gly Ala Lys Ala His		
365	370	375
Ile Leu Arg Gly Pro His Lys Gln Pro Ser Leu Pro Val Leu Tyr		
380	385	390
Thr Leu Ser Ser Gln Ala Thr His Glu Ala Val His Leu Leu Cys		
395	400	405
Arg Met Leu Val Phe Asp Pro Ser Lys Arg Ile Ser Ala Lys Asp		
410	415	420
Ala Leu Ala His Pro Tyr Leu Asp Glu Gly Arg Leu Arg Tyr His		
425	430	435
Thr Cys Met Cys Lys Cys Cys Phe Ser Thr Ser Thr Gly Arg Val		
440	445	450
Tyr Thr Ser Asp Phe Glu Pro Val Thr Asn Pro Lys Phe Asp Asp		
455	460	465
Thr Phe Glu Lys Asn Leu Ser Ser Val Arg Gln Val Lys Glu Ile		
470	475	480
Ile His Gln Phe Ile Leu Glu Gln Gln Lys Gly Asn Arg Val Pro		
485	490	495
Leu Cys Ile Asn Pro Gln Ser Ala Ala Phe Lys Ser Phe Ile Ser		
500	505	510
Ser Thr Val Ala Gln Pro Ser Glu Met Pro Pro Ser Pro Leu Val		
515	520	525
Trp Glu		

&lt;210&gt; 21

&lt;211&gt; 322

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2446646

&lt;400&gt; 21

```

Met Glu Gly Ile Ser Asn Phe Lys Thr Pro Ser Lys Leu Ser Glu
 1           5           10           15
Lys Lys Lys Ser Val Leu Cys Ser Thr Pro Thr Ile Asn Ile Pro
          20           25           30
Ala Ser Pro Phe Met Gln Lys Leu Gly Phe Gly Thr Gly Val Asn
          35           40           45
Val Tyr Leu Met Lys Arg Ser Pro Arg Gly Leu Ser His Ser Pro
          50           55           60
Trp Ala Val Lys Lys Ile Asn Pro Ile Cys Asn Asp His Tyr Arg
          65           70           75
Ser Val Tyr Gln Lys Arg Leu Met Asp Glu Ala Lys Ile Leu Lys
          80           85           90
Ser Leu His His Pro Asn Ile Val Gly Tyr Arg Ala Phe Thr Glu
          95          100          105
Ala Asn Asp Gly Ser Leu Cys Leu Ala Met Glu Tyr Gly Gly Glu
          110          115          120
Lys Ser Leu Asn Asp Leu Ile Glu Glu Arg Tyr Lys Ala Ser Gln
          125          130          135
Asp Pro Phe Pro Ala Ala Ile Ile Leu Lys Val Ala Leu Asn Met
          140          145          150
Ala Arg Gly Leu Lys Tyr Leu His Gln Glu Lys Lys Leu Leu His
          155          160          165
Gly Asp Ile Lys Ser Ser Asn Val Val Ile Lys Gly Asp Phe Glu
          170          175          180
Thr Ile Lys Ile Cys Asp Val Gly Val Ser Leu Pro Leu Asp Glu
          185          190          195
Asn Met Thr Val Thr Asp Pro Glu Ala Cys Tyr Ile Gly Thr Glu
          200          205          210
Pro Trp Lys Pro Lys Glu Ala Val Glu Glu Asn Gly Val Ile Thr
          215          220          225
Asp Lys Ala Asp Ile Phe Ala Phe Gly Leu Thr Leu Trp Glu Met
          230          235          240
Met Thr Leu Ser Ile Pro His Ile Asn Leu Ser Asn Asp Asp Asp
          245          250          255
Asp Glu Asp Lys Thr Phe Asp Glu Ser Asp Phe Asp Asp Glu Ala
          260          265          270
Tyr Tyr Ala Ala Leu Gly Thr Arg Pro Pro Ile Asn Met Glu Glu
          275          280          285
Leu Asp Glu Ser Tyr Gln Lys Val Ile Glu Leu Phe Ser Val Cys
          290          295          300
Thr Asn Glu Asp Pro Lys Asp Arg Pro Ser Ala Ala His Ile Val
          305          310          315
Glu Ala Leu Glu Thr Asp Val
          320

```

&lt;210&gt; 22

&lt;211&gt; 802

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2764911

&lt;400&gt; 22

```

Met Glu Glu Glu Gly Gly Ser Ser Gly Gly Ala Ala Gly Thr Ser
 1           5           10           15
Ala Asp Gly Gly Asp Gly Gly Glu Gln Leu Leu Thr Val Lys His
      20           25           30
Glu Leu Arg Thr Ala Asn Leu Thr Gly His Ala Glu Lys Val Gly
      35           40           45
Ile Glu Asn Phe Glu Leu Leu Lys Val Leu Gly Thr Gly Ala Tyr
      50           55           60
Gly Lys Val Phe Leu Val Arg Lys Ile Ser Gly His Asp Thr Gly
      65           70           75
Lys Leu Tyr Ala Met Lys Val Leu Lys Lys Ala Thr Ile Val Gln
      80           85           90
Lys Ala Lys Thr Thr Glu His Thr Arg Thr Glu Arg Gln Val Leu
      95          100          105
Glu His Ile Arg Gln Ser Pro Phe Leu Val Thr Leu His Tyr Ala
      110          115          120
Phe Gln Thr Glu Thr Lys Leu His Leu Ile Leu Asp Tyr Ile Asn
      125          130          135
Gly Gly Glu Leu Phe Thr His Leu Ser Gln Arg Glu Arg Phe Thr
      140          145          150
Glu His Glu Val Gln Ile Tyr Val Gly Glu Ile Val Leu Ala Leu
      155          160          165
Glu His Leu His Lys Leu Gly Ile Ile Tyr Arg Asp Ile Lys Leu
      170          175          180
Glu Asn Ile Leu Leu Asp Ser Asn Gly His Val Val Leu Thr Asp
      185          190          195
Phe Gly Leu Ser Lys Glu Phe Val Ala Asp Glu Thr Glu Arg Ala
      200          205          210
Tyr Ser Phe Cys Gly Thr Ile Glu Tyr Met Ala Pro Asp Ile Val
      215          220          225
Arg Gly Gly Asp Ser Gly His Asp Lys Ala Val Asp Trp Trp Ser
      230          235          240
Leu Gly Val Leu Met Tyr Glu Leu Leu Thr Gly Ala Ser Pro Phe
      245          250          255
Thr Val Asp Gly Glu Lys Asn Ser Gln Ala Glu Ile Ser Arg Arg
      260          265          270
Ile Leu Lys Ser Glu Pro Pro Tyr Pro Gln Glu Met Ser Ala Leu
      275          280          285
Ala Lys Asp Leu Ile Gln Arg Leu Leu Met Lys Asp Pro Lys Lys
      290          295          300
Arg Leu Gly Cys Gly Pro Arg Asp Ala Asp Glu Ile Lys Glu His
      305          310          315
Leu Phe Phe Gln Lys Ile Asn Trp Asp Asp Leu Ala Ala Lys Lys
      320          325          330
Val Pro Ala Pro Phe Lys Pro Val Ile Arg Asp Glu Leu Asp Val
      335          340          345
Ser Asn Phe Ala Glu Glu Phe Thr Glu Met Asp Pro Thr Tyr Ser
      350          355          360
Pro Ala Ala Leu Pro Gln Ser Ser Glu Lys Leu Phe Gln Gly Tyr
      365          370          375
Ser Phe Val Ala Pro Ser Ile Leu Phe Lys Arg Asn Ala Ala Val
      380          385          390
Ile Asp Pro Leu Gln Phe His Met Gly Val Glu Arg Pro Gly Val

```

	395		400		405
Thr Asn Val Ala Arg Ser Ala Met Met Lys Asp Ser Pro Phe Tyr					
	410		415		420
Gln His Tyr Asp Leu Asp Leu Lys Asp Lys Pro Leu Gly Glu Gly					
	425		430		435
Ser Phe Ser Ile Cys Arg Lys Cys Val His Lys Lys Ser Asn Gln					
	440		445		450
Ala Phe Ala Val Lys Ile Ile Ser Lys Arg Met Glu Ala Asn Thr					
	455		460		465
Gln Lys Glu Ile Thr Ala Leu Glu Leu Cys Glu Gly His Pro Asn					
	470		475		480
Ile Val Lys Leu His Glu Val Phe His Asp Gln Leu His Thr Phe					
	485		490		495
Leu Val Met Glu Leu Leu Asn Gly Gly Glu Leu Phe Glu Arg Ile					
	500		505		510
Lys Lys Lys Lys His Phe Ser Glu Thr Glu Ala Ser Tyr Ile Met					
	515		520		525
Arg Lys Leu Val Ser Ala Val Ser His Met His Asp Val Gly Val					
	530		535		540
Val His Arg Asp Leu Lys Pro Glu Asn Leu Leu Phe Thr Asp Glu					
	545		550		555
Asn Asp Asn Leu Glu Ile Lys Ile Ile Asp Phe Gly Phe Ala Arg					
	560		565		570
Leu Lys Pro Pro Asp Asn Gln Pro Leu Lys Thr Pro Cys Phe Thr					
	575		580		585
Leu His Tyr Ala Ala Pro Glu Leu Leu Asn Gln Asn Gly Tyr Asp					
	590		595		600
Glu Ser Cys Asp Leu Trp Ser Leu Gly Val Ile Leu Tyr Thr Met					
	605		610		615
Leu Ser Gly Gln Val Pro Phe Gln Ser His Asp Arg Ser Leu Thr					
	620		625		630
Cys Thr Ser Ala Val Glu Ile Met Lys Lys Ile Lys Lys Gly Asp					
	635		640		645
Phe Ser Phe Glu Gly Glu Ala Trp Lys Asn Val Ser Gln Glu Ala					
	650		655		660
Lys Asp Leu Ile Gln Gly Leu Leu Thr Val Asp Pro Asn Lys Arg					
	665		670		675
Leu Lys Met Ser Gly Leu Arg Tyr Asn Glu Trp Leu Gln Asp Gly					
	680		685		690
Ser Gln Leu Ser Ser Asn Pro Leu Met Thr Pro Asp Ile Leu Gly					
	695		700		705
Ser Ser Gly Ala Ala Val His Thr Cys Val Lys Ala Thr Phe His					
	710		715		720
Ala Phe Asn Lys Tyr Lys Arg Glu Gly Phe Cys Leu Gln Asn Val					
	725		730		735
Asp Lys Ala Pro Leu Ala Lys Arg Arg Lys Met Lys Lys Thr Ser					
	740		745		750
Thr Ser Thr Glu Thr Arg Ser Ser Ser Ser Glu Ser Ser His Ser					
	755		760		765
Ser Ser Ser His Ser His Gly Lys Thr Thr Pro Thr Lys Thr Leu					
	770		775		780
Gln Pro Ser Asn Pro Ala Asp Ser Asn Asn Pro Glu Thr Leu Phe					
	785		790		795
Gln Phe Ser Asp Ser Val Ala					
	800				

<210> 23  
 <211> 641  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte Clone Number: 3013946

<400> 23  
 Met Ala Thr Thr Val Thr Cys Thr Arg Phe Thr Asp Glu Tyr Gln  
 1 5 10 15  
 Leu Tyr Glu Asp Ile Gly Lys Gly Ala Phe Ser Val Val Arg Arg  
 20 25 30  
 Cys Val Lys Leu Cys Thr Gly His Glu Tyr Ala Ala Lys Ile Ile  
 35 40 45  
 Asn Thr Lys Lys Leu Ser Ala Arg Asp His Gln Lys Leu Glu Arg  
 50 55 60  
 Glu Ala Arg Ile Cys Arg Leu Leu Lys His Ser Asn Ile Val Arg  
 65 70 75  
 Leu His Asp Ser Ile Ser Glu Glu Gly Phe His Tyr Leu Val Phe  
 80 85 90  
 Asp Leu Val Thr Gly Gly Glu Leu Phe Glu Asp Ile Val Ala Arg  
 95 100 105  
 Glu Tyr Tyr Ser Glu Ala Asp Ala Ser His Cys Ile Gln Gln Ile  
 110 115 120  
 Leu Glu Ala Val Leu His Cys His Gln Met Gly Val Val His Arg  
 125 130 135  
 Asp Leu Lys Pro Glu Asn Leu Leu Leu Ala Ser Lys Cys Lys Gly  
 140 145 150  
 Ala Ala Val Lys Leu Ala Asp Phe Gly Leu Ala Ile Glu Val Gln  
 155 160 165  
 Gly Asp Gln Gln Ala Trp Phe Gly Phe Ala Gly Thr Pro Gly Tyr  
 170 175 180  
 Leu Ser Pro Glu Val Leu Arg Lys Glu Ala Tyr Gly Lys Pro Val  
 185 190 195  
 Asp Ile Trp Ala Cys Gly Val Ile Leu Tyr Ile Leu Leu Val Gly  
 200 205 210  
 Tyr Pro Pro Phe Trp Asp Glu Asp Gln His Lys Leu Tyr Gln Gln  
 215 220 225  
 Ile Lys Ala Gly Ala Tyr Asp Phe Pro Ser Pro Glu Trp Asp Thr  
 230 235 240  
 Val Thr Pro Glu Ala Lys Asn Leu Ile Asn Gln Met Leu Thr Ile  
 245 250 255  
 Asn Pro Ala Lys Arg Ile Thr Ala His Glu Ala Leu Lys His Pro  
 260 265 270  
 Trp Val Cys Gln Arg Ser Thr Val Ala Ser Met Met His Arg Gln  
 275 280 285  
 Glu Thr Val Glu Cys Leu Lys Lys Phe Asn Ala Arg Arg Lys Leu  
 290 295 300  
 Lys Gly Ala Ile Leu Thr Thr Met Leu Ala Thr Arg Asn Phe Ser  
 305 310 315  
 Ala Lys Ser Leu Leu Asn Lys Lys Ala Asp Gly Val Lys Pro Gln  
 320 325 330  
 Thr Asn Ser Thr Lys Asn Ser Ala Ala Thr Ser Pro Lys Gly  
 335 340 345

```

Thr Leu Pro Pro Ala Ala Leu Glu Pro Gln Thr Thr Val Ile His
350 355 360
Asn Pro Val Asp Gly Ile Lys Glu Ser Ser Asp Ser Ala Asn Thr
365 370 375
Thr Ile Glu Asp Glu Asp Ala Lys Ala Pro Arg Val Pro Asp Ile
380 385 390
Leu Ser Ser Val Arg Arg Gly Ser Gly Ala Pro Glu Ala Glu Gly
395 400 405
Pro Leu Pro Cys Pro Ser Pro Ala Pro Phe Gly Pro Leu Pro Ala
410 415 420
Pro Ser Pro Arg Ile Ser Asp Ile Leu Asn Ser Val Arg Arg Gly
425 430 435
Ser Gly Thr Pro Glu Ala Glu Gly Pro Leu Ser Ala Gly Pro Pro
440 445 450
Pro Cys Leu Ser Pro Ala Leu Leu Gly Pro Leu Ser Ser Pro Ser
455 460 465
Pro Arg Ile Ser Asp Ile Leu Asn Ser Val Arg Arg Gly Ser Gly
470 475 480
Thr Pro Glu Ala Lys Gly Pro Ser Pro Val Gly Pro Pro Pro Cys
485 490 495
Pro Ser Pro Thr Ile Pro Gly Pro Leu Pro Thr Pro Ser Arg Lys
500 505 510
Gln Glu Ile Ile Lys Thr Thr Glu Gln Leu Ile Glu Ala Val Asn
515 520 525
Asn Gly Asp Phe Glu Ala Tyr Ala Lys Ile Cys Asp Pro Gly Leu
530 535 540
Thr Ser Phe Glu Pro Glu Ala Leu Gly Asn Leu Val Glu Gly Met
545 550 555
Asp Phe His Arg Phe Tyr Phe Glu Asn Leu Leu Ala Lys Asn Ser
560 565 570
Lys Pro Ile His Thr Thr Ile Leu Asn Pro His Val His Val Ile
575 580 585
Gly Glu Asp Ala Ala Cys Ile Ala Tyr Ile Arg Leu Thr Gln Tyr
590 595 600
Ile Asp Gly Gln Gly Arg Pro Arg Thr Ser Gln Ser Glu Glu Thr
605 610 615
Arg Val Trp His Arg Arg Asp Gly Lys Trp Gln Asn Val His Phe
620 625 630
His Cys Ser Gly Ala Pro Val Ala Pro Leu Gln
635 640

```

&lt;210&gt; 24

&lt;211&gt; 588

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 067967

&lt;400&gt; 24

```

Met Gly Gly Thr Ala Arg Gly Pro Gly Arg Lys Asp Ala Gly Pro
1 5 10 15
Pro Gly Ala Gly Leu Pro Pro Gln Gln Arg Arg Leu Gly Asp Gly
20 25 30
Val Tyr Asp Thr Phe Met Met Ile Asp Glu Thr Lys Cys Pro Pro

```

	35		40		45
Cys Ser Asn Val	Leu Cys Asn Pro Ser	Glu Pro Pro Ser Pro	Arg		
	50		55		60
Arg Leu Asn Met	Thr Thr Glu Gln Phe	Thr Gly Asp His Thr	Gln		
	65		70		75
His Phe Leu Asp	Gly Gly Glu Met Lys	Val Glu Gln Leu Phe	Gln		
	80		85		90
Glu Phe Gly Asn	Arg Lys Ser Asn Thr	Ile Gln Ser Asp Gly	Ile		
	95		100		105
Ser Asp Ser Glu	Lys Cys Ser Pro Thr	Val Ser Gln Gly Lys	Ser		
	110		115		120
Ser Asp Cys Leu	Asn Thr Val Lys Ser	Asn Ser Ser Ser Lys	Ala		
	125		130		135
Pro Lys Val Val	Pro Leu Thr Pro Glu	Gln Ala Leu Lys Gln	Tyr		
	140		145		150
Lys His His Leu	Thr Ala Tyr Glu Lys	Leu Glu Ile Ile Asn	Tyr		
	155		160		165
Pro Glu Ile Tyr	Phe Val Gly Pro Asn	Ala Lys Lys Arg His	Gly		
	170		175		180
Val Ile Gly Gly	Pro Asn Asn Gly Gly	Tyr Asp Asp Ala Asp	Gly		
	185		190		195
Ala Tyr Ile His	Val Pro Arg Asp His	Leu Ala Tyr Arg Tyr	Glu		
	200		205		210
Val Leu Lys Ile	Ile Gly Lys Gly Ser	Phe Gly Gln Val Ala	Arg		
	215		220		225
Val Tyr Asp His	Lys Leu Arg Gln Tyr	Val Ala Leu Lys Met	Val		
	230		235		240
Arg Asn Glu Lys	Arg Phe His Arg Gln	Ala Ala Glu Glu Ile	Arg		
	245		250		255
Ile Leu Glu His	Leu Lys Lys Gln Asp	Lys Thr Gly Ser Met	Asn		
	260		265		270
Val Ile His Met	Leu Glu Ser Phe Thr	Phe Arg Asn His Val	Cys		
	275		280		285
Met Ala Phe Glu	Leu Leu Ser Ile Asp	Leu Tyr Glu Leu Ile	Lys		
	290		295		300
Lys Asn Lys Phe	Gln Gly Phe Ser Val	Gln Leu Val Arg Lys	Phe		
	305		310		315
Ala Gln Ser Ile	Leu Gln Ser Leu Asp	Ala Leu His Lys Asn	Lys		
	320		325		330
Ile Ile His Cys	Asp Leu Lys Pro Glu	Asn Ile Leu Leu Lys	His		
	335		340		345
His Gly Arg Ser	Ser Thr Lys Val Ile	Asp Phe Gly Ser Ser	Cys		
	350		355		360
Phe Glu Tyr Gln	Lys Leu Tyr Thr Tyr	Ile Gln Ser Arg Phe	Tyr		
	365		370		375
Arg Ala Pro Glu	Ile Ile Leu Gly Ser	Arg Tyr Ser Thr Pro	Ile		
	380		385		390
Asp Ile Trp Ser	Phe Gly Cys Ile Leu	Ala Glu Leu Leu Thr	Gly		
	395		400		405
Gln Pro Leu Phe	Pro Gly Glu Asp Glu	Gly Asp Gln Leu Ala	Cys		
	410		415		420
Met Met Glu Leu	Leu Gly Met Pro Pro	Pro Lys Leu Leu Glu	Gln		
	425		430		435
Ser Lys Arg Ala	Lys Tyr Phe Ile Asn	Ser Lys Gly Ile Pro	Arg		
	440		445		450
Tyr Cys Ser Val	Thr Thr Gln Ala Asp	Gly Arg Val Val Leu	Val		

	455		460		465
Gly Gly Arg Ser	Arg Arg Gly Lys Lys	Arg Gly Pro Pro Gly	Ser		
	470		475		480
Lys Asp Trp Gly	Thr Ala Leu Lys Gly	Cys Asp Asp Tyr Leu	Phe		
	485		490		495
Ile Glu Phe Leu	Lys Arg Cys Leu His	Trp Asp Pro Ser Ala	Arg		
	500		505		510
Leu Thr Pro Ala	Gln Ala Leu Arg His	Pro Trp Ile Ser Lys	Ser		
	515		520		525
Val Pro Arg Pro	Leu Thr Thr Ile Asp	Lys Val Ser Gly Lys	Arg		
	530		535		540
Val Val Asn Pro	Ala Ser Ala Phe Gln	Gly Leu Gly Ser Lys	Leu		
	545		550		555
Pro Pro Val Val	Gly Ile Ala Asn Lys	Leu Lys Ala Asn Leu	Met		
	560		565		570
Ser Glu Thr Asn	Gly Ser Ile Pro Leu	Cys Ser Val Leu Pro	Lys		
	575		580		585
Leu Ile Ser					

&lt;210&gt; 25

&lt;211&gt; 389

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 346275

&lt;400&gt; 25

Met Ser Asp Val	Cys Ser Ser Gln Arg	Ala Glu His Glu His	Leu
1	5	10	15
Pro Gly Leu Val	Pro Pro Pro Ser Gly	Met Gly Val Arg Lys	Gly
	20	25	30
Ser Ser Pro Leu	Lys Ser His Pro Cys	Arg Glu Lys Ser Val	Ser
	35	40	45
Asn Arg Arg Ser	Gly Lys Thr Ile Val	Arg Ser Ala Val Glu	Glu
	50	55	60
Val Arg Thr Ala	Gly Leu Phe Arg Ser	Gly Phe Ser Glu Glu	Lys
	65	70	75
Ala Thr Gly Lys	Leu Phe Ala Val Lys	Cys Ile Pro Lys Lys	Ala
	80	85	90
Leu Lys Gly Lys	Glu Ser Ser Ile Glu	Asn Glu Ile Ala Val	Leu
	95	100	105
Arg Lys Ile Lys	His Glu Asn Ile Val	Ala Leu Glu Asp Ile	Tyr
	110	115	120
Glu Ser Pro Asn	His Leu Tyr Leu Val	Met Gln Leu Val Ser	Gly
	125	130	135
Gly Glu Leu Phe	Asp Arg Ile Val Glu	Lys Gly Phe Tyr Thr	Glu
	140	145	150
Lys Asp Ala Ser	Thr Leu Ile Arg Gln	Val Leu Asp Ala Val	Tyr
	155	160	165
Tyr Leu His Arg	Met Gly Ile Val His	Arg Asp Leu Lys Pro	Glu
	170	175	180
Asn Leu Leu Tyr	Tyr Ser Gln Asp Glu	Glu Ser Lys Ile Met	Ile
	185	190	195



```

Ser Asp Phe Gly Leu Ser Lys Met Glu Gly Lys Gly Asp Val Met
200                               205                               210
Ser Thr Ala Cys Gly Thr Pro Gly Tyr Val Ala Pro Glu Val Leu
215                               220                               225
Ala Gln Lys Pro Tyr Ser Lys Ala Val Asp Cys Trp Ser Ile Gly
230                               235                               240
Val Ile Ala Tyr Ile Leu Leu Cys Gly Tyr Pro Pro Phe Tyr Asp
245                               250                               255
Glu Asn Asp Ser Lys Leu Phe Glu Gln Ile Leu Lys Ala Glu Tyr
260                               265                               270
Glu Phe Asp Ser Pro Tyr Trp Asp Asp Ile Ser Asp Ser Ala Lys
275                               280                               285
Asp Phe Ile Arg Asn Leu Met Glu Lys Asp Pro Asn Lys Arg Tyr
290                               295                               300
Thr Cys Glu Gln Ala Ala Arg His Pro Trp Ile Ala Gly Asp Thr
305                               310                               315
Ala Leu Asn Lys Asn Ile His Glu Ser Val Ser Ala Gln Ile Arg
320                               325                               330
Lys Asn Phe Ala Lys Ser Lys Trp Arg Gln Ala Phe Asn Ala Thr
335                               340                               345
Ala Val Val Arg His Met Arg Lys Leu His Leu Gly Ser Ser Leu
350                               355                               360
Asp Ser Ser Asn Ala Ser Val Ser Ser Ser Leu Ser Leu Ala Ser
365                               370                               375
Gln Lys Asp Cys Ala Tyr Val Ala Lys Pro Glu Ser Leu Ser
380                               385

```

&lt;210&gt; 26

&lt;211&gt; 343

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 283746

&lt;400&gt; 26

```

Met Ile Gly Glu Glu Ala Met Ile Asn Tyr Glu Asn Phe Leu Lys
1                               5                               10                               15
Val Gly Glu Lys Ala Gly Ala Lys Cys Lys Gln Phe Phe Thr Ala
20                               25                               30
Lys Val Phe Ala Lys Leu Leu His Thr Asp Ser Tyr Gly Arg Ile
35                               40                               45
Ser Ile Met Gln Phe Phe Asn Tyr Val Met Arg Lys Val Trp Leu
50                               55                               60
His Gln Thr Arg Ile Gly Leu Ser Leu Tyr Asp Val Ala Gly Gln
65                               70                               75
Gly Tyr Leu Arg Glu Ser Asp Leu Glu Asn Tyr Ile Leu Glu Leu
80                               85                               90
Ile Pro Thr Leu Pro Gln Leu Asp Gly Leu Glu Lys Ser Phe Tyr
95                               100                              105
Ser Phe Tyr Val Cys Thr Ala Val Arg Lys Phe Phe Phe Phe Leu
110                              115                              120
Asp Pro Leu Arg Thr Gly Lys Ile Lys Ile Gln Asp Ile Leu Ala
125                              130                              135

```

Cys Ser Phe Leu Asp Asp Leu Leu Glu Leu Arg Asp Glu Glu Leu	140	145	150
Ser Lys Glu Ser Gln Glu Thr Asn Trp Phe Ser Ala Pro Ser Ala	155	160	165
Leu Arg Val Tyr Gly Gln Tyr Leu Asn Leu Asp Lys Asp His Asn	170	175	180
Gly Met Leu Ser Lys Glu Glu Leu Ser Arg Tyr Gly Thr Ala Thr	185	190	195
Met Thr Asn Val Phe Leu Asp Arg Val Phe Gln Glu Cys Leu Thr	200	205	210
Tyr Asp Gly Glu Met Asp Tyr Lys Thr Tyr Leu Asp Phe Val Leu	215	220	225
Ala Leu Glu Asn Arg Lys Glu Pro Ala Ala Leu Gln Tyr Ile Phe	230	235	240
Lys Leu Leu Asp Ile Glu Asn Lys Gly Tyr Leu Asn Val Phe Ser	245	250	255
Leu Asn Tyr Phe Phe Arg Ala Ile Gln Glu Leu Met Lys Ile His	260	265	270
Gly Gln Asp Pro Val Ser Phe Gln Asp Val Lys Asp Glu Ile Phe	275	280	285
Asp Met Val Lys Pro Lys Asp Pro Leu Lys Ile Ser Leu Gln Asp	290	295	300
Leu Ile Asn Ser Asn Gln Gly Asp Thr Val Thr Thr Ile Leu Ile	305	310	315
Asp Leu Asn Gly Phe Trp Thr Tyr Glu Asn Arg Glu Ala Leu Val	320	325	330
Ala Asn Asp Ser Glu Asn Ser Ala Asp Leu Asp Asp Thr	335	340	

&lt;210&gt; 27

&lt;211&gt; 184

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2696537

&lt;400&gt; 27

Met Gly Asn Gly Met Asn Lys Ile Leu Pro Gly Leu Tyr Ile Gly	1	5	10	15
Asn Phe Lys Asp Ala Arg Asp Ala Glu Gln Leu Ser Lys Asn Lys	20	25	30	
Val Thr His Ile Leu Ser Val His Asp Ser Ala Arg Pro Met Leu	35	40	45	
Glu Gly Val Lys Tyr Leu Cys Ile Pro Ala Ala Asp Ser Pro Ser	50	55	60	
Gln Asn Leu Thr Arg His Phe Lys Glu Ser Ile Lys Phe Ile His	65	70	75	
Glu Cys Arg Leu Arg Gly Glu Ser Cys Leu Val His Cys Leu Ala	80	85	90	
Gly Val Ser Arg Ser Val Thr Leu Val Ile Ala Tyr Ile Met Thr	95	100	105	
Val Thr Asp Phe Gly Trp Glu Asp Ala Leu His Thr Val Arg Ala	110	115	120	

Gly Arg Ser Cys Ala Asn Pro Asn Val Gly Phe Gln Arg Gln Leu  
 125 130 135  
 Gln Glu Phe Glu Lys His Glu Val His Gln Tyr Arg Gln Trp Leu  
 140 145 150  
 Lys Glu Glu Tyr Gly Glu Ser Pro Leu Gln Asp Ala Glu Glu Ala  
 155 160 165  
 Lys Asn Ile Leu Ala Ala Pro Gly Ile Leu Lys Phe Trp Ala Phe  
 170 175 180  
 Leu Arg Arg Leu

&lt;210&gt; 29

&lt;211&gt; 118

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 619292

&lt;400&gt; 29

Met Gly Leu Ile Asp Gly Met His Thr His Leu Gly Ala Pro Gly  
 1 5 10 15  
 Leu Tyr Ile Gln Thr Leu Leu Pro Gly Ser Pro Ala Ala Ala Asp  
 20 25 30  
 Gly Arg Leu Ser Leu Gly Asp Arg Ile Leu Glu Val Asn Gly Ser  
 35 40 45  
 Ser Leu Leu Gly Leu Gly Tyr Leu Arg Ala Val Asp Leu Ile Arg  
 50 55 60  
 His Gly Gly Lys Lys Met Arg Phe Leu Val Ala Lys Ser Asp Val  
 65 70 75  
 Gly Lys Gln Pro Arg Arg Ser Ile Ser Ala Arg Pro Leu Ser Arg  
 80 85 90  
 Gly Ala Ala Arg Thr Pro Pro Gln Ala Arg His Pro Val Pro Pro  
 95 100 105  
 Gly Asp Thr Gly Leu Pro Pro Ala Phe Val Pro Val Leu  
 110 115

&lt;210&gt; 30

&lt;211&gt; 356

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2054049

&lt;400&gt; 30

Met Val Gly Val Ser Gly Lys Arg Ser Lys Glu Asp Glu Lys Tyr  
 1 5 10 15  
 Leu Gln Ala Ile Met Asp Ser Asn Ala Gln Ser His Lys Ile Phe  
 20 25 30  
 Ile Phe Asp Ala Arg Pro Ser Val Asn Ala Val Ala Asn Lys Ala  
 35 40 45  
 Lys Gly Gly Gly Tyr Glu Ser Glu Asp Ala Tyr Gln Asn Ala Glu

```

<400> 31
Met Ala Gly Ala Gly Gly Phe Gly Cys Pro Ala Gly Gly Asn Asp
 1             5             10             15
Phe Gln Trp Cys Phe Ser Gln Val Lys Gly Ala Ile Asp Glu Asp

```

	20		25		30
Val	Ala	Glu	Ala	Asp	Ile
	35		40		45
Gly	Asp	Leu	Leu	Ala	Thr
	50		55		60
Phe	Gln	Arg	Glu	Gln	Glu
	65		70		75
Glu	Tyr	Asn	Val	Tyr	Ser
	80		85		90
Asp	Tyr	Leu	Lys	Ser	Leu
	95		100		105
Arg	Trp	Leu	Pro	Gln	Gln
	110		115		120
Asn	Asp	Lys	Thr	Ile	Lys
	125		130		135
Arg	Ala	Glu	Gly	Tyr	Asn
	140		145		150
Asp	Pro	Phe	Arg	Ile	Thr
	155		160		165
Met	Asp	Leu	Met	Val	Glu
	170		175		180
Ala	His	Thr	Tyr	His	Ile
	185		190		195
Glu	Thr	Tyr	Leu	Ser	Ala
	200		205		210
Leu	Glu	Ile	Thr	Asp	Arg
	215		220		225
Ala	Asn	Met	Glu	Glu	Leu
	230		235		240
His	Pro	His	Gln	Cys	Asn
	245		250		255
Thr	Ile	Arg	Leu	Cys	Asp
	260		265		270
His	Ser	Lys	Phe	Phe	Glu
	275		280		285
Phe	Phe	Ser	Glu	Ile	Ile
	290		295		300
His	Ser	Gly	Arg	Tyr	Met
	305		310		315
Val	Trp	Asp	Leu	Asn	Met
	320		325		330
Val	His	Glu	Tyr	Leu	Arg
	335		340		345
Asp	Cys	Ile	Phe	Asp	Lys
	350		355		360
Ser	Ala	Ile	Met	Thr	Gly
	365		370		375
Asp	Arg	Asp	Thr	Arg	Arg
	380		385		390
Ser	Ser	Lys	Pro	Arg	Ala
	395		400		405
Gly	Gly	Lys	Arg	Arg	Lys
	410		415		420
Phe	Asn	Lys	Lys	Ile	Leu
	425		430		435
Val	Ile	Ala	Val	Ala	Ala

Lys Ile Asn 440

445

450

<210> 32  
 <211> 1221  
 <212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> misc\_feature  
 <223> Incyte Clone Number: 132240

<400> 32  
 cttttcctgg aatttctata atggaaagtc cattagaaag tcagccctta gattcagata 60  
 gaagcatcaa agaatcctct tttgaagaat caaatattga agatccactt attgtaacac 120  
 cagattgcc aaaaaagacc tcacaaaaag gtgtcgagaa ccctgctgta caagagagta 180  
 accaaaaaat gtttaggtcct cctttggagg tgctgaaaac gttagcctct aaaagaaatg 240  
 ctggtgcttt tcgaagtttt aacagtcata ttaatgcac caataactca gaaccatcca 300  
 gaatgaacat gacttcttta gatgcaatgg atatttcgtg tgcctacagt ggttcataac 360  
 ccattggctat aaccctact caaaaaagaa gatcctgtat gccacatcag accccaaatc 420  
 agatcaagtc gggaactcca taccgaactc cgaagagtgt gagaagaggg gtggcccccg 480  
 ttgatgatgg gcgaattcta ggaacccag actaccttgc acctgagctg ttactaggca 540  
 gggcccatgg tcctgcggtg gactgggtgg cacttgaggt ttgcttggtt gaatttctaa 600  
 caggaattcc ccctttcaat gatgaaacac cacaacaagt attccagaat attctgaaaa 660  
 gagatatccc ttggccagaa ggtgaagaaa agttatctga taatgctcaa agtgcagtag 720  
 aaatactttt aaccattgat gatacaaaag gagctggaat gaaagagcta aaacgtcatc 780  
 ctctcttcag tgatgtggac tgggaaaaac tgcagcatca gactatgcct ttcaccccc 840  
 agccagatga tgaacacgat acctcctatt ttgaagccag gaatactgct cagcacctga 900  
 ctgtatctgg atttagtctg tagcacaata attttccttt tagtctagcc ttgtgttata 960  
 gaatgaactt gcataattat atactcctta atactagatt gatctaaggg ggaaagatca 1020  
 ttatttaacc tagttcaatg tgcttttaat gtacgttaca gctttcacag agttaaaagg 1080  
 ctgaaaggaa tatagtcagt aatttatctt aacctcaaaa ctgtatataa atcttcaaaag 1140  
 cttttttcat ttatttattt tgtttattgc actttatgaa aactgaagca tcaataaaat 1200  
 tagaggacac taaaaaaaaa a 1221

<210> 33  
 <211> 542  
 <212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> misc\_feature  
 <223> Incyte Clone Number: 2180116

<400> 33  
 tggccagget gggccagca gcgcgatggc agctcagcgg ctgggcaagc gcgtgctgag 60  
 caagctgcag tctccatcgc gggcccgagg gccagggggc agtcccgggg ggatgcagaa 120  
 gcggcacgag cgcgtcaccg tcaagtatga ccggcgaggag ctgcagcggc ggctggacgt 180  
 ggagaagtgg atcgacgggc gcctggagga gctgtaccgc ggcattggagg cagacatgcc 240  
 cgatgagatc aacattgatg aattgttggg tttagagagt gaagaggaga gaagccggaa 300  
 aatccaggga ctctgaagt catgtgggaa acctgtcgag gacttcaccc aggagctgct 360  
 ggcaaagctt caaggcctcc acaggcagcc cggcctccgc cagccaagcc cctcccacga 420  
 cggcagcttc agccccctcc aggaccgggc cggactgct caccctgac cctcttgac 480  
 tctccctgcc ccccgagcc cggccagctt gcttgtgtat aagttgtatt taatggattc 540

tt

542

&lt;210&gt; 34

&lt;211&gt; 2778

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; 2548, 2557, 2645, 2722, 2557, 2762, 2765

&lt;223&gt; Incyte Clone Number: 2197671

&lt;400&gt; 34

```

cgcggtatcgt cgcggtcccg cgcgtccgct ccaggaagtg gccgtcctga ggcgccatggc 60
tcactccccg gtgcagtcgg gcctgcccgg catgcagaac cttaaaggcag acccagaaga 120
gctttttaca aaactagaga aaattgggaa gggctccttt ggagaggtgt tcaaaggcat 180
tgacaatcgg actcagaaag tggttgccat aaagatcatt gatctggaag aagctgaaga 240
tgagatagag gacattcaac aagaaatcac agtgctgagt cagtgtgaca gtccatatgt 300
aaccaaatat tatggatcct atctgaagga taaaaatta tggataataa tggatatatct 360
tgggtggaggc tccgcactag atctattaga acctggccga ttagatgaaa ccagatcgc 420
tactatatta agagaaatac tgaaggact cgattatctc cattcggaga agaaaatcca 480
cagagacatt aaagcggcca acgtcctgct gtctgagcat ggcgaggtga agctggcgga 540
ctttggcgtg gctggccagc tgacagacac ccagatcaaa aggaacacct tcgtgggcac 600
cccattctgg atggcaccgg aggtcatcaa acagtcggcc tatgactcga aggcagacat 660
ctgggtccctg ggcataacag ctattgaact tgcaagaggg gaaccacctc attccgagct 720
gcaccccatg aaagttttat tcctcattcc aaagaacaac ccaccgacgt tggaaaggaaa 780
ctacagtaaa ccctcaagg agtttgtgga ggctgtttg aataaggagc cgagctttag 840
acccactgct aaggagttat tgaagcaca gtttatacta cgcaatgcaa agaaaacttc 900
ctacttgacc gagctcatcg acaggtacaa gagatggaag gccgagcaga gccatgacga 960
ctcgagctcc gaggattccg acgcggaaac agatggccaa gcctcggggg gcagtgatcc 1020
tggggactgg atcttcacaa tccgagaaaa agatcccaag aatctcgaga atggagctct 1080
tcagccatcg gacttggaca gaaataagat gaaagacatc ccaaaggagc ctttctctca 1140
gtgtttatct acaattatct ctctctgtt tgcaagagttg aaggagaaga gccaggcggtg 1200
cggagggaac ttgggggtcca ttgaagagct gcgagggggc atctacctag cggaggaggc 1260
gtgccctggc atctccgaca ccattggtggc ccagctcgtg cagcggctcc agagatactc 1320
tctaagtggg ggaggaactt catccactg aaattccttt ggcatttggg gttttgtttt 1380
tcttttttct cttcttcac ctcctccttt tttaaaagtc aacgagagcc ttcgctgact 1440
ccaccgaaga ggtgcgccac tgggagccac ccagtgcca ggcgccgctc caggagacaca 1500
cacagtcttc actgtgctgc agccagatga agtctctcag atgggtgggg agggtcagct 1560
ccttccagcg atcattttat tttattttat tacttttgtt ttttaattta accatagtgc 1620
acatatccca ggaaagtgtc tttaaaaaca aaaacaaacc ctgaaatgta tatttgggat 1680
tatgataagg caactaaaga catgaaacct caggtatcct gctttaagtt gataactccc 1740
tctgggagct ggagaatcgc tctggtggat ggggtgtacag atttgtatat aatgtcattt 1800
ttacggaaac cctttcggcg tgcataagga atcactgtgt acaaactggc caagtgttc 1860
tgtagataac gtcagtgagg taaatattcg acaggccata acttgagtct attgccttg 1920
ctttattaca tgtacatttt gaattctgtg accagtgatt tgggttttat tttgtatttg 1980
cagggtttgt cattaataat taatgcccct ctcttacaga acactcctat ttgtacctca 2040
acaaatgcaa attttccccg tttgccctac gccctttttg gtacacctag aggttgattt 2100
cctttttcat cgatggtagt atttcttagt gttttaaatt ggaacatata ttgcctcatg 2160
aagctttaaa ttataatttt cagtttctcc ccatgaagcg ctctcgtctg acatttgttt 2220
ggaatcgtgc cactgctggt ctgcgccaga tgtaccgtcc tttccaatac gattttctgt 2280
tgcaccttgt agtggattct gcatatcatc tttccacct aaaaatgtct gaatgcttac 2340
acaaataaat tttataacac gcttattttg catactcctt gaaatgtgac tcttcagagg 2400
acagggtacc tgctgtgtat gtgtggcggt gcgtgtgtac tcgtggctgt gtgtgtgtga 2460

```

tgagacactt tggagactc cagggagaag ttcccagggc tggagctgcc gagtgtcccag 2520  
 gtcagcgcgc tgggctgctt gcgcaatngc tcaccngat gatgcattgg aggttgctga 2580  
 cctgtgcgat tgctgtagcg gttgccaggg accttaaggg gttattttgc ttccctggga 2640  
 ggggncctat gtttctagcg aagcagccat gtgtctaatt ttctgggttt gctgtgggga 2700  
 cctgattggg ggagggggaa anctttgggg ttcttgaggt gggaggggtc gtgccancaa 2760  
 tnttncctgg taaaaaag 2778

<210> 35

<211> 1424

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte Clone Number: 2594943

<400> 35

ggctcagcct ccgaccaggg tgggtctggag cctgccggga gagtgggtggc atctgagagg 60  
 ctggctcgtg actgtggttg ggggaggttg gagctgtttt aaccgtgtgc cccctctcct 120  
 gtgccgcggt gggcatcccc cggggcagtg gaacgcgggc gctcctccag cttccgagtc 180  
 cagccagcct gggcgcgggg cgccgcccc gagacaccg aggagtcctt tcctccctgg 240  
 ttacgtggac tgtggagctg gtctcttggt gctcagcgcc gtgaggaggt tgaagcgtac 300  
 ctgcggaggt cgcaccaggg cgtgaggagg aggaggaagg gcatgagccg agcttgagga 360  
 atccgtgttc caaactctac actcaagggt ggccttggg taggggtgaag atcccctgtc 420  
 tttatcctag ttccacacct tgggtgtgggt tactgggtgc aggatgaact gtcgctcgga 480  
 ggtgctggag gtgtcgggtg aggggcggca ggtggaggag gccatgctgg ctgtgctgca 540  
 cacggtgctt ctgcaccgca gcacaggcaa gttccactac aagaaggagg gcacctactc 600  
 cattggcacc gtgggcaccc aggatgttga ctgtgacttc atcgacttca cttatgtgcg 660  
 tgtctcttct gaggaactgg atcgtgccct gcgcaagggt gttggggagt tcaaggatgc 720  
 actgcgaac tctggtggcg atgggctggg gcagatgtcc ttggagtctt accagaagaa 780  
 gaagtctcgc tggccattct cagacgagtg catcccatgg gaagtgtgga cggccaaggt 840  
 gcatgtggta gccctggcca cggagcagga gcggcagatc tgccgggaga aggtgggtga 900  
 gaaactctgc gagaagatca tcaacatcgt ggaggtgatg aatcggcag agtacttgcc 960  
 caagatgccc acacagtcgg aggtggataa cgtgtttgac acaggcttgc gggacgtgca 1020  
 gccctacctg tacaagatct cttccagat cactgatgcc ctgggcacct cagtcaccac 1080  
 caccatgcgc aggtcatca aagacaccct tgccctctga gcgtcgctgg atctctggga 1140  
 gctccttgat ggtcccaga ccttggcttt tgggaattgc acttttgggc ctttgggctc 1200  
 tggaaacctgc tctgggtcat tggtagact tggaaagggc agcccccgct ggcttcttgg 1260  
 ttttgggtt gccagctca ggtcatcctt ttaatctttg ctgatgggtc agtccctgct 1320  
 ctactgtctc tccatagccc tggtaggggc cccttcttt ctccactgta cagaagagcc 1380  
 accactggga tggggaataa agttgagaac atgaaaaaaa aaaa 1424

<210> 36

<211> 1839

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte Clone Number: 1513871

<400> 36

cctcctctc ggcagctca ggttgagct tctctgggga actgtcacc tttccggagc 60  
 aggggaagct gccccgtgcc cgggagggag cgggcgcacc gcggccccca ggacacgcgc 120  
 tgaccgggt gcccagtcct tcatgatcat gaacaagatg aagaacttta agcgccgttt 180  
 ctccctgtca gtgccccgca ctgagaccat tgaagaatcc ttggctgaat tcacggagca 240



```

attcaaccag ctccacaacc ggcggaatga gaacttgacg ctgggtcctc ttggcagaga 300
ccccccgag gagtgcagca ccttctcccc aacagacagc ggggaggagc cggggcagct 360
ctccctggc gtgcagttcc agcggcgga ccaaccagcg cgcttctcca tggaggacgt 420
cagcaagagg ctctctctgc ccatggatat ccgcctgccc caggaattcc tacagaagct 480
acagatggag agcccagatc tgcccagacc gctcagccgc atgtcccgc gggcctccct 540
gtcagacatt ggctttggga aactggaaac atacgtgaaa ctggacaaac tgggagaggg 600
cacctatgcc acagtcttca aaggcgagc caaactgacg gagaaccttg tggccctgaa 660
agagatccgg ctggagcagc aggagggagc gccctgacg gccatccgag aggtgtctct 720
gctgaagaac ctgaagcagc ccaatattgt gacctgcat gacctcatcc acacagatcg 780
gtccctcacc ctgggtgttg agtacctgga cagtgcctg aagcagatc tggaccactg 840
tgggaacctc atgagcatgc acaacgtcaa gattttcatg ttccagctgc tccggggcct 900
cgcctactgt caccaccgca agatcctgca ccgggacctg aagccccaga acctgctcat 960
caacgagagg ggggagctga agctggccga ctttggactg gccaggggca agtcagtgcc 1020
caciaaagact tactccaatg aggtggtgac cctgtggtac agggcccccg atgtgctgct 1080
gggatccaca gagtactcca ccccattga tatgtggggc gtgggctgca tccactacga 1140
gatggccaca gggaggcccc tcttccggg ctccacagtc aaggaggagc tgcacctcat 1200
ctttcgctc ctccgggacc ccacagaaga gacgtggccc ggcgtgaccg ctttctctga 1260
gttccgcacc tacagcttcc cctgctacct ccgcagccg ctcatcaacc acgcgccag 1320
gttggtatag gatggcatcc acctcctgag cagcctgctc ctgtatgaat ccaagagtcg 1380
catgtcagca gaggctgccc tgagtcactc ctacttccgg tctctgggag agcgtgtgca 1440
ccagcttgaa gacactgcct ccattcttct cctgaaggag atccagctcc agaaggacct 1500
aggctaccga ggcttggcct tccagcagcc aggacgaggg aagaacaggc ggcagagcat 1560
cttctgagcc acgcccacct tgctgtggcc aagggaaca agatcacatg gagcacaat 1620
tcgggtagga tggagcctgt gtggccctcg gaggactgaa gaacgagggc tgacagcagc 1680
ctggaagacc gcttggcagg cttttggcca agtggttttc tttgtggtt cgatctgctg 1740
ccagtagttt cagtggatag aacgtgcttt aggagttggg tgggaaagtc ttgctagagg 1800
gtttaggggg aggtttctac cgttgactcg gtttagggc 1839

```

&lt;210&gt; 37

&lt;211&gt; 2024

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 156108

&lt;400&gt; 37

```

gtcagctctg gttcggagaa gcagcggtg gcgtgggcca tccggggaat gggcgccctc 60
gtgacctagt gttcggggc aaaaagggtc ttgccggcct cgctcgtgca gggcgctatc 120
tgggcgcctg agcgcggcgt gggagccttg ggagccgcg cagcaggggg cacaccgga 180
accggcctga gcgcccggga ccatgaacgg ggaggccatc tgcagcgccc tgcccaccat 240
tccctaccac aaactcgccg acctgcgcta cctgagccgc ggcgcctctg gcactgtgtc 300
gtccgccegc cagcagact ggcgcgtcca ggtggccgtg aagcacctgc acatccacac 360
tccgtgctc gacagtgaag gaaaggatgt cttaagagaa gctgaaattt tacacaaagc 420
tagatttagt tacattcttc caattttggg aatttgcaat gaggctgaat ttttgggaat 480
agttactgaa tacatgcca atggatcatt aaatgaactc ctacatagga aaactgaata 540
tcctgatgtt gcttggccat tgagatttcg catcctgcat gaaattgccc ttggtgtaaa 600
ttacctgcac aatatgactc tccctttact tcatcatgac ttgaagactc agaatatctt 660
attggacaat gaatttcatg ttaagattgc agattttggt ttatcaaagt ggcgcagatg 720
gtccctctca cagtacgaa gtagcaaatc tgcaccagaa ggagggacaa ttatctatat 780
gccacctgaa aactatgaac ctggacaaaa atcaagggcc agtatcaagc acgatataata 840
tagctatgca gttatcacat gggaagtgtt atccagaaaa cagccttttg aagatgtcac 900
caatcctttg cagataatgt atagtgtgtc acaaggacat cgacctgtta ttaatgaaga 960
aagtttgcca tatgatatac ctcaccgagc acgtatgac tctctaatag aaagtggatg 1020

```

```

ggcacaaaat ccagatgaaa gaccatcttt cttaaaatgt ttaatagaac ttgaaccagt 1080
tttgagaaca tttgaagaga taacttttct tgaagctggt attcagctaa agaaaacaaa 1140
gttacagagt gtttcaagt ccattcacct atgtgacaag aagaaaatgg aattatctct 1200
gaacatacct gtaaatacatg gtccacaaga ggaatcatgt ggatcctctc agctccatga 1260
aaatagtggg tctcctgaaa cttcaagggt cctgccagct cctcaagaca atgatttttt 1320
atctagaaaa gctcaagact gttattttat gaagctgcat cactgtcctg gaaatcacag 1380
ttgggatagc accatttctg gatctcaaag ggctgcattc tgtgatcaca agaccactcc 1440
atgctcttca gcaataataa atccactctc aactgcagga aactcagaac gtctgcagcc 1500
tggatatagc cagcagtggg tccagagcaa aagggaagac attgtgaacc aatgacaga 1560
agcctgcctt aaccagtcgc tagatgcctt tctgtccagg gacttgatca tgaaagagga 1620
ctatgaactt gttagtacca agcctacaag gacctcaaaa gtcagacaat tactagacac 1680
tactgacatc caaggagaag aatttgccaa agttatagta caaaaattga aagataacaa 1740
acaaatgggt cttcagcctt acccggaat acttgtggtt tctagatcac catctttaa 1800
ttacttcaa aataaaagca tgtaagtgc tgtttttcaa gaagaaatgt gtttcataaa 1860
aggatattta tatctctgtt gctttgactt tttttatata aaatccgtga gtattaaagc 1920
tttattgaag gttctttggg taaatattag tctccctcca tgacactgca gtattttttt 1980
taattaatac aagtaaaaag tttgaatttt gctacataaa aaaa 2024

```

&lt;210&gt; 38

&lt;211&gt; 1861

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2883243.

&lt;400&gt; 38

```

gcttcttagt gaggttgga ttatgttaag gctggtatgg aagacaactg atgaagcagg 60
agtggctgg tgacattttt ctgacttgat tggctggggc gtgtgatgta ataggtttca 120
gtgcagcccc ttatagggtt taaaatgaat tccaagacac cattacaaag aaagccggac 180
tcttttctta taactgagct cagccaagga aactcttgca caaatgtaca atactgttg 240
gaatatggaa gacctggatt tagaatatgc caagacagat ataaattgtg gcacagactt 300
gatgttttat atagaaatgg acccaccagc actgcctcct aaaccaccaa aacctactac 360
tgtagccaac aacggtatga ataacaatat gtccttaca gatgctgaat ggtactgggg 420
agatatctcg agggagaag tgaatgaaa acttcgagat acagcagacg ggaccttttt 480
ggtacgagat gcgtctacta aaatgcatgg tgattatact cttacactaa ggaaaggggg 540
aaataacaaa ttaatcaaaa tatttcacgc agatgggaaa tatggcttct ctgacctt 600
aaccttcagt tctgtggtt aattaataa cactaccgg aatgaatctc tagctcagta 660
taatcccaa ttggatgtga aattacttta tccagtatcc aaataccaac aggatcaagt 720
tgtcaaagaa gataatattg aagctgtagg gaaaaaatta catgaatata acactcagtt 780
tcaagaaaaa agtcgagaat atgatagatt atatgaagaa tatacccgca catcccagga 840
aatccaaatg aaaaggacag ctattgaagc atttaatgaa accataaaaa tatttgaaga 900
acagtgccag acccaagagc ggtacagcaa agaatacata gaaaagtta aacgtgaagg 960
caatgagaaa gaaatacaaa ggattatgca taattatgat aagttgaagt ctcgaaatcag 1020
tgaaattatt gacagtagaa gaagattgga agaagacttg aagaagcagg cagctgagta 1080
tcgagaaatt gacaaacgta tgaacagcat taaaccagac cttatccagc tgagaaagac 1140
gagagaccaa tacttgatgt ggttgactca aaaagggtgt cggcaaaaga agttgaacga 1200
gtgggtgggc aatgaaaaca ctgaagacca atattcactg gtggaagatg atgaagattt 1260
gccccatcat gatgagaaga catggaatgt tgggaagcagc aaccgaaaca aagctgaaaa 1320
cctgttgcca ggaagcgag atggcacttt tcttgtccgg gagagcagta aacagggctg 1380
ctatgcctgc tctgtagtgg tggacggcga agtaaaagcat tgtgtcataa acaaaacagc 1440
aactggctat ggctttgccc agccctataa cttgtacagc tctctgaaag aactgggtgct 1500
acattaccaa cacacctccc ttgtgcagca caacgactcc ctcaatgtca cactagccta 1560
cccagtatat gcacagcaga ggcgatgaag cgttactct ttgatccttc tctgaagtt 1620

```

cagccaccct gaggcctctg gaaagcaaag ggctcctctc cagtctgatc tgtgaattga 1680  
gctgcagaaa cgaagccaac tttttttgga tgggactagt gctttctttc acaaaaaaga 1740  
agtaggggaa gacatgcagc ctaaggctgt atgatgacca caggttcccta agctggagtg 1800  
cttatccctt ctttttcttt ttttcttttg ttttaattta agccacaacc acatacaaca 1860  
c 1861

&lt;210&gt; 39

&lt;211&gt; 2045

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 3173355

&lt;400&gt; 39

cttggctgga acctgagacg gattcgctcc caaatgatgc tccagtggca ggagcaactc 60  
aagttcatca ttgtcctgag agagaggagc agcgcggttc tcggccggga cagcagaacg 120  
ccaggggacc ctacactggg cgcgcggggg caggggcttt gattgtcctg gggtcgcgga 180  
gacccgcgcg cctgccctgc acgccgggag gcaacctttg cagtcgcgtt ggctgctgcg 240  
atcgcccggc gggtcctctg cgaaggctcg gctgcttctg tccacctctt acacttcttc 300  
atztatcggt ggatcatttc gagagtccgt cttgtaaatg tttggcactt tgctacttta 360  
ttgcttcttt ctggcgacag ttccagcact cgccgagacc ggccggagaaa ggcagctgag 420  
cccggagaag agcgaatat ggggaccccg gctaaaagca gacgtcgtcc tccccgcccg 480  
ctatttctat attcaggcag tggatacatc aggggaataaa ttcacatctt ctccaggcga 540  
aaaggtcttc caggtgaaa gttcagcacc agaggagcaa ttcactagag ttggagtcca 600  
ggtttttagac cgaagagatg ggtccttcat agtaagatac agaattgatg caagctacaa 660  
aaatctgaag gtggaaatta aattccaagg gcaacatgtg gccaaatccc catatatatt 720  
aaaaggggcg gtttaccatg agaactgtga ctgtcctctg caagatagtg cagcctgggt 780  
acgggagatg aactgccctg aaaccattgc tcagattcag agagatctgg cacatttccc 840  
tgctgtggat ccagaaaaga ttgcagtaga aatcccaaaa agatttggac agaggcagag 900  
cctatgtcac tacaccttaa aggataacaa ggtttatata aagactcatg gtgaacatgt 960  
aggttttaga attttcatgg atgccatact actttctttg actagaaagg tgaagatgcc 1020  
agatgtggag ctctttgtta atttgggaga ctggcctttg gaaaaaaaga aatccaattc 1080  
aaacatccat ccgatctttt cctgggtgtg ctccacagat tccaaggata tcgtgatgcc 1140  
tacgtacgat ttgactgatt ctgttctgga aaccatgggc cgggtaagtc tggatatgat 1200  
gtccgtgcaa gctaacacgg gtcctccctg ggaagcaaaa aattccactg ccgtctggag 1260  
agggcgagac agccgcaaag agagactcga gctgggttaa ctcagtagaa aacaccaga 1320  
actcatagac gctgctttca ccaacttttt ctcttttaaa cacgatgaaa acctgtatgg 1380  
tcccattgtg aaacatatatt cattttttga tttcttcaag cataagtatc aaataaatat 1440  
cgatggcact gtagcagctt atcgccctgc atatttgcta gttggtgaca gtgttgtgct 1500  
gaagcaggat tccatctact atgaacattt ttacaatgag ctgcagccct ggaaacacta 1560  
cattccagtt aagagcaacc tgagcgatct gctagaaaaa cttaaattggg cgaaagatca 1620  
cgatgaagag gccaaaaaga tagcaaaagc aggacaagaa tttgcaagaa ataattctcat 1680  
gggcgatgac atattctgtt attatttcaa acttttccag gaatatgcca atttacaagt 1740  
gagtgaagccc caaatccgag agggcatgaa aagggtagaa ccacagactg aggacgacct 1800  
cttcccttgt acttgccata ggaaaaagac caaagatgaa ctctgatatg caaaaataact 1860  
tctattagaa taatggtgct ctgaagactc ttcttaacta aaaagaagaa tttttttaag 1920  
tattaattcc atggacaata taaaatctgt gtgattgttt gcagtatgaa gacacatttc 1980  
tacttatgca gtattctcat gactgtactt taaagtacat ttttagaatt ttataataaa 2040  
accac 2045

&lt;210&gt; 40

<211> 1260  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte Clone Number: 5116906

<400> 40  
cgatattttt ctttcttagt ttcccatctt atattgtttt gtcaaataca ctgtgactca 60  
ttaacatctc ttttccctag gttttgctgg cacacctgga tatctttctc cagaagtttt 120  
acgtaaagat ccttatggaa agccagtggg tatgtgggca tgtggtgtca ttctctatat 180  
tctacttggt gggatccac ccttctggga tgaagaccaa cacagactct atcagcagat 240  
caaggctgga gcttatgatt ttccatcacc agaattgggac acggtgactc ctgaagccaa 300  
agacctcatc aataaaatgc ttactatcaa ccctgccaaa cgcatcacag cctcagaggc 360  
actgaagcac ccatggatct gtcaacgttc tactgttgct tccatgatgc acagacagga 420  
gactgtagac tgcttgaaga aatttaatgc tagaagaaaa cttaaagggtg ccatcttgac 480  
aactatgctg gctacaagga atttctcagc agccaagagt ttgttgaaga aaccagatgg 540  
agtaaaggag tcaactgaga gttcaaatac aacaattgag gatgaagatg tgaaagcacg 600  
aaagcaagag attatcaaag tcaactgaaca actgatcgaa gctatcaaca atggggactt 660  
tgaagcctac acaaaaatct gtgaccagg ccttactgct tttgaacctg aagctttggg 720  
taatttagtg gaagggtagg attttcaccg atttactttt gaaaatgctt tgtccaaaag 780  
caataaacca atccacacta ttattctaaa ccctcatgta catctggtag gggatgatgc 840  
cgctgcata gcatatatta ggctcacaca gtacatggat ggcagtggaa tgccaaagac 900  
aatgcagtca gaagagactc gtgtgtggca ccgccgggat ggaaagtggc agaattgtca 960  
ttttcatcgc tcgggggtcac caacagtacc catcaactaa atttcaacag tgccacttct 1020  
gcattctctg ttctcaaggc acctggatgg tgacctggg ccgtcctctc ctctcttca 1080  
tgcatgtttc tgagtgcagc aagttgtgaa ggtcctacat gtaatgcata tgtgatgcac 1140  
catcttatca tatattcctt cctatacatt gtttacactt caactacggg gatgttccac 1200  
acaaacttaa attactgttg gcaaaacaat agggggagat tagacaaaaa aaaaaaaaaa 1260

<210> 41  
<211> 2059  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte Clone Number: 940589

<400> 41  
aaaccataga aacgctaatt aaagcagaca tcaaaatctg gatccttaca ggggacaagc 60  
aagaaactgc cattaacatc ggacactcct gcaaaactgtt gaagaagaac atgggaatga 120  
ttgttataaa tgaaggctct cttgattctt tctctaatac acagaattct aggaaggagg 180  
ctgttctttt agccaaaatg aaacacccta atattgttgc cttcaaagaa tcatttgaag 240  
ctgaaggaca cttgtatatt gtgatggaat actgtgatgg aggggatcta atgcaaaaga 300  
ttaaacagca gaaaggaaaag ttatttctg aagacatgat acttaattgg ttaccacaaa 360  
tgtgccttgg agtaaatcac attcacaaga aacgtgtgct acacagagat atcaagtcca 420  
agaatatctt cctcactcag aatggaaaag tgaaattggg agactttgga tctgcccgtc 480  
ttctctccaa tccgatggca tttgcttgta cctatgtggg aactccttat tatgtgcctc 540  
cagaaatttg ggaaaacctg ccttataaca ataaaagtga catctggtcc ttgggttgca 600  
tcctgtatga actctgtacc ctttaagcatc catttcaggc aaatagtgtg aaaaatctta 660  
tcctcaaagt atgtcaaggg tgcacagtc cactgccgtc tcattactcc tatgaacttc 720  
agtctcctag caagcagatg tttaaaagga atccctcaca tcgcccctcg gctacaacgc 780  
ttctctctcg aggcacgta gctcggcttg tccagaagtg cttaccccc gagatcatca 840

```

tggaatatgg tgaggaagta ttagaagaaa taaaaaatc gaagcataac acaccaagaa 900
aaaaaacaaa cccagcaga atcaggatag ctttgggaaa tgaagcaagc acagtgcag 960
aggaagaaca agatagaaag ggtagccata ctgatttggg aagcattaat gaaaatttag 1020
ttgaaagtgc attgagaaga gtaaacagag aagaaaaagg taataagtca gtccatctga 1080
ggaaaagccag ttcaccaaatt cttcatagac gacagtggga gaaaaatgta cccaatacag 1140
ctcttacagc tttggaaaat gcatccatac tcacctccag tttaacagca gaggacgata 1200
gaggtggttc tgtaataaag tacagcaaaa atactactcg taagcagtgg ctcaaagaga 1260
ccccggacac tttgttgaac atccttaaga atgctgatct cagcttggtt tttcaaacat 1320
acacaatata tagaccaggt tcagaagggt tcttgaaagg cccctgtct gaagaaacag 1380
aagcatcgga cagtgttgat ggaggtcacg attctgtcat tttggatcca gagcgacttg 1440
agcctgggct agatgaggag gacacggact ttgaggagga agatgacaac cccgactggg 1500
tgtcagagct gaagaagcga gctggatggc aaggcctgtg cgacagataa tgctgagga 1560
aatgttcctg agtcacgctg aggagagcct tcaactcagga gtcatgctg agatgatcat 1620
gagttcatgc gacgtatatt ttccttggg aacagaatga agcagaggaa actcttaata 1680
cttaaaatcg ttcttgatta gtatcgtgag tttgaaaagt ctagaactcc tgtaaagttt 1740
tgaactcaag ggagaaggta tagtggaatg agtgtgagca tcgggctttg cagtcccata 1800
gaacagaaat gggatgctag cgtgccacta cctacttggt tgattgtggg aaattactta 1860
acctcttcaa gcccgaattt cctcaaccat aaaatgaaga taataatgcc tacctcagag 1920
ggatgctgac cacagacctt tatagcagcc cgtatgatat tattcacatt atgatatgtg 1980
tttattatta tgtgactctt tttacatttc ctaaagggtt gagaattaaa tatatttaat 2040
tatgaaaaaa aaaaaaaaaa
2059

```

&lt;210&gt; 42

&lt;211&gt; 1023

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 304421

&lt;400&gt; 42

```

gaggcagagg ggtgggcggg ctggcccatg gctgagacct ctctcccaga gctgggggga 60
gaggacaaag ccacgccttg cccagcatc ctggagctgg aggagctcct gcgggcaggg 120
aagtcttctt gcagccgtgt ggacgaagtt tggcccaacc tttcatagg agatgcgatg 180
gactcactgc agaagcagga cctccggagg cccaagatcc atggggcagt ccaggcatct 240
ccctaccagc cgccacatt ggcttcgctg cagcgttgc tgtgggtccg tcaggctgcc 300
aactgaacc atatcgatga ggtctggccc agcctcttcc tgggagatgc gtacgcagcc 360
cgggacaaga gcaagctgat ccagctggga atcacccacg ttgtgaatgc cgctgcagcc 420
aagttccagg tggacacagg tgccaaattc taccgtggaa tgtccctgga gtactatggc 480
atcgaggcgg atgacaaccc cttcttcgac ctacgtgtct actttctgcc tgttgctcga 540
tacatccgag ctgccctcag tgttcccaa ggccgcgtgc tggtagactg tgccatgggg 600
gtaagccgct ctgccacact tgtcctggcc ttcctcatga tctatgagaa catgacgctg 660
gtagaggcca tccagacggt gcaggccac cgcaatatct gccctaactc aggttctctc 720
cggcagctcc aggttctgga caaccgactg gggcgggaga cggggcggtt ctgatctggc 780
aggcagccag gatccctgac ccttgccca accccaccag cctggccctg ggaacagcag 840
gctctgctgt ttctagtac cctgagatgt aaacagcaag tgggggctga ggcagaggca 900
gggtagctg ggtggtgacc tcttagcggg tggatttccc tgacccaatt cagagattct 960
ttatgcaaaa gtgagttcag tccatctcta taataaata ttcacgtca taaaaaaaaa 1020
aaa
1023

```

&lt;210&gt; 43

&lt;211&gt; 4416

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 1213802

&lt;400&gt; 43

gaaatttttt tctgcctcat tattattaat tcatggattg agtgttggtt cgacctacag 60  
gcgtaataga ttggaactca gtgaagacac agatgttcct gttcagagca accagctaatt 120  
gattacagtt taaagacaat ttctgtgatc aagttgtcat ttggaagatt aaacccattt 180  
cacgaggact tggagcctgg tccttgcttt gaggaagcag tggcttggtt caagaagcca 240  
cttctgatct aagaatctac ccagcatgcc taatcaagga gaagactgct attttttttt 300  
ctattccaca tgtaccaaag gcgacagctg cccattccgt cactgtgaag ctgcaatagg 360  
aaatgaaact gtttgacat tatggcaaga agggcgctgt ttctgacagg tgtgcagggt 420  
tcggcacatg gagattgata aaaaacgcag tgaaattcct tgttattggg aaaatcagcc 480  
aacaggatgt caaaaattaa actgcgcttt ccatcacaat agaggacgat atgttgatgg 540  
ccttttcccta cctccgagca aaactgtgtt gccactgtg cctgagtcac cagaagagg 600  
agtgaaggct agccaacttt cagttcagca gaacaaattg tctgtccagt ccaatccttc 660  
ccctcagctg cggagcggtta tgaaagtaga aagttccgaa atgttcccta gccccacgca 720  
tccaccagtt gtaattaatg ctgcagatga tgatgaagat gatgatgatc agttttctga 780  
ggaaagtgat gaaacaaaa cacctaccct gcaaccaact cctgaagttc acaatggatt 840  
acgagtgact tctgtccgga aacctgcagt caatataaag caaggtgaat gtttgaattt 900  
tggaataaaa actcttgagg aaattaagtc aaagaaaatg aaggaataat ctaagaagca 960  
aggtgagggt tcttcaggag ttctcagctt ttactccac cctgagcccg ttccaggtcc 1020  
tgaaaaagaa aatgtcagga ctgtggtgag gacagtaact ctctccacca aacaaggaga 1080  
agaacccttg gttagattga gtcttactga gagactgggg aaacgaaaat ttccagcagg 1140  
cggtgacagt gatcctccat taaagcgtag cctggcacag aggttaggga agaaagtga 1200  
agctccagaa actaacattg acaaaacacc aaagaaagct caagtttcca agtctcttaa 1260  
ggagcgatta ggcattgtcag ctgatccaga taatgaggat gcaacagata aagttaataa 1320  
agttggtgag atccatgtga agacattaga agaaattctt cttgaaagag ccagtcagaa 1380  
acgtggagaa ttgcaaaacta aactcaagac agaaggacct tcaaaaactg atgattctac 1440  
ttcaggagca agaagctcct ccaactatccg tatcaaaacc ttctctgagg tcctggctga 1500  
aaaaaaacat cggcagcagg aagcagagag acaaaaaagc aaaaaggata caacttgcac 1560  
caagctaaag attgatagtg aaattaaaaa aacagtagtt ttgccacca ttgttgccag 1620  
cagaggacaa tcagaggagc ctgcaggtaa aacaaagtct atgcaggagg tgcacatcaa 1680  
gacgtggaa gaaattaaac tggagaaggc actgaggggtg cagcagagct ctgagagcag 1740  
caccagctcc ccgtctcaac acgaggccac tccaggggca agggcgctgc tgcgaatcac 1800  
caaaaagaaca gggatgaaag aagagaagaa ccttcaggaa ggaaatgaag ttgattctca 1860  
gagcagtatt agaacagaag ctaaaaggc ttccaggtgag accacaggag ttgacatcac 1920  
taaaattcaa gtcaagagat gtgagaccat gagagagaag cacatgcaga aacagcagga 1980  
gagggaaaaa tcagtcttga cacctcttcg gggagatgta gcctcttgca ataccctagt 2040  
ggcagagaaa ccagtgtcga ctgctgtgcc aggaatcaca cggcacctga ccaagcggct 2100  
tcccacaaag tcatcccaga aggtggagggt agaaacctca gggattggag actcattatt 2160  
gaatgtgaaa tgtgcagcac agaccttgga aaaaaggggt aaagctaaac ccaaagtga 2220  
cgtgaagcca tctgtggtta aagttgtgtc atcccccaa ttggcccaa aacgtaaggc 2280  
agtggagatg cacgtgctg tcattgccgc tgtgaagcca ctgagctcca gcagtgtcct 2340  
acaggaaccc ccagccaaaa aggcagctgt ggctgtgtc ccgcttgtct ctgaggacaa 2400  
atcagtcact gtgcctgaag cagaaaatcc tagagacagt cttgtgtgc ctccaacca 2460  
gtcctcttca gattcctcac ccccgagggt gtctggccct tcctcatccc aaatgagcat 2520  
gaaaactcgc cgactcagct ctgcctcaac aggaaagccc ccactctctg tggaggatga 2580  
ttttgagaaa ctaatatggg agatttcagg aggc aaattg gaagctgaga ttgacctgga 2640  
tcctgggaaa gatgaagatg accttctgct tgagctatca gaaatgattg atagctgaag 2700  
gtggtagtga ggacacttta aaaaaaaat cgccaaaaaa ctggacttag ttctcatctat 2760  
tgtaacattt acctgagatg atcatttctt tagtctagaa ttgccccaa atcagaagta 2820  
tacctctgaa ttatctgtat gtgtcctgga ttccttgggg tcagattttt aaagttactt 2880

```

tataaccatt ttgtccattt gatgccattg tttatcatct tttgagaaaa aagttctgtc 2940
atacccttct ctccacaaaa aagagactga gaggagatc aagtgaagg gtgcaagcga 3000
acttagtgac tccttgaggt gtttgtcagt tttggttttt ttcttctttg ttgtattctt 3060
tatgtattgt cttgatgtac ttaataattac ctgagtttga aatggatgaa gacagctgct 3120
accattaagg accaaaattt atgctaccac taaacaaaaa taccactca gtctgtgta 3180
aattgtatgt ctttttaaag gtatttaaag attcaactaa gctttaaaga gggctgagca 3240
gctcaggaag cctgtaatgt gggcataact ctttggacct gatcttgatg cttctgctgc 3300
tctgttagcc tctgaagagc aatatctaat ttattattac tgtaattttt taaaaggctt 3360
taaagtgcct caggggtccc ctgaaactaa ttttctattt ctgggattcc ctggattcat 3420
tatatgagat ggtgacatga ttagaggaa tcttttttag tatgaaaatt gtcccttttc 3480
ttcttcagta cttgcctcct tgctggcatt gaattaacac agggacaaaa tttggttaat 3540
tttttatttc taactctccc aacaaacccc tggtgccag tatttgttt gtggccttta 3600
accacctgag ggaaaaaatg agcttattca agctgccaat atttatctat gggctgtagc 3660
agtacactga attgtactgt gccagggata ttgagatgct ctgggggtgt attgtatacc 3720
tgccagtttt cttcatttct gaattgagtt ttcttttctt gatgttggtt tccttcata 3780
cacctcaagg tttagatttg tgaaggaata agcatgatgg aaataatagt cttgaaagga 3840
gatatgttgt atataatcag gaggaagagg aaggaaggac ttaccattt tgatattttg 3900
ctgtaggtgg ccagttttgt ttctcatagg gaaatctgac ccacctgtca tgttggtccc 3960
taaggaaactg ctggtgtaag cggctcatca agagttgaac ttcacgtagc cttggtggga 4020
atatggaaaa ggaagaaagc cacaggactg cccattcagt cttgggaaga ttgggatgat 4080
tctgcacaag caaaaatgac tgaagtttat gtatagacac acctctacca atccatcttc 4140
agctgactga atgttgtatg atagcccttc tccaaagcag aggtagaatg ttcaggtttc 4200
accatggatt ttctacttat ttctgttttg gaatcagctt acagattcca ggtccctttt 4260
gtatatattc tttattcttt tgctttttta aaaaataatt ttgtttcata tttaaagcac 4320
ttgtattagt caatgtttcg tgtccgcac tatttgaacc atttgccctt acagaaagag 4380
aaatacttgt ttgtgtttta aataaaactg atgtag 4416

```

&lt;210&gt; 44

&lt;211&gt; 2068

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 1378134

&lt;400&gt; 44

```

gcagtcacatc agtccgctga tgcgtcgccg ggccagcaac gctgccgccc cagcccacac 60
gattggcggc agtaagcaca caatgaatga tcacctgcat gtcggcagcc acgctcacgg 120
acagatccag gttcgacagt tgtttgagga taacagtaac aagcggacag tgctcacgac 180
acaaccaaat gggcttaciaa cagtgggcaa aacgggcttg ccagtgggtg cagagcggca 240
gctggacagc attcatagac ggcaggggag ctccacctct ctaaagtcca tggaaaggcat 300
ggggaagggtg aaagccaccc ccatgacacc tgaacaagca atgaagcaat acatgcaaaa 360
actcacagcc ttcgaacacc atgagatttt cagctaccct gaaatatatt tcttgggtct 420
aaatgctaag aagcgccagg gcatgacagg tgggccaac aatggtggct atgatgatga 480
ccagggatca tatgtgcagg tgccccacga tcacgtggct tacaggtatg aggtccctca 540
ggtcattggg aaggggagct ttgggcaggt ggtcaaggcc tacgatcaca aagtccacca 600
gcacgtggcc ctaaagatgg tgcggaatga gaagcgcttc caccggcaag cagcggagga 660
gatccgaatc ctggaacacc tgcggaagca ggacaaggat aacacaatga atgtcatcca 720
tatgtcggag aatttcacct tccgcaacca catctgcatg acgtttgagc tgctgagcat 780
gaacctctat gagctcatca agaagaataa attccagggc ttcagctctgc ctttgggttcg 840
caagtgttgc cactcgatc tgcagtgtt ggatgctttg cacaaaaaca gaataattca 900
ctgtgacctt aagcccagga acattttgtt aaagcagcag ggtagaagcg gtattaaagt 960
aattgatatt ggctccagtt gttacgagca tcagcgtgtc tacacgtaca tccagtcgcg 1020
tttttaccgg gctccagaag tgatccttgg ggccagggtat ggcatgcccc ttgatatgtg 1080

```

```

gagcctgggc tgcatttttag cagagctcct gacgggttac cccctcttgc ctggggaaga 1140
tgaagggggac cagctggcct gtatgattga actggttggc atgccctcac agaaactgct 1200
ggatgcatcc aaacgagcca aaaattttgt gagctccaag gggtatcccc gttactgcac 1260
tgtcacgact ctctcagatg gctctgtggt cctaaacgga ggccgttccc ggagggggaa 1320
actgaggggc ccaccggaga gcagagagtg ggggaacgcg ctgaaggggt gtgatgatcc 1380
ccttttcttt gacttcttaa aacagtgttt agagtgggat cctgcagtgc gcatgacccc 1440
agggcaggct ttgcggcacc cctggctgag gaggcggttg ccaaagcctc ccaccgggga 1500
gaaaacgtca gtgaaaagga taactgagag caccgtgct atcacatcta tatccaagtt 1560
acctccacct tctagctcag ctccaaact gaggactaat ttggcgaga tgacagatgc 1620
caatgggaat attcagcaga ggacagtgtt gccaaaactt gttagctgag ctcacgtccc 1680
ctgatgctgg taacctgaaa gatacgacat tgctgagcct tactgggttg aaaaggagta 1740
gctcagacct gtttttattt gctcaataac tctactcatt tgtatctttt cagcacttaa 1800
ttttaatgta agaaagtgtt tcattttgtt ttataaaaat acatgaggac aatgctttta 1860
gtttttatata tttcagaaac tttttgtgtt ctaaaagtac aatgagcctt actgtattta 1920
gtgtggcaga ataataacat cagtggcagg ccactgatta cttcatgact gccacgcatt 1980
tacagattgg tgtcaaagac attcactatg tttttatggg tcatgttata tcctccccag 2040
ggtgacagcc ccttaaggcc ctccctttt 2068

```

&lt;210&gt; 45

&lt;211&gt; 1850

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 1490070

&lt;400&gt; 45

```

gggctgcctg cctgcctgcc tgcctgcctg gcccgggccc agctccagcc tgcctcttcc 60
actggccact gcctcccacc cagggctggc atccctgctc cctgccctgg gtcccagact 120
gtgtcctcca tcaccgcagg tcggtagagg gctgggctgg acaccagggc ccgccctccc 180
atcactgagc tccactcctt cctcattttg ctgctgattc tagcccaaaa caaaacaggt 240
tgagcttttt cctcccctca gaagctctc tctggctcgt ggctgccttc tgagtgttgc 300
agacggcgcc gcccggaag gggggcctgg gccagccctg ccaggactgg gacgtgctg 360
ctggcgctg gccctccatc agggcagcct gtggcaggag agtgagcttt gccgcggcag 420
acgcctgagg atgatgcccc agctgcagtt caaagatgcc ttttgggtgca gggacttcac 480
agccacacag ggctacgagg tgctgctgca gcggtctctg gatggcagga agatgtgcaa 540
agacatgggt gagtactgt ggagagggc ccaggcgagg gagcggtacg ggaaggagct 600
ggtgcagatc gcacggaagg caggtggcca gacggagatc aactccctga gggcctcctt 660
tgactccttg aagcagcaaa tggagaatgt gggcagctca cacatccagc tggccctgac 720
cctgcgtgag gagctgcgga gtctcgagga gtttcgtgag aggcagaagg agcagaggaa 780
gaagtatgag gccgtcatgg accgggtcca gaagagcaag ctgtcgtctt acaagaaggc 840
catggagtcc aagaagacat acgagcagaa gtgccgggac gcggacgacg cggagcaggc 900
cttcgagcgc attagcgcca acggccacca gaagcaggtg gagaagagtc agaacaaagc 960
caggcagtgc aaggactcgg ccaccgaggc agagcgggta tacaggcaga gcattgcgca 1020
gctggagaag gtccgggctg agtgggagca ggagcaccgg accacctgtg aggcctttca 1080
gctgcaagag tttgaccggc tgaccattct ccgcaacgcc ctgtgggtgc acagcaacca 1140
gctctccatg cagtgtgtca aggatgatga gctctacgag gaagtgcggc tgacgctgga 1200
aggctgcagc atagacgccg acatcgacag tttcatccag gccaaagaca cgggcacaga 1260
gcccccgct ccggtgccct accagaacta ttacgatcgg gaggtcacc cgtgaccag 1320
cagccctggc atacagccgt cctgcggcat gataaagagg ttctctggac tgctgcacgg 1380
aagtcccaag accacttcgt tggcagcttc tgctgcgtcc acagagaccc tgacccccac 1440
ccccgagcgg aatgaggggtg tctacacagc catcgagtg caggagatac agggaaaccc 1500
ggcctcacca gccaggagt accggcgct ctacgattat acagcgaga acccagatga 1560
gctggacctg tccgcgggag acatcctgga ggtgatcctg gaaggggagg atggctggtg 1620

```



gactgtggag aggaacgggc agcgtggctt cgtccctggt tctacctgg agaagctttg 1680  
 aggaagggcc agggagcccct tcggacctgc cctgccagtg gagccagcag tgccccagc 1740  
 actgtcccca ccttgctagg gccagaaac aagcgtcccc cagccccgag agggagcctg 1800  
 tcgtctccca gggaataaag gagtgcgttc tgttctcaa aaaaaaaaaa 1850

<210> 46

<211> 2534

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte Clone Number: 1997814

<400> 46

gaagagggga tggagcaggg gctggaggag gaagaagagg tggatccccg gatccaggga 60  
 gaactggaga agttaaataca gtccacggat gatataca gacgggagac tgaacttgag 120  
 gatgctcgtc agaagttccg ctctgttctg gttgaagcaa cggtgaaact ggatgaactg 180  
 gtgaagaaaa ttggcaaac tgtggaagac tccaagccct actgggaggc acggagggtg 240  
 gcgagggcagg ctgagctgga agctcagaaa gccacgcagg acttcagag ggccacagag 300  
 gtgctccgtg ccgccaaggga gaccatctcc ctggccgagc agcggtgct ggaggatgac 360  
 aagcggcagc tcgactccgc ctggcaggag atgctgaatc acgccactca gagggtcatg 420  
 gaggcggagc agaccaagac caggagcgag ctggtgcata aggagacggc agccaggtac 480  
 aatgccgcca tgggccgcat gcgacagctg gagaagaaac tcaagagagc catcaacaag 540  
 tccaagcctt attttgaact caaggcaaac tactatgtgc agctcgagca actgaaaaag 600  
 actgtggatg acctgcaggc caaactgacc ctggcaaaag gcgagtacaa gatggccctg 660  
 aagaacctgg agatgatctc agatgagatc cacgagcggc gccgctccag tgccatgggg 720  
 cctcggggat gcggtgttgg tgtgagggc agcagcacat ctgtggagga tctgccaggg 780  
 agcaaacctg agcctgatgc catttctgtg gcctcggagg cctttgaaga tgacagctgt 840  
 agcaactttg tgtctgaaga tgactcggaa acccagtcgg tgtccagctt tagttcagga 900  
 ccaacaagcc cgtctgagat gcctgaccag ttcctcgagg ttgtgaggcc tggcagcctg 960  
 gatctgcca gccctgtgtc cctgtcagag tttgggatga tttcccagt gttgggccct 1020  
 cgaagtgaat gcagcggggc ctccctccct gaatgtgaag tagaacgagg agacagggca 1080  
 gaaggggcag agaataaaac aagtgacaaa gccacaaca accggggcct cagcagtagc 1140  
 agtggcagtg gtggcagcag taagagccaa agcagcacct cccctgaggg ccaggccttg 1200  
 gagaaccgga tgaagcagct ctccctacag tgctcaaagg gaagagatgg aattattgct 1260  
 gacataaaaa tgggtgcagat tggctgatc atcctggggc ctggccgatg tgcataatca 1320  
 catttataca tggaactgga gaacattgtg ccaataatca tttaatatat gccaaatctt 1380  
 acacgtctac tctaaactgc tctaataaag ttccagtgc ctgagggct aaagattggt 1440  
 cttctgggta agagctcttg ggctggtttt tcagagcaga gttcttgttg tgggtagact 1500  
 gtgactaggt tcacagcctt tgtggaacat tccgtataac ggcattgtgg aagcaataac 1560  
 tagttcctat gaaagaacca gagctgggaa gatggctggg aagccaggcc aaagtggggg 1620  
 caacagcttg cttctcttcc tctctcacc ctgagtttgt atgggaaaat ggagatgtcc 1680  
 tctccacttt atcccacgat atctaaatga aaaagaaaga aaaccacac acaaagcaaa 1740  
 aactcaagta ttaagagcac atatttttga cccagtggag gcttaaaaaa aaaaaatcc 1800  
 aagaacacaa ttcattttca ccacctctgg tgttcagagg gggcttttaa aaaagcgtgt 1860  
 atgctgggat acccattaaa accattttct agaaggctac catgagctgc actttttggg 1920  
 gtgggaaagg tgaatgccag tggggatgag gggggatgag ggtaggaggg acttatagaa 1980  
 ggggatttgg ggctgtgggg gagaaggttc tacagcataa gccttatcct gccagccaa 2040  
 gggatttatt ctaagagaag tgcagtgtga gaatggttgc cactgttatt agattgacaa 2100  
 gatgttaatt tctctgtagg ttgtaacttt aaaaataaat gaaattattt aagggttatg 2160  
 ctgcactagt attccttaga ggaaacagtt ctttaaagtt agggaaaggga gtaggcaggc 2220  
 atgtgttggc aaaggctgtt aatagtagtt aagtgttaag actgcttttc tttaacgttt 2280  
 tcatggtaat gcatatttag agcactgtat ttttgtcttg ttaagaaaat ttagcatttc 2340  
 taaaagaaaa aagcaaccct ctttcaaac gttaattctg tcacagcctg tatatttttag 2400

tcattttgtaa atctcttcat acaatagtga cttctttttt gactgataca gtatcttaat 2460  
tacaagggtta ttttgtactt gtcttaatac actaagtgtg ataaaaacgg cttgagaaaa 2520  
gttaaaaaaa aaaa 2534

<210> 47

<211> 3786

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte Clone Number: 2299715

<400> 47

ccgtcctcga ggcgaggaga gtaccggggc ggcccggctg ccgcgcgagg agcgcggctcg 60  
gcggcctggg ctgcggctga gatacacaga gcgacagaga catttattgt tatttgtttt 120  
ttgggtggcaa aaagggaaaa tggcgaacga ctcccctgca aaaagtctgg tggacatcga 180  
cctctcctcc ctgcgggatc ctgctgggat ttttgagctg gtggaagtgg ttggaaatgg 240  
cacctatgga caagtctata agggctcgaca tgttaaaacg ggtcagttgg cagccatcaa 300  
agttatggat gtcactgagg atgaagagga agaaatcaaa ctggagataa atatgctaaa 360  
gaaataactct catcacagaa acattgcaac atattatggg gctttcatca aaaagagccc 420  
tccaggacat gatgaccaac tctggcttgt tatggagttc tgtggggctg ggtccattac 480  
agaccttggt aagaacacca aagggaacac actcaaagaa gactggatcg cttacatctc 540  
cagagaaatc ctgaggggac tggcacatct tcacattcat catgtgattc accgggatat 600  
caagggccag aatgtgttgc tgactgagaa tgcaggggtg aaacttggtg actttggtgt 660  
gagtgtcag ctggacagga ctgtggggcg gagaataacg ttcataggca ctccctactg 720  
gatggctcct gaggtcatcg cctgtgatga gaaccagat gccacctatg attacagaag 780  
tgatctttgg tcttgtggca ttacagccat tgagatggca gaaggtgctc cccctctctg 840  
tgacatgcat ccaatgagag cactgtttct cattcccaga aacctcctc cccggctgaa 900  
gtcaaaaaaa tggtcgaaga agttttttag ttttatagaa ggtgacctg tgaagaatta 960  
catgcagcgg cctctacag agcagctttt gaaacatcct tttataaggg atcagccaaa 1020  
tgaaaggcaa gttagaatcc agcttaagga tcatatagat cgtaccagga agaagagagg 1080  
cgagaaagat gaaactgagt atgagtacag tgggagttag gaagaagagg aggaagtgcc 1140  
tgaacaggaa ggagagccaa gttccattgt gaacgtgcct ggtgagtcta ctcttcgccg 1200  
agatttcctg agactgcagc aggagaacaa ggaacgttcc gaggtctctc ggagacaaca 1260  
gttactacag gagcaacagc tccgggagca ggaagaatat aaaaggcaac tgcctggcaga 1320  
gagacagaag cggattgagc agcagaaaaga acagaggcga cggctagaag agcaacaaag 1380  
gagagagcgg gaagctagaa ggcagcagga acgtgaacag cgaaggagag aacaagaaga 1440  
aaagagggct ctagaggagt tggagagaag gcgcaaagaa gaagaggaga ggagacgggc 1500  
agaagaagaa aagaggagag ttgaaagaga acaggagtat atcaggcgac agctagaaga 1560  
ggagcagcgg cacttggaag tccttcagca gcagctgctc caggagcagg ccatgttact 1620  
gcatgaccat aggaggccgc acccgagca ctgcagcag ccgccaccac cgcagcagga 1680  
aaggagcaag ccaagcttcc atgctcccga gcccaaagcc cactacgagc ctgctgaccg 1740  
agcgcgagag gttcctgtga gaacaacatc tcgctcccct gttctgtccc gtcgagattc 1800  
cccactgcag ggcagtgggc agcagaatag ccaggcagga cagagaaact ccaccagtat 1860  
tgagcccagg ctctgtggg agagagtgga gaagctggtg ccagacctg gcagtggcag 1920  
ctcctcaggg tccagcaact caggatccca gcccggtct caccctgggt ctgagagtgg 1980  
ctccggggaa cgcttcagag tgagatcatc atccaagtct gaaggctctc catctcagcg 2040  
cctggaaaat gcagtgaaaa aacctgaaga taaaaggaa gttttcagac cctcaagcc 2100  
tgctgatctg accgcactgg ccaaagagct tcgagcagtg gaagatgtac ggccacctca 2160  
caaagtaacg gactactcct catccagtga ggagtcgggg acgacggatg aggaggacga 2220  
cgatgtggag caggaagggg ctgacgagtc cacctcagga ccagaggaca ccagagcagc 2280  
gtcatctctg aatttgagca atggtgaaac ggaatctgtg aaaaccatga ttgtccatga 2340  
tgatgtagaa agtgagccgg ccatgacccc atccaaggag ggcactctaa tcgtccgcca 2400  
gactcagtc gctagtagca cactccagaa acacaaatct tcctcctcct ttacaccttt 2460

```

tatagacccc agattactac agattttctcc atctagcgga acaacagtga catctgtggt 2520
gggattttcc tgtgatggga tgagaccaga agccataagg caagatccta cccggaaaagg 2580
ctcagtgggc aatgtgaatc ctaccaacac taggccacag agtgacaccc cggagattcg 2640
taaatacaag aagaggttta actctgagat tctgtgtgct gccttatggg gagtgaattt 2700
gctagtgggt acagagagtg gcctgatgct gctggacaga agtggccaag ggaaggtcta 2760
tcctcttata aaccgaagac gatttcaaca aatggacgta cttgagggct tgaatgtctt 2820
ggtgacaata tctggcaaaa aggataagtt acgtgtctac tatttgcct ggtaagaaa 2880
taaaatactt cacaatgatc cagaagtga gaagaagcag ggatggacaa ccgtagggga 2940
tttgggaagg tgtgtacatt ataaagttgt aaaatatgaa agaatacaat ttctggtgat 3000
tgctttgaag agttctgtgg aagtctatgc gtgggcacca aagccatata aaaaatttat 3060
ggcctttaag tcatttggag aattggtaca tggatcctgt gctggattcc atgctgttga 3120
tgtggattca ggatcagtct atgacattta tctaccaaca catatccagt gtagcatcaa 3180
accccatgca atcatcatc tcccaatac agatggaatg gagcttctgg tgtgctatga 3240
agatgagggg gtttatgtaa acacatatgg aaggatcacc aaggatgtag ttctacagtg 3300
gggagagatg cctacatcag tagcatatat tcatccaat cagacaatgg gctggggaga 3360
gaaggccata gagatccgat ctgtggaaac tggtcacttg gatggtgtgt tcatgcacaa 3420
aagggctcaa agactaaaat tcttgtgtga acgcaatgac aaggtgttct ttgectctgt 3480
tcggtctggt ggcagcagtc aggtttatct catgacctta ggcaggactt ctcttctgag 3540
ctggtagaag cagtgtgatc cagggattac tggcctccag agtcttcaag atcctgagaa 3600
cttgggaattc cttgtaactg gagctcggag ctgcaccgag ggcaaccagg acagctgtgt 3660
gtgcagacct catgtgttgg gttctctccc ctcttctctg ttctctttat ataccagttt 3720
atccccattc tttttttttt tcttactcca aaataaatca aggttgcaat gcagctgggtg 3780
ctgtta
3786

```

&lt;210&gt; 48

&lt;211&gt; 1182

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 209854

&lt;400&gt; 48

```

gttggtgaag tcaagcgaag ggcactagag ctccaggagg gccagttctg tgggctctag 60
tcggccatat taataaagag aaaggggaagg ctgaccgtcc ttgcctccg cccccacata 120
cacaccctt ctccactc cgctctcacg actaagctct cagattaag gcacgcctgc 180
ctcgattgtc cagcctctgc cagaagaaag cttagcagcc agcgctcag tagagaccta 240
agggcgctga atgagtggga aagggaaatg cgcaccaatt gcgctgcggc gggctgtgcc 300
actacctaca acaagcacat taacatcagc ttccacaggt ttctttgga tcctaaaaga 360
agaaaagaat gggttcgctt ggttaggcgc aaaaattttg tgccaggaaa acacactttt 420
ctttgttcaa agcactttga agcctcctgt ttgacctaa caggacaaac tcgacgactt 480
aaaatggatg ctgttccaac catttttgat tttgtaccc atataaagt cttgaaactc 540
aagtcaagga atcttttgaa gaaaaacaac agttgttctc cagctggacc atctaattta 600
aatcaaaaca ttagtagtca gcaagtacta cttgaacaca gctatgcctt taggaatcct 660
atggaggcaa aaaagaggat cattaaactg gaaaaagaaa tagcaagctt aagaagaaaa 720
atgaaaactt gcctacaaaa ggaacgcaga gcaactcgaa gatggatcaa agccacgtgt 780
ttggtaaaga atttagaagc aaatagtgtt ttacctaaag gtacatcaga acacatgtta 840
ccaactgcct taagcagtct tcctttggaa gattttaaga tccttgaaac agatcaacaa 900
gataaaacac tgctaagtct aaatctaaaa cagaccaaga gtaccttcat ttaaathtag 960
cttgacaga gcttgatgcc tctcttcat tcttttcaga agtaaagata attatggcac 1020
ttatgcaaaa attcattatt taataaagtt ttacttgaag taacattact gaatttgtga 1080
agacttgatt acaaaaagaat aaaaaacttc atatggaaat tttatttgaa aatgagtgtga 1140
agtgccttac attagaatta cggactttca aaactatgat aa
1182

```

<210> 49  
<211> 1676  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte Clone Number: 1384286

<400> 49  
tcgcccagagcc cgtccgcccgc cgccatggcc accacgggtga cctgcacccg cttcaccgac 60  
gagtaccagc tctacgagga tattggcaag ggggctttct ctgtgggtccg acgtgtgtgc 120  
aagctctgca ccggccatga gtatgcagcc aagatcatca acaccaagaa gctgtcagcc 180  
agagatcacc agaagctgga gagagaggct cggatctgcc gccttctgaa gcattccaaac 240  
atcgtgcgtc tccacgacag catctccgag gagggcttcc actacctggc cttcgatctg 300  
gtcactgggtg gggagctctt tgaagacatt gtggcgagag agtactacag cgaggctgat 360  
gccagtcact gtatccagca gatcctggag gccgttctcc attgtcacca aatgggggtc 420  
gtccacagag acctcaagcc ggagaacctg cttctggcca gcaagtgcga aggggctgca 480  
gtgaagctgg cagacttcgg cctagctatc gaggtgcagg gggaccagca ggcattggtt 540  
ggtttcgctg gcacaccagg ctacctgtcc cctgagggtcc ttcgcaaaga ggcgtacggc 600  
aagcccgtgg acatctgggc atgtgggggtg atcctgtaca tctgtctcgt gggctaccca 660  
cccttctggg acgaggacca gcacaagctg taccagcaga tcaaggctgg tgcctatgac 720  
ttcccgtccc ctgagtggga caccgtcact cctgaagcca aaaacctcat caaccagatg 780  
ctgaccatca accctgcca gcgcatacaca gcccatgagg ccctgaagca cccgtgggtc 840  
tgccaacgct ccacggtagc atccatgatg cacagacagg agactgtgga gtgtctgaaa 900  
aagttcaatg ccaggagaaa gctcaaggga gccatcctca ccaccatgct ggccacacgg 960  
aatttctcag cagccaagag ttactcaac aagaaagcag atggagtcaa gccccatacg 1020  
aatagcacca aaaacagtgc agccgccacc agcccacaaag ggacgcttcc tcctgccgcc 1080  
ctggagtctt ctgacagtgc caataccacc atagaggatg aagacgctaa agcccggag 1140  
caggagatca ttaagaccac ggagcagctc atcgaggccg tcaacaacgg tgactttgag 1200  
gcctacgcga aaatctgtga cccagggtg acctcgttg agcctgaagc actgggcaac 1260  
ctgggtgaag ggatggactt ccacagattc tacttcgaga acctgctggc caagaacagc 1320  
aagccgatcc acacgacat cctgaaccca caggtgcacg tcattggaga ggatgccgcc 1380  
tgcacgctt acatccggct cagcgagtag attgacgggc agggccggcc ccgcaccagc 1440  
cagtcctgag agaccgcgt gtggcaccgc cgcgacggca agtggcagaa cgtgcacttc 1500  
cactgctcgg gcgcgcctgt ggccccgctg cagtgaagag ctgcccctg gtttcgccc 1560  
acagagttgg tgtttggagc ccgactgccc tcgggcacac ggctgctcgt tcgcatgttt 1620  
gtgtctgcct cgttccctcc cctggtgcct gtgtctgcag aaaaacaagc ccgact 1676

<210> 50  
<211> 1597  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte Clone Number: 1512656

<400> 50  
tcggccttcg gaaagacccc cgggcccggg cagggagaga gccgagcgc gcagccgtga 60  
gccgaataga gccggagaga cccgagtatg accggagaag cccaggccgg ccggaagagg 120  
agccgagcgc ggccggaagg aaccgagccc gtccgaaggg agcggacgca gcctggcctg 180  
gggcccggtc gagcccgcgc catggcggcc gaggcgacag ctgtggccgg aagcggggct 240  
gttggcggct gcctggccaa agacggcttg cagcagtcta agtggccgga cactacccca 300  
aaacggcggc gcgcctcgtc gctgtcgcgt gacgccgagc gccgagccta ccaatggtgc 360

```

cgggagtact tgggcggggc ctggcgccga gtgcagcccg aggagctgag ggtttacc 420
gtgagcggag gcctcagcaa cctgctcttc cgctgctcgc tcccgacca cctgcccagc 480
gttggcgagg agccccggga ggtgcttctg cggtgtacg gagccatctt gcagggcg 540
gactccctgg tgctagaaag cgtgatgttc gccatacttg cggagcggtc gctggggccc 600
cagctgtacg gagtcttccc agaggggcgg ctggaacagt acatcccaag tcggccattg 660
aaaactcaag agcttcgaga gccagtgttg tcagcagcca ttgccacgaa gatggcgcaa 720
tttcatggca tggagatgcc tttcaccaag gagccccact ggctgtttgg gaccatggag 780
cggtagcctaa aacagatcca ggacctgccc ccaactggcc tccctgagat gaacctgctg 840
gagatgtaca gcctgaagga tgagatgggc aacctcagga agttactaga gtctaccca 900
tcgccagtcg tcttctgcca caatgacatc caggaaggga acatcttgct gctctcagag 960
ccagaaaatg ctgacagcct catgctggtg gacttcgagt acagcagtta taactatagg 1020
ggctttgaca ttgggaacca tttttgtgag tgggtttatg attatactca cgaggaatgg 1080
cctttctaca aagcaaggcc cacagactac cccactcaag aacagcagtt gcattttatt 1140
cgtcattacc tggcagaggc aaagaaagggt gagacctct cccaagagga gcagagaaaa 1200
ctggaagaag atttgctggt agaagtcagt cggtagctc tggcatcca tttcttctg 1260
ggtctgtggt ccatcctcca ggcatccatg tccaccatag aatttggtta cttggactat 1320
gcccagtcct gggtccagtt ctacttccag cagaaggggc agctgaccag tgtccactcc 1380
tcactctgac tccacctctc cactccttgg atttctctg gagcctccag ggcaggacct 1440
tggagggagg aacaacgagc agaaggccct ggcgactggg ctgagccccc aagtgaact 1500
gagggttcagg agaccggcct gttcctgagt ttgagtaggt ccccatggct ggcaggccag 1560
agccccgtgc tgtgtatgta acacaataaa caagctg 1597

```

&lt;210&gt; 51

&lt;211&gt; 2145

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2098635

&lt;400&gt; 51

```

cccacgcgtc cggacagctt gaccagttt gctttccaat caaaggcat ttattttgaa 60
tgtctctttg tggcgcaaga gccaacgcaa aaatgatggc ggcttacaat ggcggtacat 120
ctgcagcagc agcaggtcac caccaccacc atcaccacca ccttccacac ctccctctc 180
ctcacctgct tcaccaccac caccctcaac accatcttca tccggggtcg gctgcccgtg 240
tacacctgt acagcagcac acctcttcgg cagctgcggc agccgcagca gcggtcgcag 300
ctgcagccat gttaaacctt gggcaacaac agccatattt cccatcaccg gcaccggggc 360
aggctcctgg accagctgca gcagcccag ctgaggtaca ggctgccgca gctgctacag 420
ttaaggcgca ccatcatcag cactcgcatc atccacagca gcagctggat attgagccg 480
atagacctat tggatatgga gcctttggtg ttgtctggtc agtaacagat ccaagagatg 540
gaaagagagt agcgtcaaaa aagatgcccc acgtcttcca gaatctggct tcttgcaaaa 600
gggtcttccg ggaattgaag atgttgtgtt tttttaagca tgataatgta ctctctgccc 660
ttgacatact ccaacctcca cacattgact attttgaaga aatataatgtt gtcacagaat 720
tgatgcagag tgacctacat aaaattatcg tctctcctca accactcagc tcagatcatg 780
tcaaagtttt tctttatcag attttgcgag gtttgaaata tctccattca gctggcattt 840
tacatcgaga cattaagcca gggaatctcc ttgtgaacag caactgtgtt ctaaagattt 900
gtgattttgg attggccaga gtggaagagt tagatgaatc ccgtcatatg actcaggaag 960
ttgttactca gtattatcgg gctccagaaa tctgatggg cagccgtcat tacagcaatg 1020
ctattgacat ctggctctgt ggatgtatct ttgcagaact actaggacga agaattattg 1080
ttcaggcaca gactccatt cagcagttgg atttgatcac ggatctgttg ggcacaccat 1140
cactggaagc aatgaggaca gcttgtgaag gcgctaaggc acatatactc aggggtcctc 1200
ataaacagcc atctcttctt gtactctata cctgtctag ccaggctaca catgaagctg 1260
ttcatctcct ttgcaggatg ttggtctttg atccatccaa aagaatatcc gctaaggatg 1320
ccttagccca cccctaccta gatgaagggc gactacgata tcacacatgt atgtgtaaat 1380

```

```

gttgcttttc cacctccact ggaagagttt ataccagtga ctttgagcct gtcaccaatc 1440
ccaaatttga tgacactttc gagaagaacc tcagttctgt ccgacaggtt aaagaaatta 1500
ttcatcagtt cattttggaa cagcagaaag gaaacagagt gcctctctgc atcaaccctc 1560
agtctgctgc ttttaagagc tttattagtt ccactgttgc tcagccatct gagatgcccc 1620
catctcctct ggtgtgggag tgatgggtga agataatgta ctactgaaga tgtaatgtag 1680
ctttccactg gagtctggga tttgcaattc tggaggttaa tcatgcttgt actgtaattt 1740
tactaatgaa gttttaaatt aacaaccact acttgatga tatgaataat atttagaaat 1800
gttactagac ttttaattct gtaaagtggg tgtgctttta gaagaaaaat attttaccca 1860
gagttgcaca tgttttatga atttagtgca gctgttatgg ctacactcag aacaaaagag 1920
aattgaacca aatttgggag tttgggggtt tatgtttgt ttttcttttc taaaaagaag 1980
tgagattggt cacacacaca cacacacaca cacacacaca cacaacaca aaggacagtc 2040
atacattttg atatttgagc cattcctaaa gatttggggg tttctaaaac taaagaatct 2100
aggaaccttg cctgcgacca atcatggagc cacgtgagct gatcg 2145

```

&lt;210&gt; 52

&lt;211&gt; 1454

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2446646

&lt;400&gt; 52

```

gggttcgaat tgcaacggca gctgccgggc gtatgtgttg gtgctagagg cagctgcagg 60
gtctcgctgg gggccgctcg ggaccaattt tgaagaggta cttggccacg acttattttc 120
acctccgacc tttccttcca ggcggtgaga ctctggactg agagtggcct tcacaatgga 180
agggatcagt aatttcaaga caccaagcaa attatcagaa aaaaagaaat ctgtattatg 240
ttcaactcca actataaata tcccggcctc tccgtttatg cagaagcttg gctttggtac 300
tggggtaaat gtgtacctaa tgaaaagatc tccaagaggt ttgtctcatt ctccctgggc 360
tgtaaaaaag attaatccta tatgtaatga tcattatcga agtgtgtatc aaaagagact 420
aatggatgaa gctaagattt tgaaaagcct tcatcatcca aacattgttg gttatcgtgc 480
ttttactgaa gccaatgatg gcagtctgtg tcttgctatg gaatatggag gtgaaaagtc 540
tctaaatgac ttaatagaag aacgatataa agccagccaa gatccttttc cagcagccat 600
aattttaaaa gttgctttga atatggcaag aggggttaaag tatctgcacc aagaaaagaa 660
actgcttcat ggagacataa agtcttcaaa tgttgtaatt aaaggcgatt ttgaaacaat 720
taaaatctgt gatgtaggag tctctctacc actggatgaa aatatgactg tgactgaccc 780
tgaggcttgt tacattggca cagagccatg gaaacccaaa gaagctgtgg aggagaatgg 840
tgttattact gacaaggcag acatatttgc ctttggcctt actttgtggg aaatgatgac 900
tttatcgatt ccacacatta atctttcaaa tgatgatgat gatgaagata aaacttttga 960
tgaaagtgat tttgatgatg aagcatacta tgcagcgttg ggaactaggc cacctattaa 1020
tatggaagaa ctggatgaat cataccagaa agtaattgaa ctcttctctg tatgcactaa 1080
tgaagaccct aaagatcgtc cttctgctgc acacattgtt gaagctctgg aaacagatgt 1140
ctagtgatca totcagctga agtgtggcct gcgtaaataa ctgtttattc caaaatattt 1200
acatagttac tatcagtagt tattagactc taaaattggc atatttgagg accatagttt 1260
cttggttaaca tatggataac tatttcta atgaaatatg ctatatattg ctataagcac 1320
ttggaattgt actgggtttt ctgtaaagtt ttagaaacta gctacataag tactttgata 1380
ctgctcatgc tgacttaaaa cactagcagt aaaacgctgt aaactgtaac attaaattga 1440
atgaccatta cttt 1454

```

&lt;210&gt; 53

&lt;211&gt; 3225

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2764911

&lt;400&gt; 53

tggagcaggg ggcggtttgg ttgcgcggta ctagcgggtgc ccgccgaatg gggaggaggc 60  
gaggagcgag ccgtgcggcc agagcgggaa agagactcgt ctttgcgtcc gagttctgga 120  
gccgcgcgac cccgactcct ggggccgcgg cagcggctgc gaggggacgg gcgtccgctg 180  
tctcctgggt tccccctcgta gcgacccgcg ggatcggaaa aaaaggagaa gatggaggag 240  
gaggggtggca gcagcggcgg cgccgcgggg accagcgcgg acggcggcga cggaggagag 300  
cagctcctca ctgtcaagca cgagctgcgg actgctaatt tgacaggaca tgctgagaag 360  
gtgggaatag aaaattttga gctcctgaag gtcctaggaa ctggagctta tggaaaagta 420  
tttctagtgc gtaaaataag tggccatgat actggaaagc tgtatgccat gaaagttttg 480  
aaaaaggcaa caatcggtta aaaggccaaa accacagagc atacaaggac agaacgacaa 540  
gtcctggaaac acattaggca gtgcgcattt ttggtaacat tacattatgc tttccagaca 600  
gaaaccaaac ttcattctcat tttagattat ataatgggtg gtgaactttt taccatctt 660  
tctcaaagag agcgtttcac agagcatgag gtgcagattt atgttgaga gattgtgctt 720  
gccctcgaaac atctccacaa gttggggatt atatatcgtg atattaagct tgagaatatt 780  
ctacttgatt ctaatggcca tgtggtgctg acagattttg gtctgagtaa ggagtttgtg 840  
gtgatgaaa ctgaaagagc atattccttt tgtggaacta ttgaatacat ggcaccagat 900  
attgtcagag ggggagattc aggacatgac aaggcagttg actggtggag tttgggtgtt 960  
ctaattgtatg aattactaac tggagcatct cctttcactg ttgatggaga aaaaaattcc 1020  
caagctgaga tatctaggag aatattaaaa agtgagcctc catatcccca agaatgagt 1080  
gcttttagcga aagacctaatt tcagcgtctt ttgatgaaag atcccaagaa gagattggga 1140  
tgtggtccac gtgatgcaga tgaaatcaaa gaacatctct tctttcagaa aataaattgg 1200  
gatgatttag ccgccaaaaa agtgccctgca ccatttaagc cagtcattcg agatgaatta 1260  
gatgtgagta actttgcaga agagttcaca gaaatggatc ccacttattc tcccgcagcc 1320  
ctgccccaga gttctgagaa gctgtttcag ggctattcct ttggtgctcc ttcctccta 1380  
ttcaagcgta atgcagctgt catagaccct cttcagtttc acatgggagt tgaacgtcct 1440  
ggagtgcaca atgttgccag gagtgcfaat atgaaggact ctccattcta tcaacactat 1500  
gacctagatt tgaaggacaa acccctggga gaaggtagtt tttcaatttg tcgaaagtgt 1560  
gtgcataaaa aaagtaacca agcttttgca gtcaaaaataa tcagcaaaag gatggaagcc 1620  
aatactcaaa aggaaataac agctctggaa ctctgtgaag gacaccccaa tattgtgaag 1680  
ttgcatgaag tttttcatga tcagcttcac acgtttctag tgatggaact tctgaatgga 1740  
ggagaactgt ttgagcgcac taagaaaaag aagcacttca gtgagacgga agccagctac 1800  
atcatgagga agcttggttc agctgtaagc cacatgcatg atgttgagggt ggtgcacagg 1860  
gatctgaaac ctgagaattt attgttcacc gatgaaaatg acaatttgga aattaaata 1920  
attgattttg gatttgacag gctaaagcca ccggataatc agcccctgaa gactccatgc 1980  
ttcacccttc attatgccgc cccagagctc ttgaatcaga acggctacga tgagtcctgt 2040  
gacctgtgga gcttgggcgt cattttgtac acaatgttgt caggacaggt tcccttccaa 2100  
tctcatgacc gaagtttgac gtgtaccagc gcggtggaaa tcatgaagaa aattaaag 2160  
ggagatttct cctttgaagg agaagcctgg aagaatgtat cccaagaggc taaagatttg 2220  
atccaaggac ttctcacagt agatccaaac aaaaggctta aaatgtctgg cttgaggtac 2280  
aatgaatggc tacaagatgg aagtcagctg tcctccaatc ctctgatgac tccggatatt 2340  
ctaggatctt ccggagctgc cgtgcatacc tgtgtgaaag caaccttcca cgcctttaac 2400  
aaatacaaga gagagggtt ttgccttcag aatgttgata aggcccttt ggctaagaga 2460  
agaaaaatga aaaagactag caccagtacc gagacacgca gcagttccag tgagagttcc 2520  
cattcttctt cctctcattc tcacggtaaa actacaccca ccaagacact gcagcccagc 2580  
aatcctgccg acagcaataa cccggagacc ctcttccagt tctcggactc agtagcttag 2640  
gcatggtagg agtgtatcag tgatccattg cactttatt cctcagcat atgcctgagg 2700  
cgatctttta tgcttttaaa aatgtttccc gttggtctca ttggaatctg cctcctaattg 2760  
atttttttca ggaaaacctg tttggttatc ctcatcaaa agcactggac agagaatgtt 2820  
actgtgaata gagcacatat tactctttt agcaacctag catgatgcca acaagactat 2880  
tcttgaaaga gcaaagggtc ctgtaaatat aattagggtc agatttgagc tgcttgtaag 2940  
tcacaggttt tccagatgct tgccaacaag aaatgactca tactgtgatg atacctttt 3000  
ctttgccttg tggacaatgt gggtttttga aatttgcacc cttcaaacaa tgatttatca 3060

gagaaagggg tctgttttca aaaaagattc tgtaatgaat tttatgtgtg gcatatactt 3120  
atttcttgag agaagatttt aacttattgt ttttatttta tggttacata tgatgataac 3180  
ctgctattat taaacttttt ctaaaaagtg aaaaaaaaaa aaaaa 3225

&lt;210&gt; 54

&lt;211&gt; 2110

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 3013946

&lt;400&gt; 54

tgcgcgagcc cgtccgcgcg cgccatggcc accacgggtga cctgcacccg cttcacccgac 60  
gagtaccagc tctacgagga tattggcaag ggggctttct ctgtgggtccg acgtgtgtgc 120  
aagctctgca ccggccatga gtatgcagcc aagatcatca acaccaagaa gctgtcagcc 180  
agagatcacc agaagctgga gagagaggct cggatctgcc gccttctgaa gcattccaac 240  
atcgtgcgtc tccacgacag catctccgag gagggcttcc actacctggt cttcgatctg 300  
gtcactgggtg gggagctctt tgaagacatt gtggcgagag agtactacag cgaggctgat 360  
gccagtcact gtatccagca gatcctggag gccgttctcc attgtcacca aatgggggtc 420  
gtccacagag acctcaagcc ggagaacctg cttctggcca gcaagtgcaa aggggctgca 480  
gtgaagctgg cagacttcgg cctagctatc gaggtgcagg gggaccagca ggcatgggtt 540  
ggtttcgctg gcacaccagg ctacctgtcc cctgaggtcc ttcgcaaaga ggcgtatggc 600  
aagcctgtgg acatctgggc atgtgggggtg atcctgtaca tcctgctcgt gggctaccca 660  
cccttctggg acgaggacca gcacaagctg taccagcaga tcaaggtctg tgcttatgac 720  
ttccgctccc ctgagtggga caccgtcact cctgaagcca aaaacctcat caaccagatg 780  
ctgaccatca accctgccaa gcgcatacaca gccatgagg ccctgaagca cccgtgggtc 840  
tgccaacgct ccacggtagc atccatgatg cacagacagg agactgtgga gtgtctgaaa 900  
aagtccaatg ccaggagaaa gctcaaggga gccatcctca ccaccatgct ggccacacgg 960  
aatttctcag ccaagagttt actcaacaag aaagcagatg gagtcaagcc ccagacgaat 1020  
agcaccaaaa acagtgcagc cgccaccagc cccaaaggga cgcttctctc tgccgccctg 1080  
gagcctcaaa ccaccgtcat ccataaccca gtggacggga ttaaggagtc ttctgacagt 1140  
gccaatacca ccatagagga tgaagacgct aaagcccccga gggctcccga catcctgagc 1200  
tcagtggagg ggggctcggg agccccagaa gccgaggggc ccctgccctg cccatctccg 1260  
gctccctttg gccccctgcc agctccatcc cccaggatct ctgacatcct gaactctgtg 1320  
agaagggggt caggaacccc agaagccgag gggccctctc cagcgggggc cccgccctgc 1380  
ctgtctccgg ctctcctagg cccctgtcc tcccctgcc ccaggatctc tgacatcctg 1440  
aactctgtga ggaggggctc agggacccca gaagccaagg gccctcggc agtggggccc 1500  
ccgccctgcc catctccgac tatccctggc cccctgccc ccccatccc gaagcaggag 1560  
atcattaaga ccacggagca gctcatcgag gccgtcaaca acggtgactt tgaggcctac 1620  
gcgaaaatct gtgaccaggg gctgacctcg tttgagcctg aagcactggg caacctggtt 1680  
gaagggatgg acttccacag attctacttc gagaacctgc tggccaagaa cagcaagcca 1740  
atccacacga ccattcctgaa cccacacgtg cagtcattg gagaggatgc cgcctgcac 1800  
gcttacatcc ggctcacgca gtacattgac gggcagggcc ggccccgcac cagccagtct 1860  
gaggagaccc gcgtgtggca ccgccgcgac ggcaagtggc agaattgtga cttccactgc 1920  
tcggggcgcg ctgtggcccc gctgcagtga agagctgcgc cctgggtttcg ccggacagag 1980  
ttgggtgttg gagcccgact gccctcgggc acacggcctg cctgtcgcat gtttgtgtct 2040  
gcctcgttcc ctcctcctgt gctgtgtct gcagaaaaac aagaccagat gtgatttgtt 2100  
aaaaaaaaa 2110

&lt;210&gt; 55

&lt;211&gt; 2140

&lt;212&gt; DNA



<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte Clone Number: 067967

<400> 55

```
gtgcgctgag ctgcagtgtc tggctcgagag taccctgtggg agcgtcgcgc cgcggaggca 60
gccgtcccgg cgtagggtggc gtggccgacc ggacccccaa ctggcgccctc tccccgcgcg 120
gggtcccggag ctaggagatg ggaggcacag ctctgtgggc tgggcggaag gatgcggggc 180
cgctgggggc cgggctcccg ccccgagcagc ggagggtggg ggatggtgtc tatgacacct 240
tcatgatgat agatgaaacc aaatgtcccc cctgttcaaa tgtactctgc aatccttctg 300
aaccaccttc acccagaaga ctaaatatga ccactgagca gtttacagga gatcatactc 360
agcacttttt ggatggagggt gagatgaagg tagaacagct gtttcaagaa tttggcaaca 420
gaaaatccaa tactattcag tcagatggca tcagtgtact tgaaaaatgc tctcctactg 480
tttctcaggg taaaagttca gattgcttga atacagtaaa atccaacagt tcatccaagg 540
caccctaaagt ggtgcctctg actccagaac aagccctgaa gcaatataaa caccacctca 600
ctgcctatga gaaactggaa ataattaatt atccagaaat ttactttgta ggtccaaatg 660
ccaagaaaag acatggagtt attggtggtc ccaataatgg aggggtatgat gatgcagatg 720
gggcctatat tcatgtacct cgagaccatc tagcttatcg atatgagggtg ctgaaaatta 780
ttggcaaggg gagttttggg cagggtggcca gggcttatga tcacaaactt cgacagtacg 840
tgccctctaaa aatggtgcgc aatgagaagc gctttcatcg tcaagcagct gaggagatcc 900
ggatttttga gcatcttaag aaacaggata aaactggtag tatgaacggt atccacatgc 960
tgaaaagttt cacattccgg aacctggtt gcatggcctt tgaattgctg agcatagacc 1020
tttatgagct gattaaaaaa aataagtttc agggtttttag cgtccagttg gtacgcaagt 1080
ttgccagtc catcttgcaa tctttggatg cctccacaa aaataagatt attcactgcg 1140
atctgaagcc agaaaacatt ctctgaaac accacgggcg cagttcaacc aagggtcattg 1200
actttgggtc cagctgtttc gactaccaga agctctacac atatatccag tctcggttct 1260
acagagctcc agaatcatc ttaggaagcc gctacagcac accaattgac atatggagtt 1320
ttggctgcat ccttgagaa cttttaacag gacagcctct ctccctgga gaggatgaag 1380
gagaccagtt ggcctgcatg atggagcttc tagggatgcc accaccaaaa cttctggagc 1440
aatccaaacg tgccaagtac tttattaatt ccaagggcat accccgctac tgcctgtgta 1500
ctacccaggc agatgggagg gttgtgcttg tggggggtcg ctacagtagg ggtaaaaaagc 1560
gggggtcccc aggcagcaaa gactggggga cagcactgaa aggggtgtgat gactacttgt 1620
ttatagagtt cttgaaaagg tgtcttcact gggacccctc tgcccgttg accccagctc 1680
aagcattaag acacccttg attagcaagt ctgtcccag acctctcacc accatagaca 1740
aggtgtcagg gaaacgggta gttaatcctg caagtgttt ccagggtattg ggttccaagc 1800
tgctccagtg tgttgaata gccaataagc ttaaagctaa cttaatgtca gaaaccaatg 1860
gtagtatacc cctatgcagt gtattgccaa aactgattag ctagtggaca gagatatgcc 1920
cagagatgca tatgtgtata tttttatgat cttacaaacc tgcaaatgga aaaaatgcaa 1980
gcccattggg ggatgttttt gttagagtag acttttttta aacaagacaa aacattttta 2040
tatgattata aaagaattct tcaagggcta attacctaac cagcttgtat tggccatctg 2100
gaatatgcat taaatgactt tttataggtc aaaaaaaaaa 2140
```

<210> 56

<211> 1728

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte Clone Number: 346275

<400> 56

```
gacagacaaa gcgcgcgcac gcgtccgcat gtcggatgtt tgtagcagtc agagagcaga 60
```

```

acatgagcat ctgccaggtc tggttccccc accatcaggg atgggagtgaa gaaaggggag 120
ttcccctctg aagagccacc cctgcagggg gaaatctgtc tccaacagga gatctgggaa 180
gaccatagtg agaagtgtg tccaagaggt ccgcacagcg ggccttttcc gaagtgggtt 240
tagcgaagag aaggcaactg gcaagctctt tgctgtgaag tgtatcccta agaagggcgt 300
gaaagggcaag gaaagcagca tagagaatga gatagccgtc ctgagaaaga ttaagcatga 360
aaatattgtt gccctggaag acatttatga aagcccaaat cacctgtact tggtcacatga 420
gctgggtgtc ggtggagagc tgtttgaccg gatagtggag aaggggtttt atacagagaa 480
ggatgccagc actctgatcc gccaaagtctt ggacgcccgtg tactatctcc acagaatggg 540
catcgctccac agagacctca agcccgaata tctctgtac tacagtcaag atgaggagtc 600
caaaataatg atcagtgaat ttggattgtc aaaaatggag ggcaaaggag atgtgatgtc 660
cactgcctgt ggaactccag gctatgtcgc tctgaagtc ctgcgccaga aaccttacag 720
caaagccgtt gactgctggt ccctcggagt gattgcctac atcttgcctc gcggctaccc 780
tcctttttat gatgaaaatg actccaagct ctttgagcag atcctcaagg cggaatatga 840
gtttgactct ccctactggg atgacatctc cgactctgca aaagacttca ttcggaacct 900
gatggagaag gacccgaata aaagatacac gtgtgagcag gcagctcggc acccatggat 960
cgctgggtgac acagccctca acaaaaacat ccacgagtc gtcagcgccc agatccggaa 1020
aaactttgcc aagagcaaat ggagacaagc atttaatgcc acggccgtcg tgagacatat 1080
gagaaaaacta cacctcggca gcagcctgga cagttcaaat gcaagtgttt cgagcagcct 1140
cagtttggtc agccaaaaag actgtgcgta tgtagcaaaa ccagaatccc tcagctgaca 1200
ctgaagacga gcctggggtg gagaggaggg agccggcacc tgccgagcac ctctgtttg 1260
ccaggcgctt tctatactta atcccatgtc atgcgaccct aggacttttt ttaacatgta 1320
atcactgggc cgggtgcagt ggctcacgcc tgtaatccca acactttggg aggctgagge 1380
aggaggactg tttgagttca ggagttttta gaccagcctg accaacaatg tgaaacccca 1440
tctctactaa aatataaaaa ttagccgggt gtgggtggcg gcacctgtaa tgtcagctac 1500
ttgggaggct gaggcaggag aatcacttga acccaggaag cggaggttgc aatgagctga 1560
gatcacacca ctgcactcca gcctgggtga cagattgaga ctccctctca aaaaaaaaag 1620
ggaaatcatt gaacactcgt ggaaccctag gtattgcata ttccatttac ggtttgggaa 1680
tccagggtc aagtctcgc aggggtaccg agctcgagat cgtaataca 1728

```

&lt;210&gt; 57

&lt;211&gt; 1610

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 283746

&lt;400&gt; 57

```

gtcgccctctg aaggagaacc attttccatc tctttcatag ttttttcccc cagtcagcgt 60
ggtagcggta ttctccgagg cagtgacagt aattgttttt gcctcttttag ccaagacttc 120
cgccctcgat caagatgggtg gttggacggc ctctcctaac tttacggggc ctggcggtgc 180
tgacgcctga gctggtaggg gtggagcagg taggaaacag caaatgcaga agctgctgcg 240
cggaagtcgg ccattggactg gaaagaagtt ctctgcggc gcctagcgac gcccaacacc 300
tgtccaaaca ctgcctgctg aagatgaagt ctactacag aaattaagag aggaatcaag 360
agctgtcttt ctacaaagaa aaagcagaga actgttagat aatgaagaat tacagaactt 420
atgggtttttg ctggacaaac accagacacc acctatgatt ggagaggaag cgatgatcaa 480
ttacgaaaac tttttgaagg ttggtgaaaa ggctggagca aagtgcagc aatttttcac 540
agcaaaagtc tttgctaaac tcttccatag agattcatat ggaagaattt ccatcatgca 600
gttctttaat tatgtcatga gaaaagtttg gcttcatcaa acaagaatag gactcagttt 660
atatgatgtc gctgggcagg ggtaccttcg ggaatctgat ttagaaaact acatatttga 720
acttatccct acgttgccac aattagatgg tctggaaaaa tctttctact ccttttatgt 780
ttgtacagca gttaggaggt tcttcttctt tttagatcct ttaagaacag gaaagataaa 840
aattcaagat attttagcat gcagcttcct agatgattta ttggagctaa gggatgagga 900

```

actgtccaag gagagtcaag aaacaaattg gttttctgct ctttctgccc taagagttta 960  
tggccagtac ttgaatcttg ataaagatca caatggcatg ctcagtaaag aagaactctc 1020  
acgctatgga acagctacca tgaccaatgt cttcttagac cgtgttttcc aggagtgtct 1080  
cacttatgat ggagaaatgg actataagac ctacttgga tttgtccttg cattagaaaa 1140  
cagaaaggaa cctgcagctc tacaatatat tttcaaactg cttgatattg agaacaaagg 1200  
atacctgaat gtcttttcac ttaattattt ctttagggcc atacaggaac taatgaaaat 1260  
ccatggacaa gatcctgttt catttcaaga tgtcaaggat gaaatctttg acatggtaaa 1320  
accaaaggat cctttgaaaa tctctcttca ggatttaate aacagtaate aaggagacac 1380  
agtaaccacc attctaatec atttgaatgg cttctggact tacgagaaca gagaggctct 1440  
tggtgcaaat gacagtgaag actctgcaga ccttgatgat acatgatctc tgaaagacta 1500  
gactgtctta tattatgaga tacttgaatg ctgcatgtaa agcctttaa gcaaaatcct 1560  
cagaaatggt ctaaataaaa cacttgatat gcctagagaa aaaaaaaaaa 1610

&lt;210&gt; 58

&lt;211&gt; 1290

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2696537

&lt;400&gt; 58

ccggctcccc ccgggaagtt ctaggccgcc gcacagaaag ccctgccctc cagccggggt 60  
ctctggagcg ccctgggttg cccggccggg ccctgccgct gacttggtga cactgcgagc 120  
actcagtcct tcccgcgcgc ctctccccg cccgccccgc cgctcctcct ccctgtaaca 180  
tgccatagtg cgctgcgac cacacggccg gggcgctagc gttcgcttc agccaccatg 240  
gggaatggga tgaacaagat cctgcccggc ctgtacatcg gcaacttcaa agatgccaga 300  
gacgcggaac aattgagcaa gaacaagggt acacatattc tgtctgtcca tgatagtgc 360  
aggcctatgt tggaggaggat taaataacctg tgcacccag cagcggattc accatctcaa 420  
aacctgacaa gacatttcaa agaaagtatt aaattcattc acgagtgcg gctccgcggg 480  
gagagctgcc ttgtacactg cctggccggg gtctccagga gcgtgacact ggtgatcgca 540  
tacatcatga ccgtcactga ctttggctgg gaggatgccc tgcacaccgt gcgtgctggg 600  
agatcctgtg ccaaccccaa cgtgggcttc cagagacagc tccaggagt tgaagaagcat 660  
gaggtccatc agtatcggca gtggctgaag gaagaatatg gagagagccc tttgcaggat 720  
gcagaagaag ccaaaaacat tctggccgct ccgggaattc tgaagttctg ggcctttctc 780  
agaagactgt aatgtacctg aagtttctga aatattgcaa acccacagag tttaggctgg 840  
tgctgccaaa aagaaaagca acatagagtt taagtatcca gtagtgattt gtaaaactgt 900  
ttttcatttg aagctgaata tatacgtagt catgtttatg ttgagaacta aggatattct 960  
ttagcaagag aaaatatttt ccccttatcc ccactgctgt ggaggtttct gtacctcgct 1020  
tggtgctctg taaggatccc gggagccttg ccgactgcc ttgtgggtgg cttggcgctc 1080  
gtgattgctt cctgtgaacg cctcccaagg acgagcccag tgtagtgtg tggcgtgaac 1140  
tctgcccggtg tttctcaaa tccccagct tgggaaatag cccttggtgt gggttttatc 1200  
tctgggttgt gttctccgtg gtggaattga ccgaaagctc tatgttttctg ttaataaagg 1260  
gcaacttagc caagtttaa aaaaaaaaaa 1290

&lt;210&gt; 59

&lt;211&gt; 2281

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 551178

&lt;400&gt; 59

tgatgatcca gatgttaaag cacaagtgga agtgctgtcc gctgcactac gtgcttccag 60  
cctggatgca catgaagaga ccatcagtat agaaaagaga agtgatttgc aagatgaact 120  
ggatataaat gagctaccaa attgtaaaat aaatcaagaa gattctgtgc ctttaatcag 180  
cgatgctgtt gagaatatgg actccactct tcaactatatt cacagcgatt cagacttgag 240  
caacaatagc agtttttagcc ctgatgagga aaggagaact aaagtacaag atgttgtacc 300  
tcaggcggtt ttagatcagt atttatctat gactgaccct tctcgtgcac agacgggtga 360  
cactgaaatt gctaagcact gtgcataatg cctccctggg gtggccttga cactcggaag 420  
acagaattgg cactgcctga gagagacgta tgagactctg gcctcagaca tgcagtggaa 480  
agttcgacga actctagcat tctccatcca cgagcttgca gttattcttg gagatcaatt 540  
gacagctgca gatctggttc caatttttaa tggattttta aaagacctcg atgaagtacg 600  
gatagggtgt cttaaacact tgcagtattt tctgaagctt cttcatattg aaaaagaag 660  
agaatatctt tatcaacttc aggagttttt ggtgacagat aatagtagaa attggcggtt 720  
tcgagctgaa ctggctgaac agctgatttt acttctagag ttatatagtc ccagagatgt 780  
ttatgactat ttacgtccca ttgctctgaa tctgtgtgca gacaaagttt cttctgttcg 840  
ttggatttcc tacaagttgg tcagcgagat ggtgaagaag ctgcacgcgg caacaccacc 900  
aacgttcgga gtggacctca tcaatgagct tgtggagaac tttggcagat gtcccaagt 960  
gtctggctcg caagcctttg tctttgtctg ccagactgtc attgaggatg actgccttcc 1020  
catggaccag tttgctgtgc atctcatgcc gcatctgcta accttagcaa atgacagggg 1080  
tcctaactg cgagtgtgc ttgcaaagac attaagacaa actctactag aaaaagacta 1140  
ttctttggc tctgccagct gccaccagga ggctgtggag cagaccatca tggctcttca 1200  
gatggaccgt gacagcgatg tcaagtattt tgcaagcatc caccctgcca gtacaaaaat 1260  
ctccgaagat gccatgagca cagcgtcctc aacctactag aaggcttgaa tctcgggtgc 1320  
tttctgtctt ccatgagagc cgaggttcag tgggcattcg ccacgcagtgt gacctgggat 1380  
agcttttcggg ggaggagaga ccttctctc ctgcggactt cattgcaggt gcaagttgcc 1440  
tacacccaat accagggatt tcaagagtca agagaaagta cagtaaacac tattatctta 1500  
tcttgacttt aaggggaaat aatttctcag aggattataa ttgtcaccga agccttaaat 1560  
ccttctgtct tctgactga atgaaacttg aattggcaga gcattttcct tatggaaggg 1620  
atgagattcc cagagacctg cattgcttct tcttggtttt atttaacaat cgacaaatga 1680  
aattcttaca gcctgaaggc agacgtgtgc ccagatgtga aagagacctt cagtatcagc 1740  
cctaactctt ctctcccagg aaggacttgc tgggctctgt ggccagctgt ccagcccagc 1800  
cctgtgtgtg aatcgtttgt gacgtgtgca aatgggaaag gaggggtttt tacatctcct 1860  
aaaggacctg atgccaacac aagtaggatt gacttaaaact cttaagcgca gcataattgct 1920  
gtacacattt acagaatggt tgetgagtgt ctgtgtctga ttttttcatg ctggtcatga 1980  
cctgaaggaa atttattaga cgtataatgt atgtctggtg tttttaactt gatcatgac 2040  
agctctgagg tgcaacttct tcacatactg tacatacctg tgaccactct tgggagtgt 2100  
gcagctcttta atcatgctgt ttaaactgtt gtggcacaag ttctcttctg caaataaaat 2160  
ttattaataa gatctataga gagagatata tacacttttg attgttttct agatgtctac 2220  
caataaatgc aatttgtgac ctgtattaat gatttaaagt gggaaactag attaaaaat 2280  
a 2281

&lt;210&gt; 60

&lt;211&gt; 632

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 619292

&lt;400&gt; 60

cggacgcgtg gggccagcc gcagctccag caccgaggac ttctgctacg tcttcacggg 60  
ggagctggaa cgaggccct cgggctggg gatgggctg atcgacggga tgcacacgca 120  
cctgggccc cccggctct acatccagac cctgctccc ggcagccc cagcggccga 180  
cgggcgcctg tcgctgggg accgtatcct ggaggtgaat ggcagcagcc tctgggccc 240

```

tggctacctg agagctgtgg acctgatccg tcatggcggg aagaagatgc ggttcctggg 300
cgcgaagtcc gacgttgagg aacagccaag aagatccatt tccgcacgcc cctctcttag 360
gggggctgcg aggacacccc cacaggcccc gcacccgggc ccacctgggtg acactgggct 420
tcctcccgcc ttcgtccctg ttttgtaact gaccaagtgg ggtcccggtt ggggagcctc 480
accctgggga catgcctgtt gataacatgc atctcagtgt aggttctatt tatatggcag 540
atgacgtgaa attgtgatgt ttgttacaga gcttttatgt ttaaagactt caatggagaa 600
gtacggttca ataaactatt tttcccggtc tt                                     632

```

&lt;210&gt; 61

&lt;211&gt; 2347

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte Clone Number: 2054049

&lt;400&gt; 61

```

cccagtttta tcatggatcc atcctgaaag tcaagccaca atcactcggg gtagccagcc 60
catggttgga gtgagtggaa agcgaagcaa agaagatgaa aaataccttc aagctatcat 120
ggattccaat gccagtcctc acaaaatctt tatatttgat gcccggccaa gtggttaatgc 180
tggttccaac aaggcaaagg gtggagggtta tgaaagtga gatgcctatc aaaatgctga 240
actagttttc ctggatatcc acaatattca tgttatgaga gaatcattac gaaaacttaa 300
ggagattgtg taccccaaca ttgaggaaac ccaactgggtg tctaacttgg aatctactca 360
ttggctagaa catattaagc ttattcttgc aggggctctt aggattgctg acaaggtaga 420
gtcaggggaag acgtctgtgg tagtgcatcg cagtgatggg tgggacgca cagctcagct 480
cacttccctt gccatgctca tggtggatgg atactatcga accatccgag gatttgaaat 540
ccttgtggag aaagaatggc taagtgttgg acatcgattt caactaagag ttggccatgg 600
agataagaac catgcagatg cagacagatc gcctgttttt cttcaattta ttgactgtgt 660
ctggcagatg acaagacagt ttctaccgc atttgaattc aatgagtatt ttctcattac 720
cattttggac cacctataca gctgcttatt cggaacattc ctctgtaata gtgaacaaca 780
gagaggaaaa gagaatcttc ctaaaaggac tgtgtcactg tgggtcttaca taaacagcca 840
gctggaagac ttcactaatc ctctctatgg gagctattcc aatcatgtcc tttatccagt 900
agccagcatg cgccacctag agctctgggt gggatattac ataaggtgga atccacggat 960
gaaaccacag gaacctatcc acaacagata caaagaactt cttgctaaac gagcagagct 1020
tcagaaaaaa gttagggaac tacagagaga gatttctaac cgatcaacct catcctcaga 1080
gagagccagc tctcctgcac agtgtgtcac tctgtccaa actgttgat aaaggactgt 1140
aagatcaggg gcatcattgc tatacactct tgattacact ggcagctcta tgagttagaa 1200
gtcttcggaa tttagaacct atctatgaga gaaagttcag tcactttatt tattttaa 1260
ctctctagga tgagtttaga actgtagcag tgcagggtggc ttaagtgaag taactccata 1320
tgtaattaca tgattatgat actaatcttt taagtatcca aagaatatta aaatacttca 1380
atcctggatt cacagtggga acaagtttct attaaaaggc aaatgctgtt acaaattttt 1440
ggcatctggt aatattaaaa ccattttaga aatacactct gtgctcactg tgcagaggaa 1500
catcagtttt caaaccaaca ctgaaattct gtggcatcac atatattggg ccttgatgtc 1560
atgacagatc aaaatcattt gatatccctt tctccattct aggtttttct ttttttcagt 1620
aactgattta ccttgatcac ttttcaactt ccatattctt catatagtaa aaggcaaagt 1680
gttgaagata ctacgggtgtg gtagtagttg aaaattattg ccgtcattat ttacatactt 1740
aagacatatt agcaagttga tccaaaatgg gaggccttat agatgtgctt gggggaaaat 1800
gaaggggaga aagtagccat acaggagtcc aaagaattcc atgcccttca gattagccca 1860
attaccagaa acatcatgaa agatatttta aaaactaatt atttactaca gtgtatttca 1920
cttgtcttgt gtgtctgaac acacagaagc taattagcaa gtttttaaga agtattttaa 1980
aatcttacta ggattgacat tttttctgaa ttctgtataa atagcttata gtgagaagta 2040
ctgtgctcaa attttacatt tttttccttt gcaaattctg taatttctact caacgattaa 2100
gtctaccaaa gaacacactg catgtaaaag atgtattaca atctcaaagc cagtaaaaga 2160
aatcttgctt cactgttcac ctgctacaag taagagtttg gtgctggtag aaacatttga 2220

```

ctctgatgtc tattttattc tacataagag ccatatgtaa tgtactgtaa caaaggagct 2280  
 tcttgtcccc ttgggtctttt aattaaaaga aattccaact gactttttaa ctttaaaaaa 2340  
 aaaaaaa 2347

<210> 62

<211> 1737

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte Clone Number: 2843910

<400> 62

ccggggctga gcgctcggct gcagcggcgc ggaggcgcgc tccctggctc gccgcggctcc 60  
 ccgcccgtcc cgccgcgggc tgccatggca ggagccggag ggttcggctg ccccgccggc 120  
 ggcaacgact tccagtggcg cttctcgag gtcaaggggg ccatcgacga ggacgtggcc 180  
 gaagcggaca tcatctccac cgttgagttt aattactctg gagatcttct tgcaacagga 240  
 gacaagggcg gcagagttgt tatttttcag cgtgaacaag agaataaaag ccgccctcat 300  
 tctaggggag aatataatgt ttacagcacc tttcaaagtc atgaaccgga gtttgactat 360  
 ttgaaaagtc tagaaattga ggaaaaaatt aataaaatta ggtgggtacc acaacagaat 420  
 gctgctcatt ttctactgtc tacaatgat aaaactataa aattatggaa aataagtga 480  
 cgggataaaa gagcagaagg ttataacctg aaagacgaag atggaagact tcgagaccca 540  
 tttaggatca cggcgctacg ggtcccaata ttgaagccca tggatcttat ggtagaagcg 600  
 agtccacggc gaatttttgc aaatgctcac acatatcata taaattccat ttcagtaaat 660  
 agtgatcatg aaacatatct ttctgcagat gacctgagaa ttaatttatg gcacttagaa 720  
 atcacagata gaagctttta catcgctggac atcaagcctg ctaacatgga ggagctgacc 780  
 gaagtcatca ctgcagccga gttccacccg caccagtga acgtgttcgt ctacagcagt 840  
 agcaaaggga ccatccgcct gtgtgacatg cgctcctcgg cctgtgcga cagacactcc 900  
 aagttttttg aagagcctga agatcccagc agtaggtcct tcttctcaga aataatttca 960  
 tccatatccg atgtaaaatt cagtcatagt gggcgggtaca tgatgaccag agactacctg 1020  
 tcggtgaagg tgtgggacct caacatggag agcaggcccg tggagaccca ccagggtccac 1080  
 gagtacctgc gcagcaagct ctgctctctc tatgagaacg actgcatctt tgacaagttt 1140  
 gagtgttgct ggaacggttc ggatagcgcc atcatgaccg ggtcctataa caacttcttc 1200  
 aggatgtttg atagagacac gcggagggat gtgaccctgg aggcctcgag agagagcagc 1260  
 aaaccgcgcg ccagcctcaa accccggaag gtgtgtacgg ggggtaagcg gaggaagac 1320  
 gagatcagtg tggacagtct ggacttcaac aagaagatcc tgcacacagc ctggcaccac 1380  
 gtggacaatg tcattgccgt ggctgccacc aataacttgt acatattcca ggacaaaatc 1440  
 aactagagac gcgaacgtga ggaccaagtc ttgtcttgca tagttaagcc ggacattttt 1500  
 ctgtcagaga aaaggcatca ttgtccgctc cattaagaac agtgacgcac ctgctacttc 1560  
 ccttcacaga cacaggagaa agccgcctcc gctggaggcc cgggtgtggt ccgcctcggc 1620  
 gaggcgcgag acaggcgctg ctgctcacgt ggagacgctc tcgaagcaga gttgacggac 1680  
 actgctccca aaaggtcatt actcagaata aatgtattta tttcaaaaaa aaaaaa 1737



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C12N 15/12, C07K 14/47, C12N 9/12, 5/10, C07K 16/18, A61K 38/17</b>		A3	(11) International Publication Number: <b>WO 00/06728</b>
			(43) International Publication Date: 10 February 2000 (10.02.00)
(21) International Application Number: <b>PCT/US99/17132</b>		(72) Inventors; and	
(22) International Filing Date: <b>28 July 1999 (28.07.99)</b>		(75) Inventors/Applicants (for US only): <b>HILLMAN, Jennifer, L.</b> [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). <b>LAL, Preeti</b> [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). <b>TANG, Y., Tom</b> [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). <b>CORLEY, Neil, C.</b> [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US). <b>GUEGLER, Karl, J.</b> [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US). <b>BAUGHN, Mariah, R.</b> [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). <b>PATTERSON, Chandra</b> [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). <b>BANDMAN, Olga</b> [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). <b>AU-YOUNG, Janice</b> [US/US]; 1419 Kains Avenue, Berkeley, CA 94709 (US). <b>GORGONE, Gina, A.</b> [US/US]; 1253 Pinecrest Drive, Boulder Creek, CA 95006 (US). <b>YUE, Henry</b> [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). <b>AZIMZAI, Yalda</b> [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US). <b>REDDY, Roopa</b> [IN/US]; 1233 W. McKinley Drive, Sunnyvale, CA 94086 (US). <b>LU, Dyung, Aina, M.</b> [US/US]; 55 Park Belmont Place, San Jose, CA 95136 (US). <b>SHIH, Leo, L.</b> [US/US]; Apt. B, 1081 Tanland Drive, Palo Alto, CA 94303 (US).	
(30) Priority Data:			
09/123,494	28 July 1998 (28.07.98)	US	
Not furnished	28 July 1998 (28.07.98)	US	
09/152,814	14 September 1998 (14.09.98)	US	
Not furnished	14 September 1998 (14.09.98)	US	
09/173,482	14 October 1998 (14.10.98)	US	
Not furnished	14 October 1998 (14.10.98)	US	
60/106,889	3 November 1998 (03.11.98)	US	
60/109,093	19 November 1998 (19.11.98)	US	
60/113,796	22 December 1998 (22.12.98)	US	
09/229,005	12 January 1999 (12.01.99)	US	
Not furnished	12 January 1999 (12.01.99)	US	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications			
US	Not furnished (CIP)		
Filed on	28 July 1998 (28.07.98)		
US	09/123,494 (CIP)		
Filed on	28 July 1998 (28.07.98)		
US	09/152,814 (CIP)		
Filed on	14 September 1998 (14.09.98)		
US	Not furnished (CIP)		
Filed on	14 September 1998 (14.09.98)		
US	09/173,482 (CIP)		
Filed on	14 October 1998 (14.10.98)		
US	Not furnished (CIP)		
Filed on	14 October 1998 (14.10.98)		
US	60/106,889 (CIP)		
Filed on	3 November 1998 (03.11.98)		
US	60/109,093 (CIP)		
Filed on	19 November 1998 (19.11.98)		
US	60/113,796 (CIP)		
Filed on	22 December 1998 (22.12.98)		
US	09/229,005 (CIP)		
Filed on	12 January 1999 (12.01.99)		
US	Not furnished (CIP)		
Filed on	12 January 1999 (12.01.99)		
(71) Applicant (for all designated States except US): <b>INCYTE PHARMACEUTICALS, INC.</b> [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).		(81) Designated States: <b>AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW.</b> ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
		Published With international search report.	
		(88) Date of publication of the international search report: 4 May 2000 (04.05.00)	
(54) Title: <b>PHOSPHORYLATION EFFECTORS</b>			
(57) Abstract			
The invention provides human phosphorylation effectors (PHSP) and polynucleotides which identify and encode PHSP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of PHSP.			

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/17132

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/47 C12N9/12 C12N5/10 C07K16/18  
A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HILLIER, L., ET AL.: "WashU-NCI human EST project" EMBL SEQUENCE DATA LIBRARY, 6 February 1998 (1998-02-06), XP002121148 heidelberg, germany accession no. AA780791 ---	5,6,10, 11
X	ISHIKAWA, K., ET AL.: "prediction of the coding sequences of unidentified human genes. X. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro" DNA RESEARCH, vol. 5, no. 3, 30 June 1998 (1998-06-30), pages 169-176, XP002121149 the whole document --- -/-	1-5,9,10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

9 November 1999

Date of mailing of the international search report

17. 02. 00

Name and mailing address of the ISA

European Patent Office, P. B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Holtorf, S

# INTERNATIONAL SEARCH REPORT

Intern: ial Application No

PCT/US 99/17132

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 11234 A (HAWKINS PHILLIP R ; INCYTE PHARMA INC (US); AU YOUNG JANICE (US); G) 19 March 1998 (1998-03-19) the whole document ---	1-19
A	WO 97 02347 A (INCYTE PHARMA INC) 23 January 1997 (1997-01-23) the whole document ---	1-19
A	WALDEN, P.D. AND COWAN, N.J.: "a novel 205-kilodalton testis-specific serine/threonine protein kinase associated with microtubules of the spermatid manchette" MOLECULAR AND CELLULAR BIOLOGY, vol. 13, 1993, pages 7625-7635, XP002121150 the whole document ---	1-19
A	NAGASE, T., ET AL.: "prediction of the coding sequences of unidentified human genes. IX. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro" DNA RESEARCH, vol. 5, 1998, pages 31-39, XP002121152 especially Table 2 + 3 the whole document ---	1-19
A	HILLIER, L., ET AL.: "the WashU-Merck EST project" EMBL SEQUENCE DATA LIBRARY, 25 March 1995 (1995-03-25), XP002121151 heidelberg, germany accession no. t77135 ---	1-19
A	WO 97 48802 A (HAWKINS PHILLIP R ; INCYTE PHARMA INC (US); AU YOUNG JANICE (US); H) 24 December 1997 (1997-12-24) the whole document ---	1-19
P,X	WO 99 04265 A (SAHIN UGUR ; TURECI OZLEM (DE); PFREUNDSCUH MICHAEL (DE); GOUT IVA) 28 January 1999 (1999-01-28) pages 1-7, 537, 578, 709 claims claims 1-117 -----	1-7, 9-16, 19

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 17132

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim 19  
is directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☒ Claims Nos.: 17, 18, 20  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheets

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-20 partially

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-20 partially

Polynucleotide and polypeptide sequences that show homology to Protein Kinases; especially SEQIDs 1,12 and 32,43; the recombinant expression of the same and uses thereof.

2. Claims: 1-20 partially

Polynucleotide and polypeptide sequences that show homology to PKC-potentiated inhibitory protein of PPI; especially SEQIDs 2 and 33; the recombinant expression of the same and uses thereof.

3. Claims: 1-20 partially

Polynucleotide and polypeptide sequences that show homology to STE20-like Protein Kinases; especially SEQIDs 3 and 34; the recombinant expression of the same and uses thereof.

4. Claims: 1-20 partially

Polynucleotide and polypeptide sequences that show homology to Phosphofructokinases; especially SEQIDs 4 and 35; the recombinant expression of the same and uses thereof.

5. Claims: 1-20 partially

Polynucleotide and polypeptide sequences that show homology to Serin/Threonine Protein Kinases; especially SEQIDs 5,6,10 and 36,37,41; the recombinant expression of the same and uses thereof.

6. Claims: 1-20 partially

Polynucleotide and polypeptide sequences that show homology to Phosphatidylinositol-3-kinases; especially SEQIDs 7 and 38; the recombinant expression of the same and uses thereof.

7. Claims: 1-20 partially

Polynucleotide and polypeptide sequences that show homology to Tyrosine or Tyrosine/serine Protein Kinases; especially SEQIDs 8,13,21 and 39,44,52; the recombinant expression of the same and uses thereof.

8. Claims: 1-20 partially

Polynucleotide and polypeptide sequences that show homology

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

to Calcium /Calmodulin dependent Protein Kinases; especially SEQIDs 9,18,23,25 and 40,49,54,56; the recombinant expression of the same and uses thereof.

9. Claims: 1-20 partially

Polynucleotide and polypeptide sequences that show homology to Tyrosine Phosphatases or Dual specificity phosphatases; especially SEQIDs 11,29,30 and 42,60,61; the recombinant expression of the same and uses thereof.

10. Claims: 1-20 partially

Polynucleotide and polypeptide sequences that show homology to PEST phosphatase interacting protein; especially SEQIDs 14 and 45; the recombinant expression of the same and uses thereof.

11. Claims: 1-20 partially

Polynucleotide and polypeptide sequences that show homology to SH3-binding proteins; especially SEQIDs 15 and 46; the recombinant expression of the same and uses thereof.

12. Claims: 1-20 partially

Polynucleotide and polypeptide sequences that show homology to NIK-kinases; especially SEQIDs 16 and 47; the recombinant expression of the same and uses thereof.

13. Claims: 1-20 partially

Polynucleotide and polypeptide sequences that show homology to Interferon-induced PK regulators; especially SEQIDs 17 and 48; the recombinant expression of the same and uses thereof.

14. Claims: 1-20 partially

Polynucleotide and polypeptide sequences that show homology to Choline-kinases; especially SEQIDs 19 and 50; the recombinant expression of the same and uses thereof.

15. Claims: 1-20 partially

Polynucleotide and polypeptide sequences that show homology to MAP-related Protein kinases; especially SEQIDs 20 and 51; the recombinant expression of the same and uses thereof.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

16. Claims: 1-20 partially

Polynucleotide and polypeptide sequences that show homology to Ribosomal S6 Protein kinases; especially SEQIDs 22 and 53; the recombinant expression of the same and uses thereof.

17. Claims: 1-20 partially

Polynucleotide and polypeptide sequences that show homology to Protein kinases Dyrk2; especially SEQIDs 24 and 55; the recombinant expression of the same and uses thereof.

18. Claims: 1-20 partially

Polynucleotide and polypeptide sequences that show homology to Protein Phosphatases 2A; especially SEQIDs 26,28,31 and 57,59,62; the recombinant expression of the same and uses thereof.

19. Claims: 1-20 partially

Polynucleotide and polypeptide sequences that show homology to MAP-kinase Phosphatases; especially SEQIDs 27 and 58; the recombinant expression of the same and uses thereof.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 17,18,20

Claims 17,18 and in part 20 refer to an antagonist and agonist of the polypeptides without giving a true technical characterization. Moreover, no such compounds are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/17132

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9811234 A	19-03-1998	US 5773699 A	30-06-1998
		US 5863780 A	26-01-1999
		AU 4261197 A	02-04-1998
		EP 0927257 A	07-07-1999
WO 9702347 A	23-01-1997	AU 6405996 A	05-02-1997
		CA 2198729 A	23-01-1997
		EP 0781336 A	02-07-1997
		JP 10505510 T	02-06-1998
		US 5846778 A	08-12-1998
WO 9748802 A	24-12-1997	US 5648239 A	15-07-1997
		AU 3401497 A	07-01-1998
		EP 0910639 A	28-04-1999
		US 5922844 A	13-07-1999
WO 9904265 A	28-01-1999	AU 8571598 A	10-02-1999